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ABSTRACT
REDOX TRIGGERING OF PODOCYTE NLRP3 INFLAMMASOMES AND GLOMERULAR
INJURY IN HYPERHOMOCYSTEINEMIA
By Justine M. Abais
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2014
Major Director: Pin-Lan Li, MD, PhD, Professor, Pharmacology and Toxicology

Hyperhomocysteinemia (hHcys), an important pathogenic factor contributing to the progression
of end-stage renal disease (ESRD), has been shown to activate NOD-like receptor protein 3
(NLRP3) inflammasomes and cause podocyte dysfunction and glomerular sclerosis. hHcys
induces aggregation of the three inflammasome components – NLRP3, apoptosis-associated
speck-like protein (ASC), and caspase-1 – and its activation is indicated by increased caspase-1
activity and secretion of interleukin-1β (IL-1β). The aims of the present study sought to elucidate
the role of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-mediated redox
signaling in hHcys-induced NLRP3 inflammasome activation, to dissect the contribution of
common endogenous reactive oxygen species (ROS) including superoxide (O2•−), hydrogen
peroxide (H2O2), peroxynitrite (ONOO−), and hydroxyl radical (•OH), and to explore the
molecular mechanisms by which the NLRP3 inflammasome senses changes in oxidative stress
through thioredoxin-interacting protein (TXNIP). Specific inhibition of the gp91phox subunit of
NADPH oxidase markedly reduced Hcys-induced caspase-1 activity and IL-1β production in
cultured podocytes. Concurrently, gp91phox−/− or administration of a gp91ds-tat peptide also
exhibited diminished glomerular inflammasome formation and activation in mice fed a folatefree (FF) diet to induce hyperhomocysteinemia and displayed glomerular protection as shown by
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prevention of hHcys-induced proteinuria, albuminuria and glomerular sclerosis. Interestingly,
dismutation of O2•− by 4-Hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl and administration of
H2O2 decomposer catalase either in cultured podocytes or hyperhomocysteinemic mice inhibited
hHcys-induced NLRP3 inflammasome aggregation and activation. Hyperhomocysteinemic mice
also demonstrated a significant increase in glomerular TXNIP binding to NLRP3, confirmed by
confocal microscopy, size-exclusion chromatography, and co-immunoprecipitation studies.
Blockade of TXNIP by genetic interference or by the calcium channel blocker verapamil
prevented this hHcys-induced TXNIP-NLRP3 binding, NLRP3 inflammasome formation and
activation, as well as protected hyperhomocysteinemic mice from glomerular dysfunction and
damaged morphology. In conclusion, hHcys-induced NADPH oxidase activation is importantly
involved in the switching on of NLRP3 inflammasomes in podocytes, where NADPH oxidasederived O2•− and H2O2 primarily contribute to NLRP3 inflammasome activation. TXNIP binding
to NLRP3 is a key signaling mechanism allowing NLRP3 inflammasome to sense these changes
in oxidative stress. These findings greatly enhance our understanding of the early pathogenesis of
hHcys-induced glomerular sclerosis, which may identify new therapeutic targets for prevention
or treatment of ESRD.

1
CHAPTER ONE
INTRODUCTION

Hyperhomocysteinemia (hHcys) has been reported to be an important pathogenic factor leading
to the progression of end-stage renal disease (ESRD) and related cardiovascular complications
associated with aging and different diseases [1-6]. Despite extensive studies, the mechanisms
mediating the pathogenic actions of hHcys are not yet fully understood. Recent studies in our
laboratory provided evidence that hHcys may generate its detrimental effects by activation of a
NOD-like receptor protein (NLRP3)-centered inflammasome in podocytes. The activation of
NLRP3 inflammasomes in podocytes turns on the inflammatory response, causing chronic
inflammation in glomeruli and ultimately leading to glomerular dysfunction and sclerosis. It has
been proposed that the activation of podocyte NLRP3 inflammasomes during hHcys is a critical
mechanism inducing kidney senescence and progressive degenerative glomerular dysfunction
and sclerosis [7]. However, it remains to be determined how the NLRP3 inflammasomes are
formed and activated during hHcys and how activated NLRP3 inflammasomes induce
glomerular degenerative pathology ultimately leading to end-stage renal disease (ESRD). The
current project provided convincing evidence suggesting that elevated extracellular Hcys
concentrations activate NADPH oxidase to produce reactive oxygen species (ROS) and thereby
activate NLRP3 inflammasomes in podocytes and increase the downstream recruitment of
inflammatory cells in glomeruli, resulting in local inflammation and ultimate glomerular
sclerosis. This redox activation of podocyte inflammasomes associated with hHcys may
represent an early mechanism switching on local inflammatory responses in glomeruli. The
following section will review our current understanding of hyperhomocysteinemia, NADPH
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oxidase in the kidney, and the regulation of NLRP3 inflammasomes and their interactions as it
pertains to the development of hHcys-induced glomerular injury and ESRD.

1.1

Hyperhomocysteinemia
A considerable amount of evidence indicates that plasma homocysteine (Hcys) levels are

elevated in patients with ESRD, where hyperhomocysteinemia (hHcys) occurs in about 85% of
chronic kidney disease patients due to impairments in Hcys metabolism and excretion [8-10].
These complications associated with hHcys have also been reported in a wide range of chronic
pathological conditions, including vascular dysfunction, neurological diseases, metabolic
disorders, the development of cancer, and many complications associated with aging [11-17]. In
the kidney, hHcys has been known to directly cause deleterious effects, promoting a vicious
cycle responsible for chronic kidney disease, where hHcys decreases renal function and leads to
further increased plasma Hcys levels due to decreases in Hcys excretion in the kidney [18]. In
humans, a plasma Hcys concentration <10μM is considered to be within the normal range, 10-16
μM is clinically defined as mild hHcys, 16-30 μM as moderate hHcys, 30-100 μM as
intermediate hHcys, and >100μM as severe hHcys [18].

1.1.1 Homocysteine metabolism
Homocysteine is a thiol-containing, nonessential amino acid derived from the metabolism
of the essential amino acid methionine. Upon activation of methionine by ATP, S-adenosylmethionine (SAM) undergoes demethylation to form S-adenosyl-homocysteine (SAH). This
reaction makes SAM a major methyl group donor for many reactions including the methylation
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of DNA. SAH is then subsequently hydrolyzed to form Hcys and adenosine by SAH hydrolase
[9].

As depicted in Figure 1, the remethylation of Hcys back to methionine or its
transsulfuration to cysteine are the two major catabolic pathways metabolizing Hcys. The
remethylation pathway involves the enzyme methionine synthase (MS) using N5methyltetrahydrofolate (5-MTHF) as the methyl donor that requires cobalamin (vitamin B12), as
well as the enzyme methylenetetrahydrofolate reductase (MTHFR) that requires folates as an
essential cofactor for the reduction and formation of 5-MTHF. The transsulfuration of Hcys is
carried out via two enzymes, cystathionine-β-synthase (CBS) and γ-cystathionase. Together with
serine, Hcys first undergoes irreversible condensation by CBS using pyridoxal-5-phosphate
(vitamin B6) as a cofactor. Cystathionine is then further broken down by γ-cystathionase into
cysteine, and converted into sulfates that are then excreted in the urine. The liver and kidney are
two major sites of Hcys metabolism, with an estimated ~70% of Hcys clearance occurring in the
kidneys [19-21].

There are multiple ways by which Hcys can become elevated [22]. First, an overwhelming
intake of methionine-rich animal protein not only overwhelms the transsulfuration pathway, but
can also lead to inhibition of the remethylation pathway due to the existing overload of
methionine. Second, nutritional deficiencies in the cofactors required for these reactions may
result in enzymatic dysfunction, thus impairing either pathway of Hcys clearance. This was
substantiated in the Framingham Heart Study, where elderly patients deficient in vitamin B6 and
folates exhibited hHcys and arteriosclerosis [23]. Finally, genetic polymorphisms in the enzymes
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themselves have been identified in ESRD patients, where mutations in the MTHFR enzyme are
correlated with increased plasma level of Hcys [24-25] and are also indicative of the patients‟
response to Hcys-lowering therapies.

Figure 1. Homocysteine metabolism. When methionine is activated by ATP, S-adenosylmethionine (SAM) undergoes demethylation to form S-adenosyl-homocysteine (SAH). SAH
is then subsequently hydrolyzed to form Hcys and adenosine by SAH hydrolase.
Homocysteine levels are regulated through its remethylation back to methionine by
methionine synthase (MS) or its transsulfuration to cysteine by cystathionine β-synthase.

1.1.2 Pathogenic role of hHcys in ESRD
Recognition of hHcys as a detrimental risk factor came from the early pioneer work carried
out by Dr. Kilmer S. McCully in the 1960s on the role of deficient Hcys-metabolizing enzymes
in childhood arteriosclerosis, and was the first to propose that elevated Hcys directly causes
arterial damage [3]. This seminal work has since expanded from arteriosclerosis and
cardiovascular disease to include many other degenerative diseases and pathological processes.
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Numerous clinical and epidemiological studies demonstrated positive correlations between
elevated plasma Hcys with ESRD and its related cardiovascular complications [26-30]. In nearly
every clinical study where plasma Hcys levels were measured in patients with renal
complications, there was a strong positive correlation between plasma levels of Hcys and serum
creatinine, a marker for declining renal function [31]. Additionally, these patients exhibited
plasma Hcys concentrations three to five times higher than healthy controls [32-34].

Despite the strong associations made between ESRD and the prevalence of hHcys, the
mechanisms underlying Hcys-induced pathogenesis of glomerular injury and dysfunction are still
poorly understood. The detrimental or sclerotic actions of hHcys have been attributed to altered
extracellular matrix metabolism, reduced protection from nitric oxide (NO), and increased
production of ROS. With a diminished capacity to maintain the extracellular matrix (ECM) [7,
35-38], hyperhomocysteinemic conditions cause a serious imbalance in matrix synthesis and
degradation, resulting in vascular remodeling. Besides alterations in ECM metabolism, Hcys has
been shown to alter the local oxidative state and elevate levels of superoxide (O2•−) by
uncoupling NO synthase, directly trapping NO itself, and activating NADPH oxidase, the
dominant source of O2•− in many non-phagocytic cells, especially in the kidney [39-43].
Together, these effects of inhibiting extracellular matrix degradation and the production of local
oxidative stress all contribute to the sclerotic process that eventually leads to the loss of renal
function [37-38].

Studies from our laboratory and by others have demonstrated that hHcys directly induces
glomerular injury, affecting glomerular endothelial cells, mesangial cells, and podocytes [44-46].
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Mechanistically, our laboratory has shown that hHcys-induced glomerular sclerosis and ultimate
ESRD involve N-methyl-D-aspartate (NMDA) receptor activation and occur in an nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase-dependent manner, which is associated with
the activation of small GTPase Rac1 and guanine nucleotide exchange factor Vav2 [7, 38, 44].
Additionally, our laboratory has provided substantial evidence that increases in ROS production
are a result from activation of NADPH oxidase by Hcys [7-8, 47]. It has been shown that
knockout of the gp91phox gene, a catalytic subunit of NADPH oxidase, is protective towards
Hcys-induced glomerular injury in mice [48], preventing the accumulation of O2•− and
consequent podocyte damage, attenuating proteinuria, and preserving glomerular filtration rate
when compared to hyperhomocysteinemic wild-type mice. These results suggest a crucial role
for functioning NADPH oxidase in the sclerotic mechanism of hHcys during the progression of
glomerular injury. Most recently, Nod-like receptor protein 3 (NLRP3) inflammasome-mediated
caspase-1 activation and IL-1β production were found to be necessary for hHcys-induced
podocyte and glomerular dysfunction, where inhibition of NLRP3 inflammasomes either by
apoptosis-associated speck-like protein (ASC) gene silencing or pharmacological inhibition of
caspase-1 attenuated hHcys-induced injury [49]. However, further studies are warranted to fully
understand the mechanisms mediating Hcys-induced NLRP3 inflammasome activation and its
contribution to glomerular injury.

1.1.3 Murine models of hHcys
hHcys can be experimentally modeled in animals through dietary and genetic
manipulations, modifications, or a combination of the two. In order to hereditarily model hHcys,
the mouse genes for the enzymes CBS, MTHFR, and MS have been genetically modified.
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CBS−/− mice exhibit severely elevated levels of plasma Hcys (>200 μM), but rarely survive
beyond 3-5 weeks of age due to the severity of hHcys [50]. Therefore, the use of heterozygous
CBS mice, which develop mild hHcys, is much more common [50-52]. MTHFR−/− mice,
developed in 2001, only exhibit moderate hHcys but also undergo difficulties in survival after
just 5 weeks of age [53-54]. Finally, homozygous knockout of the Mtr gene, which encodes the
enzyme MS, is embryonic lethal, but heterozygous mutation only produces mild hHcys (5-10
μM) [55]. The advantage of these genetic models is the avoidance of potential side effects that
may arise from the global deficiency of essential cofactors, thereby making these genetic
approaches commonly used.

In regards to dietary approaches used to elevate plasma Hcys, these interventions include
directly adding Hcys to the drinking water, overwhelming the metabolic pathway depicted in
Figure 1 through administration of a high-methionine diet, limiting Hcys transsulfuration by
restricting dietary intake of vitamin B6, or limiting Hcys remethylation back to methionine
through a folate or vitamin B12-deficient deficient diet. However, excessive plasma methionine is
not a clinically observed phenomenon in patients with hHcys, thereby limiting the translational
validity of the high-methionine diet. Generally, human patients with hHcys display deficiencies
in folate, vitamin B6, or vitamin B12, making these particular diet-induced experimental models
of hHcys directly relevant to the human condition [56]. Therefore, a model of folate-free (FF)
diet-induced hHcys was selected for the current study.
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1.2

NADPH oxidase in the kidney
Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, an enzyme generating

O2•− from oxygen and NADPH, can primarily be found in phagocytic cells, where its primary
role is to generate large amounts of reactive oxygen to carry out traditional immune functions
[57]. However, this enzyme and its isoforms are also found spread throughout various organs,
where its primary function is not for defense and to kill non-host organisms, but instead to
produce small amounts of O2•− to act a signaling messengers [58]. In the kidney, there are many
enzymatic systems that contribute to the production of ROS, including mitochondrial oxidases,
xanthine/xanthine oxidase, lipoxygenases, cyclooxygenases, and cytochrome P450s. However,
unlike these other systems where the production of O2•− is a secondary process, NADPH oxidase
is the only enzyme identified to produce O2•− as its principal function. NADPH oxidase has been
considered as the major source of O2•− in the kidney, specifically in the renal cortex [39]. Its
action relies on an enzymatic complex with five subunits including two membrane-associated
flavocytochrome components (gp91phox and p22phox), three cytosolic components (p40phox,
p47phox, p67phox), and a GTPase, Rac1, all being reported to be expressed in the kidney [39].
When stimulated, the translocation of its cytosolic components to the subunits in the membrane
results in the transfer of electrons from NADPH to form O2•− from oxygen. The generation of
O2•− by NADPH oxidase is the precursor for other species of reactive oxygen, including
hydrogen peroxide, hydroxyl radical, peroxynitrite, hypochlorous acid, and singlet oxygen [5861]. Interestingly, our laboratory and others have found increased local oxidative stress, for the
most part mediated through NADPH oxidase, to be strongly associated with the cardiovascular
complications related to ESRD as well as with the damaging effects of hHcys [47, 62-65].
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1.2.1 Regulation of NADPH oxidase by Rac1 GTPase and GEF Vav2
The activation of NADPH oxidase is dependent on the aggregation of its membrane and
cytosolic components to the plasma membrane, which requires phosphorylation of the p47phox
subunit, its translocation to the membrane along with the remaining cytosolic subunits, proteinprotein interactions between all components, and Rac GTPase activation [66-68]. Rac1 is a
member of the Rho-family of GTPases which are binary switches important for the regulation of
many cellular functions including cell cycle progression, apoptosis, differentiation, adhesion, and
migration and vesicle trafficking through control of actin polymerization [69-71]. In 1991, Abo
et al identified phagocytic NADPH oxidase to be the first Rac effector [72]. Since then, a central
role for Rac, in particular, Rac1, has been established in the regulation and activation of NADPH
oxidase.

NADPH oxidase activation and production of O2•− are dependent on the switching of Rac1
between two conformations – the active GTP-bound and inactive GDP-bound states. The cycling
of Rac1 between these two states is highly and mainly regulated by GTPase-activating proteins
(GAPs) and guanine nucleotide exchange factors (GEFs). GAPs promote GTP hydrolysis and
push GTPases to the inactive GDP-bound state, while GEFs facilitate the exchange of GDP for
GTP to promote the active GTP-bound state [73]. With over 30 GEFs identified, the Vav
subfamily of GEFs has been shown to exhibit high specificity to and importantly regulate Rac
GTPase and NADPH oxidase [74-77].

With substantial evidence our laboratory has demonstrated these NADPH oxidaseactivating pathways to be involved in Hcys-induced glomerular injury. These previous studies
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have shown that through de novo ceramide synthesis, Hcys stimulated NADPH oxidase
activation by enhancing Rac GTPase activity in rat mesangial cells [65]. Furthermore, inhibition
of GEF Vav2, the predominant isoform was found to be expressed in these cells, prevented
Hcys-induced increase in Rac1 activity and consequent activation of NADPH oxidase [38, 44].
Together, these results signify the importance of Rac1 and its regulation by Vav2 in the
development of hHcys-induced production of oxidative stress and glomerular injury. However,
how ROS from NADPH oxidase activation produces glomerular injury remains unclear, which
will be a major focus of the present study.

1.2.2 Physiological and pathological role of NADPH oxidase in the kidney
ROS play a very critical role in normal physiology in a variety of renal activities. It has
been reported that in the kidney the major source of ROS production is through NADPH oxidase
[78-79]. Many homeostatic processes of the kidney are affected by the activation of NADPH
oxidase, including renal glucogenesis and transport, tubuloglomerular feedback, hemodynamics,
and electrolyte transport [80]. Especially in the diabetic kidney, NADPH oxidase regulates
proximal tubular cell glucose balance as well as the transport of glucose through sodium/glucose
cotransporters [81-82].

O2•− increases tubuloglomerular feedback and, therefore, NADPH

oxidase also helps control the hemodynamic response in situations of high salt [83]. Along the
nephron, NADPH oxidase has been demonstrated to be important for control of proximal tubular
Na+/K+-ATPase activity, Na+/K+/2Cl– cotransporters, and epithelial sodium channel (ENaC)
activity [84-86], all suggesting regulation of tubular ion transport by NADPH oxidase.

11
However, as with any organ, the kidney is vulnerable when exposed to continuous,
excessive levels of oxidative stress [87-88]. Diabetic mice have increased gp91phox/Nox2
expression in the renal cortex, where Nox2 downregulation proved protective from diabetesinduced oxidative stress, glucose intolerance, and renal fibrosis [89]. O2•− production has been
demonstrated to impair endothelial function and perhaps lead to increased arterial responsiveness
to vasoconstricting stimuli [90-91]. Previous studies have demonstrated NADPH oxidase-derived
O2•− production to also regulate renal medullary blood flow, where persistently increased
oxidative stress may contribute to the development of hypertension [92]. During hHcys, our
laboratory has demonstrated the importance of NADPH oxidase in the pathogenesis of hHcysinduced glomerular sclerosis by showing that inhibition or deletion of NADPH oxidase and its
subunits, in particular, gp91phox, can attenuate glomerular damage and restore normal renal
function [48]. Similarly, antioxidants have been shown to ameliorate Hcys-induced toxicity
[64]. The current study seeks to further explore the mechanisms by which elevated Hcys and its
activation of NADPH oxidase lead to glomerular dysfunction and the pathological progression to
ESRD via NLRP3 inflammasomes, an intracellular inflammatory machinery.

1.3

The NLRP3 inflammasome
The Nod-like receptor protein 3 (NLRP3) inflammasome, found to be a key mediator of the

innate immune system in response to a host of initiating factors, has been extensively
demonstrated to be activated in response to a wide range of danger signals derived from disease
and infection [93-97]. Oligomerization of the NLRP3 protein, the adaptor molecule apoptosisassociated speck-like protein containing a CARD (caspase recruitment domain) (ASC), and the
cysteine protease caspase-1 forms this cytosolic multiprotein complex, causing the maturation of
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pro-inflammatory cytokines IL-1β and IL-18. It is assumed that this inflammasome activation
and extracellular secretion of inflammatory cytokines sense diverse danger signals and instigate
the innate inflammatory response, in particular, the sterile inflammatory response during chronic
degenerative diseases [98-99]. More recently, NLRP3 inflammasome activation has been
reported to trigger many other cell injury responses far beyond inflammation [100]. It has been
assumed that the inflammatory and non-inflammatory actions produced by activation of NLRP3
inflammasomes together induce cell or tissue degenerative injuries during many chronic diseases
such as atherosclerosis, Alzheimer‟s diseases, cancer, metabolic disorders and gout [101]. Recent
studies in our laboratory have found that the activation of these inflammasomes during hHcys
turns on local inflammatory response in glomeruli, inducing kidney senescence and progressive
degenerative glomerular dysfunction and sclerosis, where active caspase-1 promotes maturation
of IL-1β to induce decreases in nephrin expression in podocytes [49].

1.3.1 Types of inflammasomes
The pro-inflammatory cytokine IL-1β, one of most powerful inflammatory mediators, is the
most studied cytokine due to its key role in the inflammatory process. Jurg Tschopp and his
research group identified the inflammasome as the molecular platform required for the activation
of caspase-1, previously known as interleukin converting enzyme (ICE), which is responsible for
the maturation of IL-1β from its precursor form [102]. There are various types of inflammasomes
centered around different members of the Nod-like receptor (NLR) family, and although 23 NLR
genes have been identified to date, only a few form oligomeric complexes and result in
posttranslational activation of caspases [103]. Although caspases are generally thought to be pro-
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apoptotic, a subclass of inflammatory caspases is responsible for the maturation of inactive
cytokine precursors like IL-1β and IL-18 [104].

The major caspase-processing inflammasomes currently found throughout the literature
include the NLRP1, NLRC4, AIM2, and NLRP3 inflammasomes. The NLRP1 inflammasome,
shown to minimally require only NLRP1 and caspase-1 for its activation, has been demonstrated
to be sensitive to bacterial cell wall component muramyl dipeptide (MDP) as well as Bacillus
anthracis lethal toxin [105-106]. However, it was also shown that the addition of the adaptor
protein ASC resulted in a more robust activation of the NLRP1 inflammasome. The NLRC4
inflammasome is most associated with caspase-1 activation and IL-1β in response to various
gram-negative bacteria. As with the NLRP1 inflammasome, NLRC4 can also directly interact
with the CARD domain of caspase-1, and it has been hypothesized that NLRC4 activates
caspase-1 upon sensing the presence of bacteria-specific and conserved proteins: flagellin, rod,
and needle [107-109]. AIM2 inflammasomes become activated by preferentially binding to
cytosolic double-stranded DNA, where ASC then becomes recruited to AIM2, leading to the
proteolytic cleavage of caspase-1 [110].

However, because of its important role in sterile inflammation, the most widely studied
member of the NLR family is the NLRP3 inflammasome. The NLRP3 inflammasome responds
to a very diverse range of activators, including those of microbial origin, endogenous danger
signals, and exogenous non-microbial stimuli. It has become of great scientific interest in not
only trying to identify activators of the NLRP3 inflammasome, but also importantly trying to
understand how such a broad range of stimuli can activate the same molecular platform [111].
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1.3.2 Exogenous and endogenous NLRP3 inflammasome activators
Many studies have provided evidence of NLRP3 inflammasome activation in response to a
whole host of various exogenous danger signals and microbes, including the influenza virus,
adenoviruses, Staphylococcus aureus, E. coli, Neisseria gonorrhoe, and Candida albicans [112117]. Although the ability of the toxins from many of these microbes to form membrane pores is
linked to an ability to activate NLRP3, it still remains unknown whether a single or a
combination of pathogen-associated molecular patterns (PAMPs) is directly responsible for
inflammasome activation. Another group of NLRP3 stimulators are the non-microbial
phagocytosed materials, where monosodium urate crystal accumulation associated with gout was
one of the first inflammatory diseases linked to the activation of NLRP3 [118]. In a similar
manner, silica, asbestos, and aluminum salts have also been shown to trigger caspase-1 cleavage
and IL-1β production via NLRP3 activation [119-120].

The activation of NLRP3 inflammasomes to a very wide range of endogenous danger
signals is what makes NLRP3 unique among all other inflammasomes. Excessive levels of ATP
was described as one of the first endogenous damage-associated molecular patterns (DAMPs) to
induce NLRP3 inflammasome formation and activation, a mechanism involving high
concentrations of extracellular ATP binding to the purinergic P2X7 receptor [121]. The
aggregation of endogenous peptides like amyloid-β are also sensed by NLRP3 [122], leading to
the production of pro-inflammatory cytokines, which explains the elevation of IL-1β detected in
the brains of patients with Alzheimer‟s disease [123]. Cholesterol crystals are known to cause
phagolysosomal damage, and have been recently shown to lead to the early activation of NLRP3
and the promotion of a pro-atherosclerotic phenotype [124], while endogenous danger signal of
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trauma, hyaluronan, also triggers chemokine release in affected tissues through NLRP3 [125].
Finally, damage to pancreatic islet cells by hyperglycemia caused NLRP3 inflammasome
activation, ultimately developing to glucose intolerance and insulin resistance in a murine model
of diabetes [126]. We have since demonstrated that the elevated levels of the amino acid Hcys
also cause NLRP3 inflammasome formation and activation, leading to podocyte injury and
eventually glomerular sclerosis [49]. Inhibition of NLRP3 via ASC shRNA or the caspase-1
inhibitor, WEHD, prevented Hcys-induced detrimental effects on glomerular structure and
dysfunction, signifying a critical role for NLRP3 in the pathogenesis of ESRD related to hHcys
[49].

1.3.3 NLRP3 inflammasomes in disease
Deficiencies in this multiprotein complex have been associated with autoimmune disorders
such as familial Mediterranean fever and Muckle-Wells syndrome, but aberrant NLRP3
inflammasome activation has extended to many traditionally considered non-inflammatory
disorders including diabetes, obesity, silicosis, liver toxicity, and kidney diseases [118, 120, 127130]. Here we will focus on the role of NLRP3 in metabolic disorders.

Demonstrated in clinical trials, levels of circulating IL-1β are predictive of type 2 diabetes
[131], and treatment with IL-1β antagonist anakinra demonstrated protective effects in these
diabetic patients [132]. NLRP3−/− mice as well as adipocytes isolated from NLRP3−/− mice
exhibited marked improvement in glucose tolerance and insulin, with reduced IL-1β production
[133]. Most interestingly, weight loss in obese patients with type 2 diabetes resulted in a
reduction of NLRP3 expression and activity in adipose tissue and improved glucose handling
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[134], altogether suggesting an important role for NLRP3 in the pathogenesis of type 2 diabetes
associated with obesity. Highly associated with obesity and diabetes, these patients are also at
risk for cardiovascular disease (CVD). Recent studies have defined the potential benefit of
caspase-1 inhibition as an intervention for myocardial infarction and ischemia [135-136]. NLRP3
inflammasome

activation

occurs

mainly

in

cardiac

fibroblasts

after

myocardial

ischemia/reperfusion injury, where ASC−/− protects mice from phagocytic infiltration,
myocardial fibrosis and dysfunction, and enlarged infarct size [137].

NLRP3−/− has also been shown to protect mice from both renal ischemic acute tubular
necrosis as well as the progression of chronic kidney disease (CKD) in the unilateral ureteral
obstruction model [138-139]. NLRP3 mRNA levels correlated with renal function in CKD
patients, and IL-1β and IL-18 levels are increased in both animal models and patients with CKD
[139-140]. Thus, these studies strongly support a crucial role for NLRP3 inflammasome
involvement in the progression of acute kidney injury and CKD. Glomerular IL-1β mRNA is
enhanced after the first day of the mouse model of streptozotocin-induced diabetic
glomerulosclerosis [141]. With podocytes being a major site of IL-1β synthesis [142], we further
demonstrated that hHcys-induced glomerular injury and IL-1β production occurs in an NLRP3dependent mechanism [49].

1.4

Regulation of NLRP3 inflammasome activation
Despite rapid and extensive efforts in identifying various agents that stimulate the NLRP3

inflammasome, the underlying mechanisms by which these diverse danger signals activate the
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same molecular machinery remain poorly understood. This next section will review the current
status of this controversial area.

1.4.1 Primary models of NLRP3 inflammasome activation
The activation of NLRP3 inflammasomes has been implicated in a growing number of
diverse pathological conditions, ranging from bacterial infections to cardiovascular dysfunction
and metabolic syndrome [124, 143-145]. Despite the plethora of studies demonstrating the
widespread prevalence of NLRP3 activation in disease, it remains poorly understood how this
unique molecular machinery is activated in response to a very diverse range of stimuli.
Particularly in phagocytes such as macrophages, it is known that NLRP3 inflammasome
activation requires two signals – a „priming‟ transcriptional step that involves TLR/NF-κB
signaling, followed by post-translational regulation responsible for the oligomerization of the
inflammasome components and the maturation of pro-inflammatory cytokine IL-1β [146-147].
In some other cells like endothelial cells and podocytes, such a two signal pattern may not be
needed, where a constitutive or basal expression of pro-IL-1 and other associated molecules may
be adequate to form and activate NLRP3 inflammasomes, albeit to a lesser extent than those in
phagocytes, but sufficient enough to produce pathological changes, in particular, in chronic
degenerative disease [142]. Whether or not its activation needs priming, NLRP3 inflammasomes
are usually triggered through three major signaling pathways, stimulated either separately or in
combination. In this regard, K+ efflux and low intracellular K+ concentration caused by
activation of the P2X7 purinergic receptor in response to ATP is considered as an important
signaling pathway to activate NLRP3 inflammasomes [115, 148]. ATP has also been
demonstrated to cause transient pore formation through pannexin-1, allowing NLRP3 stimulators
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to cross the plasma membrane and directly activate inflammasome assembly [121]. Another
activating mechanism of NLRP3 inflammasomes is related to the actions of lysosomal enzymes
in response to asbestos, silica, monosodium urate (MSU) crystals, and other stimulations that are
too large to cross the membrane and instead are taken up into the cell via phagocytosis. When
frustrated or incomplete phagocytosis occurs, lysosomal rupture or permeability changes release
cathepsin B, a lysosomal enzyme that activates NLRP3 inflammasomes [120]. In addition,
reactive oxygen species (ROS) produced by many known activators of NLRP3 inflammasomes
are also shown to be an critical mechanism triggering NLRP3 inflammasome formation and
activation in response to many exogenous stimuli as well as endogenously produced or secreted
molecules from damaged cells such as DAMPs [149]. It has been demonstrated that the crystal
structure of NLRP3 has a highly conserved disulfide bond connecting the PYD domain and the
nucleotide-binding site domain, which is highly sensitive to or regulated by altered redox states
[150].

1.4.2 ROS and its role in NLRP3 inflammasome activation
Due to the leucine-rich repeats (LRR) found in the C-terminus of NLRP3, it was originally
hypothesized to act as a cytosolic receptor and directly bind to a ligand. However, this
hypothesis was neglected after the discovery of many diverse stimuli that were all found to
activate NLRP3, and it became much more accepted that NLRP3 sensed some molecular
intermediate generated by these broad activators. The generation of ROS was one of the first
intermediates discovered to be common to ATP, MSU, asbestos, and silica-induced NLRP3
activation [120]. Since then, there have been many conflicting reports regarding the role of ROS
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in this process, creating much controversy in trying to understand the regulation of NLRP3
inflammasome activation.

Some of the first studies reported the importance of NADPH oxidase-derived ROS in
activating NLRP3 in response to ATP, asbestos, and silica [120, 151-152]. This has since been
extended to more recent reports, where NADPH oxidase inhibition via diphenylene iodonium
(DPI) or more specifically through gp91phox blockade, can prevent free fatty acid, TNFα, and
atheroprone oscillatory flow-induced NLRP3 inflammasome activation [153-155]. It has been
disputed, however, that ROS are not involved in the activation of NLRP3 inflammasomes, but
instead are derived from Toll-like receptors (TLRs) and contribute to the priming mechanism
responsible for the transcriptional upregulation of NLRP3 and pro-IL-1β [156]. Additionally,
macrophages isolated from gp91phox−/− mice or patients with chronic granulomatous disease
(CGD) and deficient NADPH oxidase display normal inflammasome function when challenged
with NLRP3 agonists [119, 157]. Caspase-1 activation and IL-1β secretion in response to cyclic
stretch was undisturbed in murine alveolar macrophages, even in those isolated from gp91phox−/−
mice, demonstrating the dispensability of NADPH oxidase to NLRP3 activation in this particular
mechanism [158]. Alternatively, there is an emerging role for mitochondrial ROS (mtROS) in
the mechanism of NLRP3 inflammasome activation [159-160]. The same study by Wu et al
revealed that mtROS inhibition by mitochondrial antioxidant SS-13 prevented cyclic stretchinduced IL-1β. These greatly varying effects between ROS of NADPH oxidase or mitochondrial
origin suggest that the mechanism of NLRP3 activation may be a very cell and stimuli-specific
phenomenon.
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While there is a plethora of evidence supporting ROS activation of NLRP3
inflammasomes, the exact mechanisms by which NLRP3 senses these changes in oxidative stress
are still largely unknown. In this regard, the canonical work done by Zhou et al provided strong
evidence of thioredoxin-interacting protein (TXNIP) as a binding partner to NLRP3, where
association between these two proteins was necessary for downstream inflammasome activation
[126]. TXNIP, the negative regulator of the antioxidant thioredoxin (TRX), may timedependently dissociate from TRX to bind with NLRP3 leading to inflammasome formation and
activation. This study also seeks to determine the involvement of TXNIP as a potential mediator
between hHcys-induced oxidative stress and consequent NLRP3 inflammasome activation.

1.5

Aims of the study
The hypothesis to be tested in the present study states that: NADPH oxidase redox

signaling mediates inflammasome activation in podocytes and glomerular injury during hHcys,
ultimately resulting in glomerular sclerosis and ESRD.

The specific aims are:
1. To determine whether the in vitro formation and activation of NLRP3 inflammasomes by
Hcys are associated with NADPH oxidase-mediated redox signaling in mouse podocytes
and to explore the mechanisms mediating the action of NADPH oxidase-derived ROS on
this inflammasome activation, including the potential involvement of specific ROS and
TXNIP.
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2. To determine whether in vivo hHcys-induced activation of NLRP3 inflammasomes and
associated glomerular injury are blocked by selective inhibition of local NADPH oxidase
activity or by knocking out the gp91phox gene in mice.
3. To determine whether in vivo activation of NADPH oxidase by overexpression of Vav2
gene, an endogenous NADPH oxidase activator, enhances the inflammasome formation
and glomerular injury in glomeruli of hyperhomocysteinemic mice.

The overall hypothesis and the specific aims of this project are schematically represented in
Figure 2.

Figure 2. The working hypothesis. Through its inhibition both in vitro and in vivo, Aim 1
and 2 will explore the role of NADPH oxidase in Hcys-induced NLRP3 inflammasome
activation. These aims will include further understanding which ROS are responsible for
NLRP3 activation as well as determine the potential role of TXNIP in this mechanism. Aim 3
will further substantiate the role of NADPH oxidase by observing the effects of its
overexpression of its endogenous activator and determining if that is sufficient to activate
NLRP3 inflammasomes.
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CHAPTER TWO
GENERAL METHODS

2.1

Culture of mouse podocytes
A conditionally immortalized mouse podocyte cell line, graciously provided by Dr. Paul E.

Klotman (Division of Nephrology, Department of Medicine, Mount Sinai School of Medicine,
New York, USA), was constructed with a temperature-sensitive variant of the simian virus
(SV40) containing a large T antigen (tsA58) inducible by interferon-γ at 33°C, allowing for
cellular proliferation. These cells were cultured and maintained on collagen-coated flasks in
RPMI 1640 medium supplemented with 10% fetal bovine serum, 10 U/ml recombinant mouse
interferon-γ, 100 U/ml penicillin and 100 mg/ml streptomycin.

The podocytes were then

passaged and allowed to differentiate to a mature cell type at 37°C for two weeks without
interferon-γ before use in experiments.

2.1.1 In vitro podocyte treatments
Podocytes were treated with L-Hcys, which is considered to be the pathogenic form of
Hcys, at a concentration of 40 μM for 24 hours, a dose and treatment time chosen based on
previous studies [49]. Pharmacological NADPH oxidase inhibitors apocynin (100 μM),
diphenylene iodonium (10 μM), and gp91ds-tat peptide (5 μM) were added to the cells 1 hour
prior to Hcys treatment. ROS scavengers were used at the following doses: TEMPOL (100 μM),
catalase (50 U/ml), tetramethylthiourea (TMTU, 100 μM), manganese (III) tetrakis (1-methyl-4pyridyl) porphyrin (MnTMPyP, 25 μM), polyethylene glycol-superoxide dismutase (PEG-SOD,
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50 U/ml), and ebselen (10 μM). The calcium channel blocker verapamil, which has been
demonstrated to be a potent inhibitor of TXNIP, was used at a dose of 50 μM.

2.1.2 siRNA transfection
ASC and gp91phox small interfering RNAs (siRNA) were purchased from Qiagen (Valencia, CA),
while TXNIP siRNA was purchased from Life Technologies (Grand Island, NY). A
nonsilencing, double-stranded RNA (Qiagen) was used as a negative control. Briefly, podocytes
were incubated with the serum-free medium for 15 minutes prior to ASC, gp91phox, TXNIP, or
scrambled siRNA transfection using the siLentFect Lipid Reagent (Bio-Rad, Hercules, CA)
according to the manufacturer‟s instructions. After 18 hours of incubation at 37°C, the medium
was changed, and cells were treated with 40 μM Hcys for 24 hours.

2.1.3 Nucleofection
Podocytes were transfected with a scrambled or Vav2 shRNA, or a constitutively active form of
Vav2 (oncoVav2) plasmid directly to the nucleus via nucleofector technology developed by
Lonza (Basel, Switzerland). This dominant active oncoVav2 plasmid containing an N-terminal
truncation was a generous gift from Dr. Keith Burridge from the University of North Carolina at
Chapel Hill [161]. The nucleofector technology involves the temporary creation of small pores in
the membrane through electrical impulses together with cell-specific solutions to deliver
substrates through the cytoplasm and into the nuclear membrane. Podocytes were trypsinized,
counted, and 1 x 106 cells were gently centrifuged at 90xg for 10 min at RT. Cells were
resuspended in SF Cell Line nucleofector solution containing 2 μg plasmid DNA and then
transferred into a certified cuvette. The cuvette was placed into the nucleofector system and
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subject to cell-type specific program CM-137, chosen based on optimization experiments.
Nucleofected cells were resuspended with pre-warmed medium and transferred to culture plates
for use in experiments.

2.2

Mouse model of hyperhomocysteinemia
For all animal studies, eight-week old male C57BL/6J mice (Jackson Laboratories, Bar

Harbor, ME, USA) were uninephrectomized to accelerate renal injury, as described previously
[162]. After allowing a week for recovery after surgery, mice were fed either a normal diet or a
folate-free (FF) diet for 4 weeks to induce hHcys [48]. Folates are a cofactor required for the
breakdown of Hcys, and restricting folate consumption in the diet prevents the remethylation of
Hcys back to methionine, causing elevated levels of plasma Hcys [38, 163]. After 4 weeks of
treatment, all mice were placed in metabolic cages and urine samples were collected for 24 hours
before collecting blood samples, sacrificing, and harvesting tissues for analysis. The Institutional
Animal Care and Use Committee of Virginia Commonwealth University approved all protocols.

2.2.1 In vivo mouse treatments
For in vivo NADPH oxidase inhibition studies, gp91phox−/− mice (Jackson Laboratories, Bar
Harbor, ME, USA) as well as gp91phox+/+ mice that were injected intraperitoneally with gp91dstat or scrambled gp91ds-tat at a dose of 5 mg/kg every day were used [164]. Developed by
Pagano and his research group, this custom gp91ds-tat peptide constructed with a tat sequence
(first 9 amino acids) to enable cell membrane penetration and inhibition of NADPH oxidase, was
synthesized by RS Synthesis (Louisville, KY) with the following amino acid sequence:
YGRKKRRQRRR-CSTRIRRQL [165].
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For in vivo ROS scavenging studies, mice received vehicle, 4-Hydroxy-2,2,6,6tetramethylpiperidine-1-oxyl (TEMPOL), or catalase treatment and were fed either a normal diet
or a FF diet for 4 weeks to induce hHcys. 3 mM TEMPOL (~100 mg/kg/day, Sigma, St. Louis,
MO) was administered to the mice through the drinking water, while catalase (Sigma) was
injected intraperitoneally at a dose of 5 kU/kg/day [166-167].

For in vivo TXNIP inhibition studies, one group of mice received plasmids encoding either
the reporter gene luciferase or TXNIP short hairpin RNA (shRNA) by ultrasound-microbubble
transfection. Another group of mice received verapamil in the drinking water (1 mg/ml),
equating to a dose of approximately 100 mg/kg/day [168].

For in vivo Vav2 overexpression and inhibition studies, mice received either Vav2 shRNA
or constitutively active variant oncoVav2 via ultrasound-microbubble transfection. Following
transfection, mice were maintained on either the normal or FF diet for 4 weeks. All of these
treatment paradigms can be found in Figure 3.
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Figure 3. Different mouse treatment groups used in the present study.
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2.2.2 Mouse genotyping
Each mouse used in the in vivo NADPH oxidase inhibition studies was genotyped for the
gp91phox gene to confirm its deletion prior to use in experiments. Briefly, genomic DNA
extracted from the tail was subjected to PCR amplification using taq DNA polymerase
(Invitrogen, Inc., Grand Island, NY). Using a Bio-Rad iCycler, PCR was performed using a
validated protocol provided by Jackson Laboratories: denaturing the DNA at 94°C for 3 min,
followed by a first round of 12 cycles: 94°C for 20 sec, 64°C for 30 sec (-0.5°C per cycle), 72°C
for 35 sec, and then a second round of 25 cycles: 94°C for 20 sec, 58°C for 30 sec, 72°C for 35
sec, and a final extension step at 72°C for 2 min. The following gp91phox-specific primers were
provided by Jackson Laboratory and used for genotyping: oIMR0517 (AAG AGA AAC TCC
TCT GCT GTG AA), oIMR0518 (CGC ACT GGA ACC CCT GAG AAA GG), and oIMR0519
(GTT CTA ATT CCA TCA GAA GCT TAT CG). The PCR products were separated by gel
electrophoresis on a 3% agarose gel, visualized by ethidium bromide fluorescence, and compared
to a 100 bp DNA ladder (New England Biosystems, Ipswich, MA).

2.2.3 Ultrasound-microbubble transfection and in vivo imaging
After allowing one week for recovery from uninephrectomy surgery, a preparation of
plasmid encoding either TXNIP shRNA, oncoVav2, Vav2 shRNA or the reporter gene luciferase
was mixed with cationically charged Optison microbubbles (GE Healthcare, Piscataway, NJ),
then injected into the femoral artery and locally transfected to the kidney by sonoporation with a
continuous wave output of 1 MHz at 10% power output at 30 sec intervals for a total of 6 min.
To daily monitor the efficiency of gene expression, mice were anesthetized with ketamine (100
mg/kg IP) and xylazine (10 mg/kg IP), and an aqueous solution of luciferin (150 mg/kg IP) was
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injected 5 minutes before imaging, as described previously [49]. The anesthetized mice were
imaged using the Xenogen IVIS200 in vivo imaging system (Perkin Elmer, Waltham, MA).
Photons emitted from luciferase-expressing cells and transmitted through tissue layers were
quantified over a defined period of time ranging up to 5 minutes using the software program
Living Image (Xenogen) as an overlay on an Igor program (Wavemetrics). If transfection was
not detected by in vivo imaging, the mice were sacrificed and experiments terminated due to
unsuccessful transgene expression.

2.3

Preparation of cell and tissue homogenates
Cell homogenates were freshly prepared by washing cultured cells three times with ice-

cold PBS, followed by scraping the cells in ice-cold sucrose buffer (20 mM Tris-Hcl, 250 mM
sucrose, pH 7.2) and transferring to a microcentrifuge tube pre-chilled on ice. Renal cortical
tissue lysate was prepared by homogenizing the tissue in ice-cold sucrose buffer using a
motorized microcentrifuge conical pestle. These homogenates from cells and tissues then
underwent sonication using a handheld sonicator for 10 pulses on ice. This was repeated until all
samples underwent sonication for a total of 3 times. Samples were incubated on ice for 30
minutes prior to centrifugation at 7,500 x g for 15 minutes at 4° C to remove cellular debris, and
the supernatant was transferred to a new, pre-chilled microcentrifuge tube for use in downstream
assays.

2.4

Microsome preparation
Podocyte lysate was subject to centrifugation at 1,000g for 10 minutes at 4° to remove the

nuclear fraction. The collected supernatant was then centrifuged at 10,000g for 20 minutes at 4°
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to remove the granular fraction. The resulting supernatant was assayed for protein concentration
to normalize protein loading across all samples, and subject to a final centrifugation at 100,000g
for 90 minutes at 4° to separate the microsomes (pellet) and cytosolic fraction (supernatant). The
isolated pellet was then immediately assayed for O2•− production using electromagnetic spin
resonance analysis as described in the following sections.

2.5

Western blot analysis
Cell or tissue homogenates were loaded in equal protein concentration (10-20 μg) and run

at 120V for 1.5 hrs using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE). The proteins were transferred from the gel onto polyvinylidene fluoride nitrocellulose
membranes for 1 hr at 100V. After blocking the membranes for 1 hr with 5% non-fat dry milk in
Tris-buffered saline with 0.1% Tween 20 (TBS-T), the membrane was probed with rabbit antiASC (1:1000, Enzo, Farmingdale, NY), rabbit anti-NLRP3 (1:500, Abcam, Cambridge, MA) or
mouse anti-TXNIP (1:1000, MBL, Woburn, MA) overnight at 4°C, followed by incubation with
the appropriate horseradish peroxidase-labeled IgG (1:5000) at RT for 1 hr. The bands were
detected by chemiluminescence and visualized on Kodak Omat X-ray films, and band density
was analyzed by ImageJ software (NIH, Bethesda, MD).

2.6

Confocal microscopy and immunofluorescence of frozen tissue and cell slides
Indirect immunofluorescent staining was used to observe the colocalization of

inflammasome and podocyte marker proteins in both cultured cells as well as frozen mouse
kidney sections. Podocytes seeded in 8-well chambers were fixed in 4% paraformaldehyde
(PFA), washed with phosphate-buffered saline (PBS), and blocked with 1% bovine serum
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albumin (BSA) in PBS before being incubated in primary antibodies (1:100) overnight at 4°C.
The primary goat anti-NLRP3 (Abcam, Cambridge, MA) antibody was used in combination with
the following: rabbit anti-ASC (Santa Cruz, Dallas, TX), rabbit anti-caspase (Santa Cruz), or
mouse anti-TXNIP (MBL, Woburn, MA). Frozen mouse kidney tissue slides were fixed in
acetone, blocked with 3% donkey serum, then incubated with the same aforementioned primary
antibodies (1:50) overnight at 4°C. Some coverslips with podocytes and frozen kidney sections
were only stained for podocyte markers podocin (1:50; Sigma, St. Louis, MO) or desmin (1:50;
BD Biosciences, San Jose, CA), or also in combination with goat anti-NLRP3 antibody. Double
immunofluorescent staining was performed by Alexa-488 or Alexa-555-labeled secondary
antibody (1:200 podocytes, 1:50 frozen kidney slides; Life Technologies, Grand Island, NY)
incubation for 1 hr at room temperature. Slides were then washed, mounted, and observed using
a confocal laser scanning microscope (Fluoview FV1000, Olympus, Japan) and tools in Image
Pro Plus 6.0 software (Media Cybernetics, Bethesda, MD) was used to analyze colocalization, or
the degree of overlap between the two wavelengths, which was expressed as the Pearson
Correlation Coefficient.

2.7

Size-exclusion chromatography
As described in our previous studies [169-170], homogenates from either treated podocytes

or renal cortical tissue was prepared using the following protein extraction buffer: 20 mM 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid-KOH (pH 7.5), 10 mM KCl, 1.5 mM Na-EDTA,
1 mM Na-EGTA, and 1x protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN).
Samples were centrifuged at 16,000g for 10 minutes at 4°C, the supernatant filtered through a
0.45 μm centrifuge tube filter, and the protein concentration was measured. Samples were
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normalized by loading 1 mg protein in less than 500 μl total volume onto a Superose 6 10/300
GL Column using an ÄKTAprime plus fast-protein liquid chromatography (FPLC) system (GE
Healthscience, Uppsala, Sweden). Fractions were collected (600 μl), protein precipitated using
tricholoroacetic acid, and analyzed by Western blot as described above.

2.8

Co-immunoprecipitation
Renal cortical tissue was homogenized on ice in IP lysis buffer (30 mM Tris-HCl, 150 mM

NaCl, 2 mM EDTA, 1% Triton X-100, 10% glycerol, 1x Protease Inhibitor) followed by brief
pulses of hand sonication. After a 30 minute incubation on ice, the lysate was centrifuged and the
supernatant precleared by incubation with Protein A/G PLUS-Agarose Beads (Santa Cruz, sc2003) in 4°. The precleared supernatant was incubated with 2 µg antibody against NLRP3
(Abcam) for 4 hours on a rocker in 4°. Beads were added for an additional 1 hr, and then
immunoprecipitates collected by centrifugation at 1,000g for 5 minutes and washed three times
with IP lysis buffer with centrifugation after each wash. The pellet was resuspended in 2x sample
buffer, boiled, and analyzed for NLRP3 and TXNIP protein expression by Western blot.

2.9

Caspase-1 activity, IL-1β production, and VEGF measurements
Caspase-1 activity was measured by a commercially available colorimetric assay

(Biovision, Mountain View, CA), while IL-1β production and vascular endothelial growth
factor-A (VEGF-A) secretion was measured in the supernatant of cultured podocytes using an
enzyme-linked immunosorbent assay (R&D System, Minneapolis, MN) according to
manufacturer‟s instructions.
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2.10 Electron spin resonance spectrophotometry of O2•− production
Protein from cultured podocytes or renal cortical tissue was extracted using a sucrose
buffer, and then prepared for analysis by resuspension in a modified Krebs-Hepes buffer
containing deferoximine (100 μM; Sigma, St. Louis, MO, USA) and diethyldithiocarbamate (5
μM; Sigma). To measure NADPH oxidase-dependent superoxide production, 1 mM NADPH
substrate was added to 50 μg protein, and each sample was read twice on an ESR spectrometer
and examined in the presence or absence of superoxide dismutase (SOD, 200 U/ml; Sigma). 1hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH, 1mM), a superoxide specific
spin trapping compound, was added to the sample before being loaded into a glass capillary, and
analyzed in an ESR spectrometer for 10 minutes [171]. Results were obtained by taking the
difference between the total CMH signal without SOD and the SOD-specific signal, and all
values were expressed as the fold change from the control.

2.11 RNA isolation and real time RT-PCR
Total RNA was isolated from both podocytes and renal cortical tissue using the TRIzol
reagent (Grand Island, NY), reverse transcribed to cDNA, and subject to PCR amplification
according to the procedures described previously [172]. All primers were synthesized by Operon
(Huntsville, AL) with the following sequences: Nox1, sense 5-AATGCCCAGGATCGAGGT,
antisense

5-GATGGAAGCAAAGGGAGTGA-3;

Nox2,

sense

5-

TGGCACATCGATCCCTCACTGAAA-3, antisense 5-GGTCACTGCATCTAAGGCAACCT3;

Nox4,

sense

5-GAAGGGGTTAAACACCTCTGC-3,

antisense

5-

ATGCTCTGCTTAAACACAATCCT-3; TXNIP, sense 5-CAGCCTACAGCAGGTGAGAAC3, antisense 5-CTCATCTCAGAGCTCGTCCG-3.
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2.12 F-actin staining of podocytes
To determine the role of NADPH oxidase and inflammasome activation in Hcys-induced
cytoskeleton changes, podocytes were cultured in 8-well chambers. After washing with PBS, the
cells were fixed in 4% PFA for 15 min at room temperature, permeabilized with 0.1% Triton X100, and blocked with 3% bovine serum albumin. F-actin was stained with rhodamine–phalloidin
(Invitrogen, Carlsbad, CA) for 15 min at room temperature. After mounting, the slides were
examined by a confocal laser scanning microscope (Fluoview FV1000, Olympus, Japan). Cells
with distinct F-actin fibers were counted as described previously [173]. Scoring was obtained
from 100 podocytes from each group on each slide.

2.13 Immunohistochemistry
Kidneys were embedded with paraffin and 5 μm sections were cut from the embedded
blocks. After heat-induced antigen retrieval, CD43 staining of T cells and WT-1 staining of
podocytes required citrate buffer antigen retrieval, while F4/80 staining of macrophages required
Proteinase K antigen retrieval. After a 20 min wash with 3% H2O2 and 30 min blocking with
serum, slides were incubated with primary antibodies diluted in phosphate-buffered saline (PBS)
with 4% serum. Anti-CD43 (1:50; Santa Cruz Biotechnology, Santa Cruz, CA), anti-F4/80 (1:50;
AbD Serotec, Raleigh, NC), and anti-WT-1 (1:50; Abcam, Cambridge, MA) antibodies were
used in this study for detection of macrophages and T-cells. After incubation with each of these
primary antibodies overnight, the sections were washed in PBS and incubated with biotinylated
IgG (1:200) for 1 h and then with streptavidin-HRP for 30 min at room temperature. 50 μl of
DAB was added to each kidney section and stained for 1 min. After washing, the slides were
counterstained with hematoxylin for 5 min. The slides were then mounted and observed under a
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microscope, and photographs were taken at 100x magnification. All of the glomeruli in the
cortical fields were counted and blindly used for analysis of each slide [174].

2.14 Chronic catheterization and arterial blood pressure measurement
Mean arterial pressure (MAP) was measured for 3 days in mice involved with the TXNIP
inhibition studies, including luciferase-transfected, TXNIPsh-transfected, or verapamiladministered mice, to make sure there were no effects of diet or treatment on blood pressure. As
we described previously [175-176], mice were anaesthetized by isoflurane inhalation, and a
telemetry transmitter catheter implanted into the carotid artery. The transmitter was placed
subcutaneously, allowing mice to be housed unrestrained, with the arterial blood pressure signal
transmitted to a remote receiver (Data Sciences International, St. Paul, MN, USA).

2.15 Urinary protein and albumin measurements
Total urinary protein excretion was determined spectrophotometrically using the Bradford
assay (Sigma) using a standard curve of BSA, and urinary albumin excretion was measured
using a commercially available mouse albumin ELISA kit (Bethyl Laboratories, Montgomery,
TX).

2.16 Glomerular morphological examination
Renal tissues were fixed with a 10% formalin solution, paraffin-embedded, and stained
with periodic acid–Schiff (PAS). Renal morphology was observed using a light microscope, and
glomerular sclerosis was assessed semiquantitatively and expressed as glomerular damage index
(GDI) [177]. Fifty glomeruli per slide were counted and blindly scored as 0, 1, 2, 3, or 4,
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according to 0, <25, 25–50, 51–75, or >75% sclerotic changes, respectively, across a longitudinal
kidney section. The GDI for each mouse was calculated by the formula ((N1 ×1) + (N2 ×2) +
(N3 ×3) + (N4 ×4))/n, where N1, N2, N3, and N4 represent the numbers of glomeruli exhibiting
grades 1, 2, 3, and 4, respectively, and n is the total number of glomeruli scored.

2.17 HPLC analysis of plasma Hcys
Total plasma Hcys levels were measured by HPLC as previously described [178-179]. A
100 µL plasma or standard solution mixed together with 10 µL of the internal standard
thioglycolic acid (2.0 mmol/L) solution, was treated with 10 µL of 10% tri-n-butylphosphine
(TBP) solution in dimethylformamide at 4°C for 30 minutes. In order to precipitate and remove
proteins in the sample, 80 µL of ice-cold 10% trichloroacetic acid (TCA) in 1 mmol/L EDTA
was added and followed with centrifugation. 100 µL of the resulting supernatant was transferred
into the mixture of 20 µL of 1.55 mol/L sodium hydroxide, 250 µL of 0.125 mol/L borate buffer
(pH 9.5), and 100 µL of 1.0 mg/mL 7-fluoro-2,1,3-benzoxadiazole-4-sulfonamide (ABD-F)
solution, then incubated at 60°C for 30 minutes to achieve derivatization of thiols. HPLC was
performed with a HP 1100 series instrument equipped with a binary pump, a vacuum degasser, a
thermo stated column compartment, and an auto sampler (Agilent Technologies, Waldbronn,
Germany). Separation was carried out at ambient temperature on a Supelco LC-18-DB (Supelco;
150×4.6 mm i.d., 5 µm particle size) analytical column with a Supelcosil LC-18 guard column
(Supelco; 20×4.6 mm i.d., 5 µm particle size). Fluorescence intensities were measured with a
Hewlett-Packard Model 1046A fluorescence detector (excitation: 386 nm, emission: 515 nm),
with a Hewlett-Packard 3392 integrator quantifying the peak area of the chromatographs. The
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analytical column was eluted with 0.1 mol/L potassium dihydrogen phosphate buffer (pH 2.1)
containing 6% acetonitrile (v/v) as the mobile phase with a flow rate of 2.0 mL/min.

2.18 Statistical analysis
All results were expressed as the arithmetic mean ± SEM; n represents the number of
independent experiments. Data obtained from multiple animal or experimental groups were
tested for significance using one- or two-way ANOVA, and a paired and unpaired Student‟s ttest was used for two animal or experimental groups. A χ2 test was used to determine the
significance of ratio and percentage data. Results with p<0.05 were considered statistically
significant.
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CHAPTER THREE
NADPH oxidase-mediated triggering of inflammasome activation in mouse podocytes and
glomeruli during hyperhomocysteinemia

3.1

Rationale and Hypothesis
As depicted in Figure 4 the present study hypothesized that NADPH oxidase-mediated

redox signaling play an essential role in triggering hHcys-induced inflammasome activation
within podocytes, thereby inducing glomerular inflammatory injury such as immune cell
infiltration and consequently leading to glomerular sclerosis. To test this hypothesis, we first
used cultured murine podocytes to examine whether inhibition of NADPH oxidase attenuates
Hcys-induced NLRP3 inflammasome formation and activation and also addressed the functional
relevance of this early inflammatory event. Using pharmacological inhibitors or mice lacking the
gp91phox gene, we also tested the in vivo role of NADPH oxidase activation in hHcys-induced
NLRP3 inflammasome formation and activation, glomerular inflammatory pathology and
glomerular sclerosis compared with wild-type littermates.
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Figure 4. Representative schematic for Aims 1 and 2. Through the specific inhibition of
gp91phox both in vitro and in vivo, Aim 1 and 2 will explore the role of NADPH oxidase in
Hcys-induced NLRP3 inflammasome activation.

3.2

Results

3.2.1 Attenuation of Hcys-induced NLRP3 inflammasome formation through inhibition
of NADPH oxidase
As shown in Figure 5A, confocal microscopic analysis demonstrated that Hcys induced the
colocalization of inflammasome markers (NLRP3 with ASC and NLRP3 with caspase-1) in
podocytes compared to untreated control cells. Pretreatment of podocytes with NADPH oxidase
inhibitors DPI or gp91ds-tat peptide significantly abolished the Hcys-induced aggregation of
NLRP3 with ASC and NLRP3 with caspase-1, suggesting blockade of inflammasome formation
in these cells. Furthermore, small interfering RNA against ASC and gp91 phox also blocked Hcys-
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induced inflammasome formation. The Pearson correlation coefficient was calculated for each of
the groups using the colocalization analysis program in the Image Pro Plus 6.0 software and
summarized in Figure 5B. In addition, co-immunoprecipitation experiments demonstrated that
Hcys significantly increased the binding of NLRP3 and caspase-1 together with ASC compared
to control cells, which is attenuated in the presence of apocynin and gp91ds-tat peptide (data not
shown). Together, these results suggest that inhibition of NADPH oxidase or silencing ASC gene
attenuates Hcys-induced inflammasome formation in podocytes.
Size-exclusion chromatography (SEC) was employed to further determine the role of
NADPH oxidase in the process of Hcys-induced inflammasome complex formation. A
representative chromatogram is shown in Figure 6A, illustrating the peaks produced from both a
standard and typical protein sample when run and separated by the Sepharose 6 column. As
depicted in Figure 6B, under control conditions the specific bands for NLRP3 and ASC were
located in the low molecular weight fractions (18-22). Upon stimulation with Hcys for 24 hours,
the NLRP3 and ASC bands markedly shifted to high molecular weight fractions (3-7), termed
the inflammasome fractions due to complex formation. However, when NADPH oxidase was
inhibited in podocytes by treatment with gp91ds-tat or DPI prior to the addition of Hcys, a clear
decrease in inflammasome protein complex aggregation was observed in the high-molecular
weight fractions. The intensity of these bands were quantified by ImageJ software and
summarized in Figure 6C.
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Figure 5. NADPH oxidase inhibition attenuated inflammasome formation induced by
hHcys in podocytes. A. Confocal images representing the colocalization of NLRP3 (green)
with ASC (red) and NLRP3 (green) with caspase-1 (red) in podocytes. B. Summarized data
showing the fold change of PCC for the colocalization of NLRP3 with ASC and NLRP3 with
caspase-1. (n=6-7). Ctrl: Control; Vehl: Vehicle; gp91pep: gp91ds-tat; DPI: diphenylene
iodonium; Scram: Scramble siRNA; ASCsi: ASC siRNA; gp91si: gp91phox siRNA. * P<0.05
vs. Control; # P<0.05 vs. Hcys.
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Figure 6.
Distribution of inflammasome components after size-exclusion
chromatography of podocytes. A. Elution profile of proteins from both a standard and
podocyte samples at an absorbance of 280 nm. Molecular mass of the samples were
determined by comparison to a gel filtration standard. B. Western blot analysis of FPLC
protein fractions obtained from untreated, Hcys-treated, and gp91ds-tat-treated podocytes
probed with anti-NLRP3 and ASC antibodies. C. Summarized data showing the band
intensities measured from the inflammasome complex fractions (fractions 3-7) of NLRP3 and
ASC (n=4-6). Ctrl: Control; Vehl: Vehicle; gp91pep: gp91ds-tat; DPI: diphenylene iodonium;
gp91sh: gp91phox shRNA, APO: apocynin. * P<0.05 vs. Control; # P<0.05 vs. Hcys.
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3.2.2 Inhibition of NADPH oxidase blocked NLRP3 inflammasome functionality by
suppressing caspase-1 activity and IL-1b secretion
We further tested whether inhibition of NADPH oxidase also attenuates Hcys-induced
caspase-1 activity and IL-1β production in podocytes. As shown in Figure 7A, the increase in
caspase-1 activity caused by Hcys was markedly inhibited by the NADPH oxidase inhibitors
apocynin, DPI, gp91ds-tat, and gp91phox siRNA, implicating an important role for NADPH
oxidase in inflammasome activation. ASC siRNA also produced a similar significant decrease in
caspase-1 activity. Figure 7B demonstrated that these decreases in caspase-1 activity also
resulted in less IL-1β being converted from the pro-inflammatory cytokine form to the active
form during the simultaneous treatment of Hcys with either NADPH oxidase or inflammasome
inhibitors.

3.2.3 Effect of NLRP3 inflammasome inhibition on Hcys-induced O2•− production
To determine whether NADPH oxidase-derived O2•− plays a role in inflammasome
activation, O2•− levels were measured in podocytes pretreated with NADPH oxidase or
inflammasome inhibitors in the presence of Hcys. As expected, treatment of podocytes with
DPI, gp91ds-tat, or gp91phox siRNA produced a distinct decrease in O2•− production when
compared to Hcys alone (Figure 7C).

Additionally apocynin or gp91ds-tat peptide also

significantly attenuated the Hcys-induced O2•− production in the plasma membranes of podocytes
(Figure 7D). However, ASC siRNA or caspase-1 inhibition could not prevent the Hcys-induced
increase in O2•−. This suggests that NADPH oxidase activation by Hcys and subsequent
production of O2•− is upstream of inflammasome activation, given that inhibition of the
inflammasome did not affect the levels of NADPH oxidase-derived O2•−.
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Figure 7. Effects of NADPH oxidase inhibition and ASC silencing on Hcys-induced
caspase-1 activity, IL-1β secretion, and O2•− production in podocytes. A. Caspase-1
activity in groups treated with Hcys in the presence of various genetic and pharmacologic
inhibitors of NADPH oxidase and the inflammasome (n=6). B. IL-1β production in
podocytes treated with Hcys in the presence of various genetic and pharmacologic inhibitors
of NADPH oxidase and the inflammasome (n=6). C. Hcys-induced O2•− production
decreased with treatment of NADPH oxidase inhibitors, but not genetic or pharmacologic
inhibitors of the inflammasome (n=5). D. Hcys induced superoxide production in microsomes
isolated from cultured podocytes, which was prevented by pharmacological NADPH oxidase
inhibitors APO and gp91pep (n=4-5). Ctrl: Control; Vehl: Vehicle; gp91pep: gp91ds-tat; DPI:
diphenylene iodonium; Scram: Scramble siRNA; ASCsi: ASC siRNA; gp91si: gp91phox
siRNA; APO: apocynin. * P<0.05 vs. Control; # P<0.05 vs. Hcys.
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3.2.4 Inhibition of NADPH oxidase or NLRP3 inflammasomes attenuated Hcys-induced
podocyte injury
As shown in Figure 8A, immunofluorescent analysis demonstrated that Hcys stimulation
increased desmin expression in podocytes compared to untreated cells. Prior treatment with
gp91phox siRNA, ASC siRNA, gp91ds-tat, apocynin, DPI, or caspase-1 inhibitor WEHD
decreased this Hcys-induced desmin expression in podocytes. Another podocyte marker,
podocin, was markedly reduced upon Hcys stimulation in podocytes, and prior treatment with
the same inhibitors almost completely attenuated the decrease in podocin expression. Positive
cells were counted and summarized in Figure 8B. These results signify the importance of both
NADPH oxidase and inflammasome functionality in this injurious process of podocytes when
exposed to Hcys. Using rhodamine-phalloidin to stain F-actin, the control condition exhibited
well-defined F-actin fibers which run along the longitudinal axis of these podocytes, and as
demonstrated by the obvious lack of distinct fibers, Hcys resulted in a significant loss of these
longitudinal fibers as they reorganize to the cell border. Puromycin aminonucleoside (PAN), a
classic and specific inducer typical used to cause podocyte injury [180], served as a positive
control (Figure 8C). However, inhibition of NADPH oxidase or inflammasomes hindered the
Hcys-induced decrease and rearrangement of F-actin. These changes in F-actin staining were
summarized in Figure 8D.
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Figure 8. Amelioration of Hcys-induced podocyte dysfunction by NADPH oxidase and
inflammasome inhibitors. A. Immunofluorescence staining showed that inhibition of
NADPH oxidase activation by gp91phox siRNA, gp91ds-tat, apocynin and DPI, or
inflammasome inhibition by ASC siRNA or WEHD rescued Hcys-induced expression of
podocyte marker podocin (original magnification, x400). Inhibition of NADPH oxidase or
inflammasome activation also resulted in suppressed expression of podocyte injury marker
desmin. B. Summarized data shows the percentage of podocyte cells positive for podocin and
desmin. C. Microscopic images of F-actin by rhodamine-phalloidin staining (original
magnification, x400). PAN treatment served as a positive control. D. Summarized data from
counting the cells with distinct, longitudinal F-actin fibers. Scoring was determined from 100
podocyte cells on each slide (n=5-6). Ctrl: Control; Vehl: Vehicle; gp91pep: gp91ds-tat; DPI:
diphenylene iodonium; Scram: Scramble siRNA; ASCsi: ASC siRNA; gp91si: gp91phox
siRNA. * P<0.05 vs. Control; # P<0.05 vs. Hcys.
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3.2.5 gp91phox−/− and gp91ds-tat-treated mice had no hHcys-induced glomerular NLRP3
inflammasome formation and activation
To further confirm the role of NADPH activation in vivo in experimental hHcys mice,
double fluorescent-immunostaining of kidney slides was performed. As shown in Figure 9A,
under control condition NLRP3, ASC and caspase-1 were expressed at low levels within the
glomeruli, and very few colocalizations of these inflammasome molecules could be detected by
confocal microscopy. In gp91phox+/+ mice, the colocalization of NLRP3 with ASC or caspase-1
markedly increased in glomeruli of FF diet-fed hHcys mice. However, the increased
colocalization of NLRP3 with ASC or caspase-1 was suppressed in glomeruli of
hyperhomocysteinemic gp91phox−/− and gp91ds-tat-treated mice. The summarized data were
shown in Figures 9B and 9C. In addition, using podocin and desmin as podocyte markers we
showed that hHcys-induced inflammasome activation in glomeruli was mostly located in
podocytes, as demonstrated by the colocalization of podocin with NLRP3 or caspase-1 and
desmin with NLRP3 or caspase-1. This colocalization was substantially blocked in
hyperhomocysteinemic gp91phox−/− mice and gp91ds-tat-treated mice (Figure 9A). The
summarized data were shown in Figures 9D and 9E.
Consistent with decreased aggregation of inflammasome components in the glomeruli,
hHcys-enhanced caspase-1 activity and IL-1β production were markedly attenuated in glomeruli
of gp91phox−/− and gp91ds-tat-treated mice (Figures 10A and 10B). In addition, hHcys-induced
glomerular superoxide production was significantly attenuated in gp91ds-tat-treated and
gp91phox−/− mice compared to their wild-type littermates (Figure 10C). The plasma Hcys
concentration was similar in gp91phox+/+, gp91phox−/− and gp91ds-tat-treated mice on the normal
diet. However, the FF diet significantly increased the plasma Hcys concentration in all three
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groups compared to normal diet fed mice (gp91phox+/+ mice: 12.6 ± 2.0 versus 4.1 ± 0.41 μM for
control; gp91phox−/− mice: 13.0 ± 1.6 versus 4.0 ± 0.8 μM for control; gp91ds-tat mice: 11.6 ± 1.0
versus 5.1 ± 0.41 μM for control).
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Figure 9. Attenuation of Hcys-induced inflammasome activation in the glomeruli of
gp91phox−/− and gp91ds-tat-treated mice on a FF diet. A. Colocalization of NLRP3 (green)
with ASC (red), NLRP3 (green) with caspase-1 (red), and NLRP3 (green) with podocyte
marker podocin (red) in the mouse glomeruli of gp91phox+/+, gp91ds-tat, and gp91phox−/− mice
fed a normal or FF diet. B and C. Summarized data showing the correlation coefficient
between NLRP3 with ASC and NLRP3 with caspase-1 (n=7). D and E. Summarized data
showing the correlation coefficient between NLRP3 with podocin and caspase-1 with podocin
(n=4-5). *P<0.05 vs. gp91phox+/+ on Normal Diet; # P<0.05 vs. gp91phox+/+ on FF Diet.
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Figure 10. In vivo effect of NADPH oxidase inhibition on Hcys-induced caspase-1
activity, IL-1β secretion, and O2•− production. A. Caspase-1 activity in gp91phox+/+,
gp91ds-tat, and gp91phox−/− mice with hHcys induced by the FF diet (n=6). B. IL-1β
production induced by hHcys was inhibited in both the mice treated with gp91ds-tat and in
gp91phox−/− mice (n=6). C. Hcys-induced superoxide production was attenuated in the gp91dstat and gp91phox−/− groups (n=5). * P<0.05 vs. gp91phox+/+ on Normal Diet; # P<0.05 vs.
gp91phox+/+ on FF Diet.
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3.2.6 In vivo inhibition of NADPH oxidase prevented hHcys-induced glomerular
inflammation and injury
As shown in Figures 11A and 11C, immunohistochemical analysis demonstrated that
Hcys stimulation induced macrophage (F4/80+) and T-cell (CD43+) infiltration in the glomeruli
of hHcys gp91phox+/+ mice. However, the glomeruli of gp91phox−/− and gp91ds-tat-treated mice
had significantly less macrophage and T-cell recruitment when compared to gp91phox+/+ mice on
the FF diet. The summarized data were shown in Figures 11B and 11D. These results suggest
that normal NADPH oxidase gene expression and activity are required for inflammasome
activation and consequent inflammatory response, which includes macrophage and T-cell
recruitment and aggregation in glomeruli of mice during hHcys.
Next, we tested whether gp91phox contributes to hHcys-induced glomerular injury. As
shown in Figure 12, hHcys significantly increased the urinary protein and albumin in gp91phox+/+
mice compared to normal diet-fed mice. Mice treated with gp91ds-tat and gp91phox−/− mice had
significantly attenuated hHcys-enhanced urinary protein and albumin excretion in FF diet-fed
mice, but had no effect in normal diet-fed mice (Figures 12A and 12B). Morphological
examinations revealed a typical pathological change in glomerular sclerotic damage indicated by
capillary collapse, fibrosis, cellular proliferation and mesangial cell expansion in glomeruli of
hHcys gp91phox+/+ mice (Figure 12C). The average glomerular damage index was significantly
higher in glomeruli of hHcys gp91phox+/+ mice compared to normal diet-fed mice. However, in
gp91phox−/− or gp91ds-tat-treated mice, hHcys-induced glomerular injuries were significantly
inhibited (Figure 12D).
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Figure 11. Inhibition of NADPH oxidase expression and activity prevented hHcysinduced infiltration of macrophages and T-cells into the glomeruli. A. gp91ds-tat and
gp91phox−/− mice prevented the increased expression and staining of macrophage marker F4/80
that is seen in gp91phox+/+ on FF Diet. B. Summarized counts of F4/80 positive glomeruli
(n=6). C. gp91ds-tat and gp91phox−/− mice prevented the increased expression and staining of
T-cell marker CD43 that is seen in gp91phox+/+ on FF Diet. D. Summarized counts of CD43
positive glomeruli (n=6). * P<0.05 vs. gp91phox+/+ on Normal Diet; # P<0.05 vs. gp91phox+/+ on
FF Diet.
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Figure 12. Inhibition of NADPH oxidase expression and activity protected glomerular
function from hHcys-induced injury. A. Hyperhomocysteinemic gp91phox+/+ mice produced
proteinuria, which was alleviated in the gp91phox−/− or in the gp91ds-tat-treated mice (n=6). B.
Hyperhomocysteinemic gp91phox+/+ mice produced albuminuria, where blockade of NADPH
oxidase in gp91phox−/− mice or in gp91ds-tat-treated mice prevented this glomerular damage
(n=6). C. Glomerular morphological examination by PAS staining demonstrated that gp91dstat administration or gp91phox−/− mice prevented capillary collapse, fibrosis, cellular
proliferation and expansion induced by hHcys (n=4-6). D. Glomerular damage index (GDI)
was assessed by a standard semiquantitative analysis to determine severity of glomerular
sclerosis. * P<0.05 vs. gp91phox+/+ on Normal Diet; # P<0.05 vs. gp91phox+/+ on FF Diet.
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3.3

Summary
In summary, these studies demonstrated that at the very early stages of glomerular damage,

Hcys in vitro or hHcys in vivo stimulated the formation and activation of the NLRP3
inflammasome, which initiated early injurious events in podocytes and glomeruli, leading to
more serious glomerular injury and ultimate sclerosis. This NLRP3 inflammasome activation,
podocyte injury, and the glomerular pathology induced by hHcys could be substantially
suppressed by inhibition of NADPH oxidase. These results may establish a new concept that
NADPH oxidase-derived ROS upon Hcys stimulation trigger the formation and activation of
NLRP3 inflammasomes and thereby produce IL-1β and other factors, leading to podocyte and
glomerular injury, potentially progressing into glomerular sclerosis.
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CHAPTER FOUR
Contribution of endogenously produced reactive oxygen species to the activation of
podocyte NLRP3 inflammasomes in hyperhomocysteinemia

4.1

Rationale and Hypothesis
Much evidence demonstrates that many inflammasome stimulators are also known to

produce ROS, and the ROS model of inflammasome activation proposes NLRP3 to be a general
sensor for changes in local and intracellular oxidative stress, allowing it to become activated in
response to a diverse range of stimuli [126, 149, 181-182]. Although homocysteine (Hcys)induced ROS production in podocytes has been documented, it remains unknown how this Hcysinduced ROS production is involved in the activation of NLRP3 inflammasomes in podocytes
and ultimate glomerular injury. We have previously reported, and also shown above in Chapter
3, that inhibition of NADPH oxidase prevented Hcys-induced podocyte dysfunction, and more
recently confirmed that inhibition of NADPH oxidase and the downstream production of O2•−
abrogates NLRP3 inflammasome formation and activation [48, 169]. However, it is still poorly
understood which species of ROS is responsible for NLRP3 inflammasome activation and how
ROS lead to the formation or activation of this inflammasome. In this regard, recent studies have
indicated that ROS may serve as important signaling messengers and that O2•− and hydrogen
peroxide (H2O2) are common ROS that may act as second messengers to activate
inflammasomes within podocytes. Hence, the present study, as depicted in Figure 13, sought to
dissect the potential role of these endogenously produced ROS in Hcys-induced NLRP3
inflammasome activation and to determine which ROS are required for glomerular injury
associated with such activation of NLRP3 inflammasomes.
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Figure 13. Representative schematic for ROS dissection in Aim 1. Deeper investigation in
Aim 1 sought to understand which specific ROS are responsible for hHcys-induced NLRP3
inflammasomes activation.

4.2

Results

4.2.1 Reduction of intracellular O2•− and H2O2 levels prevented Hcys-induced NLRP3
inflammasome formation in podocytes
Using the O2•− dismutase mimetic TEMPOL, the H2O2 destroying enzyme catalase, or the
•

OH scavenger TMTU, we tested whether Hcys-induced inflammasome formation and activation

can be altered. By confocal microscopy analysis, we demonstrated that Hcys induced
colocalization (yellow spots) of inflammasome molecules (NLRP3 (green) vs. ASC or caspase-1
(red)) in podocytes compared to control cells, suggesting increased formation of NLRP3
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inflammasomes (Figure 14A). However, prior treatment of podocytes with TEMPOL or catalase
blocked Hcys-induced colocalization of NLRP3 with ASC or caspase-1. In contrast, TMTU did
not block Hcys-induced inflammasome formation, suggesting that O2•− and H2O2, but not •OH, is
involved in Hcys-induced inflammasome formation in podocytes. The colocalization coefficient
analyses were summarized and shown in Figure 14B. These effects are thought to originate from
ROS derived by specific Nox2, and not Nox1 or Nox4, activation (Figure 15). Furthermore, this
Hcys-induced Nox2 mRNA upregulation was unaffected by O2•− scavenging, suggesting that the
subsequent effects of scavenging these ROS are due to events occurring downstream of NADPH
oxidase activation (Figure 15).
To further confirm inflammasome formation in response to elevated Hcys, size exclusion
chromatography was employed and further provided evidence that TEMPOL or catalase
treatment prevented Hcys-induced inflammasome formation, as shown by the inhibited shift of
ASC proteins into higher-molecular weight fractions (Figure 16B). These fractions are
compared to a standard protein size marker in Figure 16A, a representative chromatogram where
proteins that are part of the inflammasome complex elute within fractions 3-7 and are analyzed
by SDS-PAGE. The intensity of bands were quantified and summarized in Figure 16C, showing
that scavenging of O2•− and H2O2, but not •OH, was able to inhibit inflammasome formation in
podocytes treated with Hcys.
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Figure 14. TEMPOL and catalase attenuated Hcys-induced inflammasome formation in
podocytes. A. Confocal images representing the colocalization of NLRP3 (green) with ASC
or caspase-1 (red) in cultured podocytes. B. Summarized data showing the fold change of
PCC for the colocalization of NLRP3 with ASC and NLRP3 with caspase-1 (n=4). Ctrl:
Control; Vehl: Vehicle; TMTU: tetramethylthiourea, PCC: Pearson coefficient correlation. *
P<0.05 vs. Control; # P<0.05 vs. Hcys.
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Figure 15. Hcys specifically induced Nox2 mRNA expression. A. As detected by real-time
RT-PCR, 24 hr treatment of podocytes with 40 µM Hcys caused significant upregulation of
Nox2, but not Nox1 or Nox4 (n=3). B. Scavenging of O2•− by TEMPOL and PEG-SOD had
no effect on Hcys-induced Nox2 mRNA upregulation (n=3). * P<0.05 vs. Ctrl.
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Figure 16. Size-exclusion chromatography demonstrated inhibition of Hcys-induced
ASC protein redistribution after O2•− and H2O2 scavenging. A. Representative
chromatogram illustrating the elution profile of proteins from both a standard and podocyte
sample taken from an absorbance of 280 nm. Elution of a gel filtration standard allowed for
the determination of the molecular mass of the samples. B. Western blot was performed on
selected FPLC protein fractions and probed with an anti-ASC antibody. C. Summarized data
determined from the ASC band intensities of the inflammasome complex fractions (3-7) (n=46). Ctrl: Control; Vehl: Vehicle; TMTU: tetramethylthiourea. * P<0.05 vs. Control; # P<0.05
vs. Hcys.
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4.2.2 TEMPOL and catalase, but not TMTU or ebselen, blocked activation of NLRP3
inflammasomes in podocytes
Aside from measures of NLRP3 inflammasome formation, previous studies have indicated
that caspase-1 activation and IL-1β production reflect the activation of NLRP3 inflammasomes
[169, 183]. In the present study, we tested whether TEMPOL and catalase abolish Hcys-induced
NLRP3 inflammasome activation. As shown in Figures 17A and 17B, Hcys treatment
significantly increased caspase-1 activity and IL-1β production compared to control cells.
However, pretreatment of podocytes with either TEMPOL or catalase significantly attenuated
Hcys-induced increases in caspase-1 activity and IL-1β secretion, indicating that O2•− and H2O2
are necessary for the functionality of inflammasomes in response to Hcys. In addition, we also
tested the role of another SOD mimetic MnTMPyP as well as cell permeable PEG-SOD in
podocytes with or without Hcys stimulation. We found that pretreatment with either MnTMPyP
or PEG-SOD significantly attenuated the Hcys-induced caspase-1 activity and IL-1β production
(Figures 17C and 17D). We demonstrated that scavenging of •OH by TMTU or ONOO− by
ebselen did not have effects on Hcys-induced NLRP3 inflammasome formation and activation in
podocytes. In the following in vivo studies, therefore, six groups of experiments are presented
that include mice on the normal or FF diet with or without TEMPOL and catalase.
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Figure 17. Effects of ROS scavenging on caspase-1 activity and IL-1β secretion in the
presence of Hcys. A. Caspase-1 activity, shown as folds versus Ctrl, measured in podocytes
treated with Hcys in the presence of various ROS scavengers (n=6-8). B. IL-1β production
measured in the supernatant of podocytes treated with Hcys in the presence of various ROS
scavengers (n=6-8). C. Inhibition of O2•− by MnTMPyP and PEG-SOD significantly inhibited
Hcys-induced caspase-1 activation (n=3-4). D. Treatment of podocytes with either MnTMPyP
or PEG-SOD prevented Hcys-induced maturation of IL-1β (n=4-5).Ctrl: Control; Vehl:
Vehicle; TMTU: tetramethylthiourea. * P<0.05 vs. Control; # P<0.05 vs. Hcys.
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4.2.3 Inhibition of NLRP3 inflammasome formation and activation in the glomeruli of
hyperhomocysteinemic mice by TEMPOL and catalase
To further determine whether O2•− and H2O2 are implicated in inflammasome formation
and activation in vivo, C57BL/6J wild type mice were treated with TEMPOL or catalase and fed
a normal diet (ND) or FF diet for 4 weeks. HPLC analysis revealed that folate free (FF) diet
treatment significantly increased the plasma total Hcys levels in uninephrectomized C57BL/6J
mice compared with ND fed mice. Neither uninephrectomy nor the treatment of TEMPOL or
catalase altered the Hcys levels on either diet, indicating that any observed effects were not due
to a reduction in plasma Hcys (Figure 18). As shown in Figure 19, the glomeruli of mice
maintained on the FF diet had increased colocalization of NLRP3 with ASC or NLRP3 with
caspase-1 compared to ND fed mice, suggesting the enhanced formation of NLRP3
inflammasomes in glomeruli of hHcys mice. hHcys, known to cause podocyte injury,
significantly decreased the amount of podocin staining in the glomeruli, thus resulting in
minimal colocalization with inflammasome protein NLRP3 (Figure 20). However, the formation
of hHcys-induced NLRP3 inflammasomes mainly occurred in podocytes within glomeruli,
evidenced by the increased colocalization of NLRP3 with podocyte damage marker desmin
(Figure 20). This colocalization of NLRP3 was not evident with either VE-cadherin or α-SMA,
respective markers of glomerular endothelial and mesangial cells (data not shown). hHcys also
resulted in podocyte injury, demonstrated by the increase in protein expression of podocyte
damage marker desmin. Correspondingly, caspase-1 activity and IL-1β production were
significantly enhanced in hHcys mice compared to normal diet fed mice, further confirming
NLRP3 inflammasome activation (Figures 21A and 21B). Concurrent with this inflammasome
activation, SOD-sensitive O2•− production was 2.1 fold greater in mice fed the FF diet than those
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on the ND (Figure 21C). All of these hHcys-induced effects on parameters of inflammasome
formation and activation were abolished by administration of either SOD mimetic TEMPOL or
H2O2 decomposer catalase. Taken together, these data suggest that both O2•− and H2O2 play a
pivotal role in hHcys-induced NLRP3 inflammasome formation and activation in glomeruli of
hHcys mice.

Figure 18. Effects of uninephrectomy or in vivo TEMPOL and catalase administration
on FF diet-induced plasma Hcys levels. A. Measured by HPLC, uninephrectomy had no
effect on plasma Hcys levels in mice receiving either ND or FF diet (n=4-6). B. Mice
maintained on the FF diet for 4 weeks displayed significantly elevated plasma Hcys
concentrations compared to those on the ND. TEMPOL and catalase did not alter these levels
either in the normal or FF diet mice (n=4-6). * P<0.05 vs. ND.
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Figure 19. In vivo effect of O2•− and H2O2 inhibition on hHcys-induced inflammasome
formation in glomeruli of hyperhomocysteinemic mice. A. Colocalization of NLRP3
(green) with ASC or caspase-1 (red) in the mouse glomeruli of vehicle, TEMPOL, or
catalase-treated mice fed a normal or FF diet. B-C. Summarized data showing the correlation
coefficient between NLRP3 with ASC or caspase-1 (n=6). Casp1: caspase-1, Vehl: Vehicle,
ND: Normal diet, FF: Folate-free diet. *P<0.05 vs. Vehl on ND; # P<0.05 vs. Vehl on FF
Diet.
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Figure 20. hHcys-induced inflammasome formation occurred primarily in podocytes of
hyperhomocysteinemic mice. A. Colocalization of NLRP3 (green) with podocyte markers
podocin or desmin (red) in the mouse glomeruli of vehicle, TEMPOL, or catalase-treated
mice fed a normal or FF diet. B-C. Summarized data showing the correlation coefficient
between NLRP3 with podocin or desmin (n=6). Podo: Podocin; Des: Desmin, Vehl: Vehicle,
ND: Normal diet, FF: Folate-free diet. *P<0.05 vs. Vehl on ND; # P<0.05 vs. Vehl on FF
Diet.
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Figure 21. In vivo administration of TEMPOL and catalase prevented caspase-1
activation, IL-1β production, and O2•− production. A. Caspase-1 activity in Vehl,
TEMPOL, or catalase-treated mice with hHcys induced by the FF diet (n=7). B. TEMPOL
and catalase administration prevented hHcys-induced IL-1β production (n=6-7). C. O2•−
production induced by hHcys was inhibited in mice treated with TEMPOL or catalase (n=6).
Vehl: Vehicle, ND: Normal diet, FF: Folate-free diet. *P<0.05 vs. Vehl on ND; # P<0.05 vs.
Vehl on FF Diet.
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4.2.4 In vivo TEMPOL and catalase administration protected mouse glomeruli from
hHcys-induced dysfunction and injury
As shown in Figure 22, FF diet-induced hHcys resulted in significantly elevated urinary
protein excretion as well as marked pathological changes in glomerular morphology, compared
to mice on the ND. However, hHcys-induced proteinuria and glomerular injury were not evident
in hyperhomocysteinemic mice treated with TEMPOL or catalase. Dismutation of O 2•− and
decomposition of H2O2 was able to prevent hHcys-induced renal dysfunction and glomerular
damage, signifying the importance of O2•− and H2O2 in the mechanism of hHcys-induced injury.
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Figure 22. Renal protective effects of O2•− and H2O2 inhibition on hHcys-induced
glomerular injury. A. hHcys-induced proteinuria was attenuated in mice receiving
TEMPOL or catalase treatment (n=6). B. Microscopic observation of glomeruli in PAS
stained kidney sections demonstrated TEMPOL and catalase prevented hHcys-induced
changes in glomerular morphological structure by preventing capillary collapse, fibrosis,
cellular proliferation and mesangial cell expansion (n=4-6). C. Extent of glomerular sclerosis
was assessed semiquantitatively and expressed as the Glomerular damage index (GDI). Vehl:
Vehicle, ND: Normal diet, FF: Folate-free diet. *P<0.05 vs. Vehl on ND; # P<0.05 vs. Vehl
on FF Diet.
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4.3

Summary
In summary, this series of studies demonstrated that reducing O2•− and H2O2 inhibited

NLRP3 inflammasome formation and consequent processing of IL-1β, suggesting that both
species are importantly implicated in the instigation of Hcys-induced NLRP3 inflammasome
activation in cultured podocytes. Similar effects were seen in vivo in glomerular podocytes of
hyperhomocysteinemic mice, where dismutation of O2•− by TEMPOL and decomposition of
H2O2 by catalase not only prevented glomerular NLRP3 inflammasome formation and activation,
but also importantly protected against hHcys-induced glomerular injury and dysfunction.
Together, these results indicate that O2•− and H2O2 contribute to inflammasome triggering and
consequent podocyte injury, ultimately leading to the potential progression toward glomerular
sclerosis and ESRD during hHcys.
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CHAPTER FIVE
NLRP3 inflammasome activation and podocyte injury via thioredoxin-interacting protein
during hyperhomocysteinemia

5.1

Rationale and Hypothesis
Thus far, this hHcys-induced NLRP3 inflammasome activating process was shown to

depend on NADPH oxidase and the reactive oxygen species (ROS) derived from its activation,
specifically O2•− and H2O2, where inhibition of the gp91phox subunit of NADPH oxidase or
scavenging of O2•− and H2O2 suppressed NLRP3 inflammasome activation and furthermore
ameliorated subsequent glomerular dysfunction [169-170]. However, the exact mechanism of
how the NADPH oxidase-derived ROS are sensed by podocytes to form and activate the NLRP3
inflammasome and thereby lead to its activation in glomerular podocytes is still largely
unknown. In this regard, the work done by Zhou et al provided strong evidence of thioredoxininteracting protein (TXNIP) as a binding partner to NLRP3, where association between these two
proteins was necessary for downstream inflammasome activation [126]. TXNIP, the negative
regulator of the antioxidant thioredoxin (TRX), may time-dependently dissociate from TRX to
bind with NLRP3 leading to inflammasome formation and activation. In this series of studies, we
attempted to investigate the role of TXNIP during hHcys and to explore its potential effects on
NLRP3 inflammasome activation and consequent podocyte injury and glomerular sclerosis
(Figure 23). We first characterized the feature of TXNIP binding to NLRP3 and its related role
in the formation and activation of NLRP3 inflammasomes using cultured podocytes. Then, we
determined the pathological role of TXNIP-mediated activation of NLRP3 inflammasomes in
mice with hHcys. These studies together elucidate the key role of TXNIP in bridging redox
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signals with activation of NLRP3 inflammasomes leading to podocyte injury and ultimate
glomerular sclerosis.

Figure 23. Diagram showing the potential TXNIP involvement in Aim 1. Further studies
in Aim 1 will elucidate the potential role of TXNIP-NLRP3 binding in this mechanism of
hHcys-induced NLRP3 inflammasome activation and subsequent glomerular injury.
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5.2

Results

5.2.1 TXNIP inhibition prevented TXNIP protein recruitment to NLRP3 inflammasome
fractions
In the chromatogram illustrating a typical standard and sample elution profile, the elution
of inflammasome proteins in earlier fractions signifies the aggregation of inflammasome proteins
to higher molecular weight complexes and the formation of inflammasomes (Figure 24A).
Demonstrated by SEC in previous studies, Hcys stimulation of podocytes resulted in increased
NLRP3 inflammasome formation [49, 169]. The present study further validated this concept as
shown by the increased expression of NLRP3 protein in fractions 4-7, termed the inflammasome
fractions in Hcys-treated podocytes (Figure 24B). In these podocytes stimulated by Hcys, we
observed increased expression of TXNIP as well as the recruitment of TXNIP to the
inflammasome fractions, suggesting TXNIP aggregation to the NLRP3 inflammasome complex.
To further elucidate the role of TXNIP, we pretreated Hcys-stimulated podocytes with siRNA or
verapamil to inhibit its expression and found that inhibition of TXNIP not only prevented its own
shift to the inflammasome fractions, but also blocked the formation of NLRP3 complex in
podocytes in response to Hcys stimulations. The relative band intensities at fractions 4-7 were
quantified and summarized in Figure 24C. These SEC results provided strong evidence for a
possible role of TXNIP and its aggregation with the inflammasome complex in Hcys-induced
NLRP3 inflammasome formation.
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Figure 24. TXNIP and NLRP3 recruitment to the high molecular weight inflammasome
fractions upon stimulation with Hcys. A. SEC chromatogram illustrating the elution curves
of a typical standard and podocyte protein sample. B. Representative Western blot gel
documents depicting the shift of NLRP3 and TXNIP protein during Hcys treatment, which
was prevented during TXNIP inhibition. C. Summarized quantification of either NLRP3 or
TXNIP protein residing in the inflammasome fractions (n=4). Ctrl: Control, Vehl: Vehicle,
TXNIPsi: TXNIP siRNA. * P<0.05 vs. Ctrl, # P<0.05 vs. Hcys.
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5.2.2 Inhibition of Hcys-induced TXNIP-NLRP3 binding and NLRP3 inflammasome
formation upon TXNIP blockade
As an additional method for detection of NLRP3 inflammasome formation, confocal
microscopy was used to observe the colocalization of inflammasome proteins in podocytes.
Shown in Figure 25A, Hcys increased the colocalization of NLRP3 (green) and ASC (red)
compared to control cells, suggesting the formation of NLRP3 inflammasomes in podocytes.
Furthermore, Hcys stimulation also increased the colocalization of NLRP3 (green) with TXNIP
(red), suggesting that Hcys induces the aggregation of TXNIP together with NLRP3. However,
prior treatment with TXNIP siRNA or verapamil significantly attenuated the colocalization of
NLRP3 with either ASC or TXNIP. This reveals that TXNIP expression and its binding to
NLRP3 are necessary for NLRP3 inflammasome formation in Hcys-treated podocytes. The
colocalization of NLRP3 with ASC and NLRP3 with TXNIP was quantified and summarized in
Figures 25B and 25C.
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Figure 25. TXNIP inhibition prevented Hcys-induced NLRP3 inflammasome formation.
A. Confocal microscopic detection of NLRP3 (green) with ASC (red) and NLRP3 (green)
with TXNIP (red) and their colocalization together (yellow), indicative of the inflammasome
formation. B-C. Summarized data showing the quantification of the extent of colocalization
between NLRP3 with ASC and NLRP3 with TXNIP (n=4-6). Ctrl: Control, Vehl: Vehicle,
TXNIPsi: TXNIP siRNA. * P<0.05 vs. Vehl-Ctrl, # P<0.05 vs. Vehl-Hcys.
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5.2.3 Blocking TXNIP abrogated Hcys-induced increases in caspase-1 activity and IL-1β
secretion
It is known that the formation of NLRP3 inflammasomes results in downstream caspase-1
activation and subsequent IL-1β maturation. These effects reflect the functionality of the formed
inflammasomes and thus were used to determine the effect of TXNIP inhibition on Hcys-induced
inflammasome activation in the current study. Hcys treatment significantly increased caspase-1
activity and IL-1β production in podocytes compared to control cells, suggesting activation of
NLRP3 inflammasomes (Figures 26A and 26B). Both TXNIP siRNA transfection and
pretreatment with verapamil significantly attenuated Hcys-induced caspase-1 activity and IL-1B
production.

Figure 26. Attenuation of Hcys-induced NLRP3 inflammasome activation by TXNIP
blockade. A. Effect of TXNIPsi and verapamil on Hcys-induced NLRP3 inflammasome
activation, shown as the fold change of caspase-1 activation versus Vehl-Ctrl (n=7-8). B.
Measured in the supernatant of cultured podocytes, TXNIP inhibition suppressed Hcysinduced IL-1β production (n=8). Ctrl: Control, Vehl: Vehicle, TXNIPsi: TXNIP siRNA. *
P<0.05 vs. Vehl-Ctrl, # P<0.05 vs. Vehl-Hcys.
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5.2.4 Protection from Hcys-induced podocyte damage by TXNIP inhibition
To assess the extent of podocyte damage, the protein expression of slit diaphragm
molecules like podocin and desmin was monitored. Podocin, a podocyte-specific marker,
decreases in expression during injury, while podocyte damage marker desmin increases during
injury [184-185]. Immunofluorescence analysis demonstrated that Hcys-treated podocytes
displayed a dramatic decrease in podocin staining and increase in desmin staining, signifying
podocyte damage (Figure 27A). However, TXNIP inhibition resulted in the reversal of these
podocyte damages as shown by restoration of podocin and desmin protein expression to control
levels. Quantification of fluorescence was summarized in Figure 27B. Moreover, the ability of
podocytes to secrete VEGF is considered to be an additional measure of podocyte functionality
[186]. Hcys-injured podocytes displayed impaired secretion of VEGF, which was precluded in
TXNIP siRNA or verapamil treated cells (Figure 27C). Together, these data suggest that TXNIP
mediates Hcys-induced podocyte dysfunction and that inhibition of TXNIP ameliorates the
deleterious effects of Hcys or inflammation activation on podocytes.
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Figure 27. Inhibition of TXNIP preserved podocyte integrity. A. Immunofluorescence
staining of podocyte-specific marker podocin and podocyte injury marker desmin, where
Hcys-induced decrease in podocin and increase in desmin expression were attenuated by
TXNIPsi and verapamil. B. Summarized data showing the relative intensity of podocin and
desmin staining (n=6). C. VEGF was measured in the supernatant of podocytes and used as an
indicator of podocyte functionality, where Hcys-damaged podocytes suppressed VEGF
secretion, which was restored upon TXNIP inhibition (n=6). Ctrl: Control, Vehl: Vehicle,
TXNIPsi: TXNIP siRNA. * P<0.05 vs. Vehl-Ctrl, # P<0.05 vs. Vehl-Hcys.

79
5.2.5 Local in vivo TXNIP shRNA transfection inhibited TXNIP mRNA and protein
expression in mouse kidneys
To further determine the role of TXNIP in NLRP3 inflammasome activation and
glomerular injury in mice, we transfected TXNIP shRNA into the kidney via the renal artery to
locally silence the TXNIP gene. Our previous reports have demonstrated that introduction of
plasmids locally into mouse kidneys by the ultrasound-microbubble technique displayed stable
expression of transfected gene for at least 4 weeks [187]. In order to monitor plasmid
transfection efficiency, a plasmid with a luciferase expression vector was cotransfected together
with the targeting TXNIP shRNA plasmid to act as a reporter. Figure 28A represents in vivo
imaging of gene expression in mouse kidneys monitored 3, 7, and 14 days post-transfection by
an IVIS rodent animal imaging system. In a semidissected kidney 4 days after transfection, a
strong luciferase signal was detected in the renal cortex, where the observed signal represents
efficient transfection and gene expression (Figure 28B). It was demonstrated that efficient
transfection of plasmids and gene expression were maintained throughout experiments and such
in vivo imaging of gene expression was used to determine whether mice can continue for further
functional studies. After transfected mice were maintained on either a normal or FF diet for 4
weeks, the TXNIP mRNA levels in the kidney were assessed by real time RT-PCR to validate
the efficiency of plasmid transfection and gene expression. As shown in Figure 28C, TXNIP
shRNA transfection significantly decreased TXNIP mRNA expression in mice on the ND when
compared to those transfected only with luciferase plasmids. Although TXNIP mRNA
expression increased in luciferase-transfected mice maintained on the FF diet, TXNIP shRNAtransfected mice exhibited substantially reduced TXNIP mRNA expression. These findings were
translated to the protein level, demonstrated by immunofluorescent staining of TXNIP in the
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glomeruli of transfected mice (Figure 28D). Together, we concluded that TXNIP shRNA is
efficiently delivered locally to the mouse kidney and successfully being expressed, as evidenced
by the markedly reduced TXNIP expression in glomeruli of mice.

Figure 28. Efficiency of local in vivo transfection of TXNIP shRNA into the renal cortex
by the ultrasound-microbubble technique. A. Images taken 3, 7, and 14 days posttransfection by an in vivo imaging system daily confirmed transfection efficiency. B. Ex vivo
image 4 days after transfection of semidissected kidney demonstrated successful localized
gene expression. C. Real time RT-PCR data quantifying mRNA silencing efficiency of the
plasmid after 4 weeks of maintenance on either a ND or FF diet (n=6). D. Immunofluorescent
staining of TXNIP in the glomeruli of transfected mice. ND: Normal diet, FF: Folate-free diet,
Luci: Luciferase, TXNIPsh: TXNIP shRNA. * P<0.05 vs. Luci-ND.
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5.2.6 Effect of in vivo TXNIP inhibition on hHcys-induced TXNIP-NLRP3 binding and
NLRP3 inflammasome formation in glomeruli
After 4 weeks of uninephrectomized mice receiving the FF diet regiment, mice developed
hHcys which resulted in NLRP3 inflammasome formation in their glomeruli, mainly in
podocytes as shown in our previous studies [49, 170]. Illustrated in Figure 29A, confocal
microscopic analysis demonstrated that FF diet-fed mice increased colocalization of NLRP3 with
ASC (increased yellow staining) in glomeruli of luciferase transfected mice compared to ND fed
mice, suggesting glomerular NLRP3 inflammasome formation during hHcys. This was further
accompanied with an increase in TXNIP expression, which colocalized significantly with
NLRP3, and possible binding to the NLRP3-ASC-caspase-1 inflammasome complex. However,
TXNIP inhibition (either by verapamil or TXNIP shRNA transfection) substantially suppressed
colocalization of NLRP3 with either ASC or TXNIP (Figure 29A). This colocalization was
quantified and summarized in Figure 29B and 29C. Further exemplified by coimmunoprecipitation studies, hyperhomocysteinemic mice displayed robust amounts of TXNIP
protein pulled down together with NLRP3 compared to ND fed mice, suggesting that NLRP3TXNIP binding was enhanced during hHcys (Figure 29D). However, this enhanced NLRP3TXNIP binding was not observed in glomeruli of TXNIP shRNA transfected or verapamil
treated mice.
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Figure 29. In vivo inhibition of TXNIP and its effect on NLRP3 inflammasome
formation. A. Confocal microscopy demonstrated the colocalization between NLRP3 (green)
with ASC (red) and NLRP3 (green) with TXNIP (red) in the glomeruli of Luci, TXNIPsh, and
verapamil treated mice maintained on either a ND or FF diet. B-C. Summarized data showing
the quantification of the extent of colocalization between NLRP3 with ASC and NLRP3 with
TXNIP (n=6). D. Co-immunoprecipitation studies demonstrated robust in vivo TXNIPNLRP3 binding in mice with hHcys, which was not evident after TXNIP inhibition (n=5).
ND: Normal diet, FF: Folate-free diet, Luci: Luciferase, TXNIPsh: TXNIP shRNA. * P<0.05
vs. Luci-ND, # P<0.05 vs. Luci-FF.
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5.2.7 TXNIP inhibition diminished renal caspase-1 activation and IL-1β secretion
induced by hHcys
Caspase-1 activity and IL-1β production was measured to evaluate the effects of in vivo
TXNIP inhibition on hHcys-induced NLRP3 inflammasome activation (Figure 30A and 30B).
Mice with hHcys induced by the FF diet displayed increased caspase-1 activation and IL-1β
production compared to those on the ND, suggesting increased NLRP3 inflammasome activity in
the cortical tissue. This activation was not apparent in the mice where TXNIP was inhibited by
either shRNA transfection or verapamil treatment.

Figure 30. In vivo TXNIP shRNA transfection and verapamil treatment blocked
caspase-1 activation and IL-1β production. A. Caspase-1 activity, shown as fold change
versus Luci-ND, in Luci, TXNIPsh, and verapamil-treated mice with FF diet-induced hHcys
(n=5-6). B. In vivo TXNIP inhibition prevented hHcys-induced IL-1β production (n=6). ND:
Normal diet, FF: Folate-free diet, Luci: Luciferase, TXNIPsh: TXNIP shRNA. * P<0.05 vs.
Luci-ND, # P<0.05 vs. Luci-FF.
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5.2.8 Attenuation of hHcys-induced glomerular dysfunction by TXNIP inhibition
As

shown

above

and

documented

by

many of

our

previous

studies,

the

hyperhomocysteinemic mouse model successfully induced significant glomerular dysfunction
and ultimate sclerosis [48, 169, 179]. Demonstrated in Figures 31A and 31B, luciferase
transfected mice on the FF diet also exhibited severe urinary protein and albumin excretion
compared to control mice on the ND, suggesting glomerular injury or dysfunction. Furthermore,
mice with hHcys displayed aberrant glomerular morphology, characterized by a shrunken
phenotype with extracellular matrix and collagen deposition, capillary collapse, and mesangial
cell expansion (Figure 31C). Decreased expression of podocyte specific marker, podocin and
increase in podocyte damage marker, desmin, both hallmarks of podocyte injury, were also
observed in the glomeruli of mice on the FF diet (Figures 31E and 31F). In vivo TXNIP
inhibition by shRNA transfection or verapamil treatment was able to prevent all of the
aforementioned destructive changes induced by hHcys as shown by the reduction of proteinuria,
albuminuria, glomerular pathological changes, and restored expression of podocin and desmin. It
should be noted that all of these observed effects occurred independently of changes to blood
pressure, as there was no measurable difference in mean arterial pressure between all groups of
mice (data not shown). These data provided solid evidence that TXNIP plays a detrimental role
in hHcys-induced podocyte and glomerular damage, which is due to its ability to mediate
NLRP3 inflammasome activation.
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Figure 31. Amelioration of hHcys-induced glomerular damage by in vivo TXNIP
inhibition. A-B. hHcys-induced increases in proteinuria and albuminuria were diminished by
TXNIPsh transfection and verapamil administration (n=6-8). C. Observation of glomerular
morphology in PAS stained slides revealed severe pathological changes in the glomeruli of
Luci-FF mice, which were prevented in TXNIP inhibited mice. D. Pathological changes in the
glomeruli were semiquantitatively scored and summarized as the glomerular damage index
(GDI) (n=5). E-F. In vivo immunofluorescent staining of podocin and desmin to assess
glomerular podocyte condition (n=6). ND: Normal diet, FF: Folate-free diet, Luci: Luciferase,
TXNIPsh: TXNIP shRNA. * P<0.05 vs. Luci-ND, # P<0.05 vs. Luci-FF.
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5.3

Summary
Taken together, we provided direct evidence that inhibition of TXNIP and diminished

TXNIP-NLRP3 binding reduced NLRP3 inflammasome formation and activation, even in the
continued presence of elevated Hcys or during hHcys in mice. This reduction in TXNIP–
mediated inflammasome activation protected podocytes from the early deleterious effects of
Hcys that, if left unattended, may ultimately progress to glomerular sclerosis and potential
ESRD.
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CHAPTER SIX
Contribution of guanine nucleotide exchange factor Vav2 to hyperhomocysteinemiainduced NLRP3 inflammasome activation

6.1

Rationale and Hypothesis
Our evidence thus far demonstrated that NADPH oxidase-derived reactive oxygen species

(ROS) mediate the activation of podocyte NLRP3 inflammasomes in response to elevated levels
of Hcys or in vivo during hHcys. Our laboratory has also previously provided evidence that the
guanine nucleotide exchange factor Vav2 exhibits high specificity to Rac1-mediated NADPH
oxidase activation by elevated Hcys [44]. Vav2 overexpression alone and its subsequent NADPH
oxidase activation were able to cause glomerular injury, even without the presence of hHcys.
However, it remains unknown whether NADPH oxidase activator, Vav2, is involved in NLRP3
inflammasome activation. Therefore, this last series of studies was designed to further validate
the central role of NADPH oxidase by testing whether its molecular activator, Vav2 contributes
to hHcys-induced NLRP3 inflammasome activation. In order to test this hypothesis, which is
schematically represented in Figure 32, podocytes were transfected with either a scramble,
constitutively active form of Vav2 (oncoVav2) or Vav2 shRNA plasmid directly to the nucleus
via nucleofection. Mice were also locally transfected with either the oncoVav2 or Vav2sh
plasmid into the renal cortex, maintained on the normal or FF diet to induce hHcys, and then
assessed for NLRP3 inflammasome formation and activation after 4 weeks of treatment.
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Figure 32. Diagram showing the participation of Vav2 in NLRP3 inflammasome
activation. Aim 3 tested whether enhanced NADPH oxidase activity via Vav2
overexpression, both in vitro and in vivo, is sufficient to cause NLRP3 inflammasome
activation. Additionally, Aim 3 further confirmed the central role of NADPH oxidase by
looking at the effect of Vav2 inhibition.

6.2

Results

6.2.1 OncoVav2 induced NLRP3 inflammasome activation and podocyte injury
As demonstrated earlier, Hcys treatment of podocytes significantly increased NLRP3
inflammasome activation measured through caspase-1 activation and IL-1β production (Figures
33A and 33B). We now found that the inhibition of Vav2 attenuated both of these measures of
inflammasome activation. Additionally, overexpression of Vav2 by nucleofection of the
oncoVav2 plasmid resulted in increased caspase-1 activity and IL-1β secretion even in the
absence of Hcys, importantly suggesting that NADPH oxidase activation alone is sufficient to
stimulate NLRP3 inflammasome activation. Hcys treatment or oncoVav2 nucleofection also
caused podocyte dysfunction, seen in the impaired ability of these podocytes to secrete VEGF
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(Figure 33C). Inhibition of Vav2, however, protected podocytes from this injury and restored
VEGF secretion levels. Altogether, these in vitro results demonstrate an essential role for Vav2
in Hcys-induced NLRP3 inflammasome activation and podocyte injury.

Figure 33. Overexpression of Vav2 induced NLRP3 inflammasome activation and
podocyte injury. A-B. Hcys treatment of podocytes, as well as oncoVav2 nucleofection
alone, increased caspase-1 activation and IL-1β production, which was inhibited upon Vav2sh
nucleofection. (n=4-5). C. Inhibition of Vav2 protected podocytes from Hcys-induced
dysfunction, seen in restored levels of VEGF secretion (n=5). Ctrl: Control, Scram: Scramble,
Vav2sh: Vav2 shRNA. * P<0.05 vs. Scram-Ctrl, # P<0.05 vs. Scram-Hcys.
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6.2.2 In vivo inhibition of Vav2 prevented glomerular NLRP3 inflammasome formation
and activation
Through confocal microscopy observation, mice maintained on the FF diet exhibited
glomerular NLRP3 inflammasome formation and increased colocalization between NLRP3 with
ASC and NLRP3 with caspase-1 (Figure 34A). Mice locally transfected with oncoVav2 plasmid
displayed a similar pattern of NLRP3 inflammasome formation despite not being
hyperhomocysteinemic, suggesting that Vav2 overexpression-induced activation of NADPH
oxidase is adequate to form NLRP3 inflammasomes regardless of elevated homocysteine.
However, inhibition of Vav2 hindered hHcys-induced NLRP3 inflammasome formation, seen by
reduced colocalization of NLRP3 with ASC or caspase-1, depicting an important role of Vav2
and NADPH oxidase in the aggregation of inflammasome proteins in the glomeruli of
hyperhomocysteinemic mice. This same pattern was observed for hHcys-induced NLRP3
inflammasome activation and measurement of caspase-1 activation (Figure 34B). Finally, hHcys
as well as oncoVav2 transfection induced glomerular dysfunction and albuminuria, which was
diminished in Vav2sh-transfected mice (Figure 34C). Although our laboratory has already
implicated an important role for Vav2 in hHcys-induced glomerular dysfunction [44], these data
newly implicate a critical role for Vav2 in hHcys-induced glomerular NLRP3 inflammasome
formation and activation. Additionally, in vivo NADPH oxidase activation via Vav2
overexpression was sufficient to activate NLRP3 inflammasomes, signifying that these
mechanisms can occur independently of elevated Hcys.
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Figure 34. In vivo inhibition of Vav2 prevented glomerular NLRP3 inflammasome
formation and activation. A-B. Mice with hHcys and those transfected with oncoVav2
plasmid demonstrated increased NLRP3 inflammasome formation and activation, seen by
increased colocalization (yellow staining) between inflammasome proteins NLRP3 with ASC
and NLRP3 with caspase-1, as well as increased caspase-1 activation. These effects were
inhibited upon Vav2sh transfection (n=4). C. hHcys-induced increases in albuminuria were
diminished by Vav2sh transfection (n=4). ND: Normal diet, FF: Folate-free diet, Scram:
Scramble, Vav2sh: Vav2 shRNA.
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6.3

Summary
Together, these preliminary results indicate a necessary role for Vav2 in the activation of

hHcys-induced NLRP3 inflammasomes via its activating action on NADPH oxidase, where
inhibition of Vav2 can prevent its activation as well as the deleterious effects of Hcys on the
glomeruli. These studies further validate the central role of NADPH oxidase activation in this
mechanism of podocyte NLRP3 inflammasome activation. Importantly, experiments using
oncoVav2 demonstrate that NADPH oxidase activation occurring independently of hHcys can
also result in NLRP3 inflammasome formation and activation, suggesting that this redox
activating mechanism of NLRP3 inflammasomes is not necessarily specific to Hcys alone, but
perhaps to any activators of NADPH oxidase.
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CHAPTER SEVEN
DISCUSSION

7.1

Role of NADPH oxidase in mediating NLRP3 inflammasome formation and

activation in podocytes in response to elevated Hcys levels
The primary goal of our first series of studies was to reveal whether NADPH oxidasemediated redox signaling contributes to Hcys-induced inflammasome formation or activation and
consequent glomerular injury. In vitro studies using cultured podocytes and an in vivo animal
model of hHcys demonstrated that NADPH oxidase is necessary for the formation and activation
of NLRP3 inflammasomes in podocytes upon Hcys stimulation, thereby leading to podocyte
dysfunction, glomerular immune cell recruitment, and ultimately glomerular injury and sclerosis.
These results for the first time demonstrate Hcys-induced redox activation of podocyte NLRP3
inflammasomes as an early mechanism switching on local inflammatory responses in glomeruli.

hHcys has been known to directly cause deleterious effects in the kidney, promoting a
vicious cycle responsible for chronic renal disease, where hHcys decreases renal function and
leads to further increased plasma Hcys levels due to decreases in Hcys excretion in the kidney
[18]. Our most recent work demonstrated through concentration and time dependent studies that
in an in vitro setting, a 40 μM treatment for 24 hours in cultured podocytes is sufficient to
activate an inflammasome-stimulating response, verifying the effect we have seen in vivo [49].
Indeed, the present study showed significant glomerular damage observed in gp91phox+/+ mice fed
a FF diet for 4 weeks. Coinciding with this glomerular damage characterized by our laboratory
and others to include mesangial cell expansion, overall cell proliferation, and capillary collapse
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[48, 188], hHcys caused a significant increase in proteinuria and albuminuria, indicative of an
impaired glomerular filtration membrane. In previous studies, these damaging effects of hHcys
have been well correlated with its ability to stimulate the inflammatory response.
Proinflammatory mediators, like MCP-1, NF-kB, interleukin-8, and adhesion molecules VCAM1 and E-selectin, have been demonstrated to be upregulated during hHcys [189-190].
Furthermore, it has been shown that hHcys results in the recruitment of lymphocytes [191].
However, it remains unknown how hHcys or Hcys in vitro activates this response of the innate
immune system in glomeruli. We have recently reported that Hcys can activate NLRP3
inflammasomes in podocytes, an intracellular molecular switch of inflammation [49].
Inflammasome activation has also been implicated in a number of inflammatory and metabolic
diseases, including obesity, gout, hypersensitivity, silicosis, and diabetes, where inhibition of the
inflammasome proteins NLRP3, ASC, or caspase-1 significantly attenuates the downstream
inflammatory reaction produced under these conditions [118, 120, 126-127]. Similarly, our
report showed that inhibition of either ASC or caspase-1 could prevent podocyte and glomerular
damage induced by hHcys, improving renal structural and functional integrity [49], suggesting
an important role for inflammasome activation in mediating the deleterious effects of hHcys.

We further explored the mechanism by which NLRP3 inflammasomes are activated in
podocytes in vitro by Hcys and in vivo by experimental hHcys. It has been reported that many
endogenous and exogenous danger signals activate the inflammasome, and it has been of great
interest as to how all of these very diverse signals can activate the same molecular machinery to
turn on inflammation. Of the proposed models of inflammasome activation, the ROS model
provides a unifying link, utilizing the common aspect that all these danger signals produce
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changes in oxidative stress, making NLRP3 a more general sensor detecting these changes in
oxidative stress [149]. Interestingly, our laboratory and others have found the damaging effects
of hHcys to be strongly associated with increased local oxidative stress, chiefly through NADPH
oxidase [47, 64-65]. With reports of gp91phox/Nox2 being the predominant isoform found in
podocytes, our laboratory has also demonstrated that this NADPH oxidase isoform and its
activity are essential for hHcys to induce glomerular injury, since knockout of the gp91phox gene
in mice protected podocytes and glomeruli from hHcys-induced glomerular sclerosis [48].
Therefore, we hypothesized that redox signaling associated with NADPH oxidase in podocytes
may be critical in triggering NLRP3 inflammasome formation and activation upon Hcys
stimulation. Although there are reports that NLRP3 inflammasomes can be activated by ROS in
different cells or tissues [126, 149, 181], to our knowledge, our results for the first time link
NADPH oxidase to the formation and activation of these inflammasomes in podocytes, where
Hcys-induced NADPH oxidase activation produces O2•− to conduct redox signaling that triggers
the formation of NLRP3 inflammasomes and production of inflammatory cytokines like IL-1.

Next, we tested the in vivo triggering action of NADPH oxidase activation in the formation
of NLRP3 inflammasomes using mice lacking the gp91phox gene and in mice treated with
NADPH oxidase inhibitory peptide, gp91ds-tat. Although the strategies used to genetically and
pharmacologically inhibit NADPH oxidase in mice were not podocyte-specific, confocal results
demonstrated that this inhibition prevented hHcys-induced NLRP3 inflammasome formation as
shown by less colocalization of NLRP3 with ASC and NLRP3 with caspase-1, which mainly
occurred in podocytes given the increased colocalization of NLRP3 molecules with podocin and
desmin within glomeruli. Correspondingly, both interventions also inhibited hHcys-induced
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activation of NLRP3 inflammasomes, confirmed by decreased caspase-1 activity and IL-1β
production. The inflammatory response in glomeruli during hHcys, indicated by recruitment of
macrophages and T-cells, was also significantly suppressed by both RNA interference and
pharmacological inhibition of NADPH oxidase. These results from in vivo animal experiments
further support the view that NADPH oxidase-mediated redox signaling promotes the formation
and activation of NLRP3 inflammasomes in podocytes during hHcys. Again, to our knowledge,
these findings represent the first in vivo experimental evidence that triggering of NLRP3
inflammasomes is attributed to NADPH oxidase-mediated redox signaling, which results in local
inflammation in glomeruli during hHcys.

We also performed in vitro and in vivo experiments to address the functional relevance of
NADPH oxidase-mediated triggering of NLRP3 inflammasomes on Hcys-stimulated podocyte
and glomerular injury. Podocytes, the epithelial cells lining the outermost layer of the glomeruli,
are essential for proper filtration, and the injury to podocytes is indicative of impaired glomerular
filtration and proteinuria, ultimately leading to glomerular sclerosis [192-193]. Foot process
effacement, considered as the hallmark sign of podocyte injury, is usually accompanied by the
destruction of the actin cytoskeleton, increased expression of slit diaphragm molecule and
podocyte injury factor desmin, and reduction of the slit diaphragm molecule podocin, an
important marker for cell polarity and survival. Although such protection of podocytes observed
in in vivo experiments may be due to a suppressed inflammatory response, it is interesting to note
that in in vitro experiments the direct effects of suppressed inflammasome or NADPH oxidase
also protect the functional and structural integrity of podocytes, even before a typical
inflammatory response is instigated. This non-inflammatory effect or direct action on podocytes
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has been reported to be associated with IL-1β-induced podocyte dysfunction, which is beyond
inflammation [194]. In addition to the detrimental actions of hHcys-induced inflammatory
response, the early effect of activated inflammasome products, like IL-1β, directly on podocytes
may also importantly contribute to podocyte injury. If triggering of such inflammasomes by
NADPH oxidase-derived ROS is blocked, both direct and indirect effects of inflammasome
activation in the induction of podocytes injury may be blocked, as shown in our results.

Corresponding to protection of podocytes from Hcys-induced injury, inhibition of
inflammasome activation by deletion of gp91phox gene or inhibition of NADPH oxidase activity
significantly ameliorated hHcys-induced glomerular injury in mice, which may be due to
decreased podocyte injury as well as suppressed local glomerular inflammatory response.
Together, this NADPH oxidase-derived ROS may act as redox signaling messengers to activate
the NLRP3 inflammasome, which serves as the bridging and amplifying mechanism leading to
an eventual robust inflammatory response which promotes the progression to glomerular
sclerosis.

7.2

Redox activation of NLRP3 inflammasomes in response to elevated Hcys or during

hHcys depends on both O2•− and H2O2
The goal for this portion of the study was to dissect which endogenously produced ROS in
response to increased Hcys in podocytes in vitro and in vivo contributes to hHcys-induced
NLRP3 inflammasome formation and activation. Studies using cultured podocytes revealed that
reduction of intracellular O2•− and H2O2 levels attenuated Hcys-induced NLRP3 inflammasome
formation and suppressed downstream caspase-1 activation and IL-1β production. In vivo,
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dismutation of O2•− and decomposition of H2O2 in hyperhomocysteinemic mice not only
prevented NLRP3 inflammasome formation in glomeruli, but also protected mice with hHcys
from renal dysfunction and glomerular sclerosis. To our knowledge, this study is the first effort
to dissect endogenously produced ROS in NLRP3 inflammasome activation in podocytes and
glomeruli during exposure to high Hcys levels or hHcys.

Many studies provided increasing evidence for the central role of ROS in NLRP3
inflammasome activation [126, 195-196]. Additional studies have demonstrated that IL-1β
production in response to even more diverse stimuli could be prevented through the use of either
NADPH oxidase inhibitors or general ROS scavengers such as diphenylene iodonium (DPI) and
N-acetyl-cysteine (NAC) [151, 197-199]. However, by using these general ROS scavengers, it
remains largely unexplored as to exactly which species of ROS is being sensed and is indeed
contributing to NLRP3 inflammasome activation. Aside from O2•−, other species derived from
NADPH oxidase include H2O2, peroxynitrite (ONOO-), and •OH [200]. A small subset of reports
has attempted the use of ROS scavengers, but to our knowledge, the present study is the first to
dissect the action of these common endogenously produced ROS to elucidate their role in hHcysinduced NLRP3 inflammasome activation.

TEMPOL, used for its antioxidant properties, has been widely demonstrated to have
protective effects against many disease models including diabetes, cardiovascular complications,
heart failure, angiogenesis, ischemia-reperfusion injury, cancer, and glomerular injury [201-203].
Catalase is responsible for the enzymatic decomposition of H2O2 down to H2O and O2 [204-205],
and TMTU has been used as a specific •OH scavenger [203]. These pharmacologic tools enabled
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the dissection of the ROS participating in Hcys-induced NLRP3 inflammasome formation and
activation. However, the use of TEMPOL is fairly limited in that its selectivity for O 2•− is quite
restricted due to a number of nonspecific targets, hence our use of PEG-SOD as well as an
additional SOD mimetic, MnTMPyP, in in vitro experiments to further verify our results. But,
similar to our findings in podocytes or glomeruli, a recent report provided evidence that
scavenging of extracellular O2•− by SOD mimetic Mn(III)tetrakis(N-ethylpyridinium-2-yl)
porphyrin (MnTE-2-PyP) could prevent NLRP3 inflammasome activation in a model of
hypoxia-induced pulmonary hypertension [183]. In addition, Zhou et al demonstrated the ability
of exogenous H2O2 to directly activate NLRP3 inflammasomes to produce IL-1β [126]. Taken
together, these data suggest the requirement of O2•− dismutation to H2O2 in ROS-stimulated
inflammasomes, which proposes an important role for H2O2 not only in Hcys-induced NLRP3
inflammasome formation, but also in inflammasome formation in response to other stimuli that
increase H2O2 production.

The •OH scavenger TMTU did not significantly inhibit any measure of Hcys-induced
NLRP3 inflammasome formation or activation, suggesting that in comparison to O2•− and H2O2,
•

OH does not play a crucial role to inflammasome stimulation. Although TMTU did not produce

inhibitory effects that were of statistical significance, caspase-1 activity and IL-1β production
appeared lower when TMTU was used. This effect may be due to some non-specific action of
TMTU because thiourea compounds, although commonly used as potent scavengers of •OH, are
also able to scavenge O2•− and H2O2 at higher doses [206-207].
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An important role for ONOO- in many disease processes is supported throughout the
literature, including Hcys-induced cardiovascular and renal injury where ONOO- participates in
detrimental events such as endothelial dysfunction and renal ischemia-reperfusion injury [208209]. Therefore, we examined the role of ONOO- scavenging on Hcys-induced NLRP3
inflammasome formation and activation in podocytes. It was found that ebselen, a specific
ONOO- scavenger, failed to decrease the formation and activation of NLRP3 inflammasomes in
podocytes treated with Hcys, suggesting that ONOO- may not play a critical role in this
particular pathological process in podocytes.

With respect to the models of NLRP3 inflammasome activation, there is debate whether
pro- or antioxidant events contribute to this phenomenon. Our study, along with many of the
aforementioned studies, provided supportive evidence for a ROS-dependent mechanism that can
be hindered when these species are scavenged. This concept, however, has been challenged with
evidence demonstrating that ROS inhibition prevents the priming, but not activation of
inflammasomes [156]. Furthermore, monocytes and macrophages isolated from patients with
chronic granulomatous disease and NADPH oxidase-deficient mice exhibited typical IL-1β
secretion [119, 157], which was different from our results in podocytes [169]. It is possible that
different cell types may have altered sensitivity to redox regulation of NLRP3 inflammasomes or
to different danger signals. Activation of NLRP3 or other inflammasomes in macrophages in
vitro may require a priming process, a step that perhaps is not necessary in other cell types [49,
210]. In addition, since NLRP3 inflammasome activation only requires a low level of
intracellular O2•− or H2O2 as a signaling mechanism rather than a injurious event, monocytes and
macrophages isolated from patients with chronic granulomatous disease and NADPH oxidase-
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deficient mice may still potentially generate enough ROS to stimulate NLRP3 inflammasome
activation and IL-1β production. Perhaps other ROS-producing pathways in these sick cells may
also exert compensatory redox regulation to NLRP3 inflammasome activation. Additional
studies are needed to further explore such potential for the redox regulation of NLRP3
inflammasomes in different cell types.

These findings importantly implicate a specific role for both O2•− and H2O2 in the
instigation of NLRP3 inflammasome activation in cultured podocytes and in glomeruli of mice
with hHcys. O2•− and H2O2 may be the redox signaling messengers linking NADPH oxidase
activation to the stimulation of the innate immune system through NLRP3 inflammasome
activation, where initiation of the inflammatory response may lead to more extensive oxidative
stress that is responsible for hHcys-induced detrimental and pathological glomerular changes.

7.3

TXNIP senses redox signals to activate NLRP3 inflammasomes in response to

increased Hcys in vitro or during hHcys in vivo
Additional experiments in this study were designed to address the role of TXNIP in hHcysinduced NLRP3 inflammasome activation and associated podocyte injury and glomerular
sclerosis. It was found that Hcys treatment of podocytes upregulated protein expression of
TXNIP, which resulted in increased binding of TXNIP with inflammasome protein NLRP3. Both
in vitro and in vivo inhibition of TXNIP by its inhibitor verapamil or RNA interference blocked
TXNIP

expression

and

prevented

TXNIP-NLRP3

binding

and

subsequent

NLRP3

inflammasome activation in response to Hcys. These findings demonstrate the critical role of
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TXNIP binding in the activation of NLRP3 inflammasomes and subsequent podocyte injury and
glomerular dysfunction or sclerosis.
Despite studies that have demonstrated an important role for ROS in inflammasome
activation, it remains unclear how NLRP3 is able to sense redox changes in a variety of cells, in
particular, in podocytes during hHcys. Through a yeast two hybrid screen, it has been shown that
thioredoxin-interacting protein (TXNIP), a ROS sensor and an endogenous inhibitor of the
antioxidant thioredoxin, is a binding partner of NLRP3. TXNIP, also known as vitamin D3
upregulated protein 1 (VDUP-1) and thioredoxin-binding protein-2 (TBP-2), plays a critical role
in growth suppression, making it particularly important in cancer progression by causing G1 cell
cycle arrest. It is also a crucial regulator of lipid metabolism where overexpression of TXNIP
during hyperglycemia causing β-cell death and impaired insulin secretion [211]. Zhou et al
confirmed an important role for TXNIP in the pathogenesis of type 2 diabetes by showing that
TXNIP binding to NLRP3 was essential for ROS-mediated inflammasome activation [126].
Additionally, in human and rat kidneys, TXNIP mRNA and protein is most abundantly
expressed in the glomeruli [212], and although some studies have demonstrated its upregulation
in response to high glucose [213-214], there have been no studies to date determining the effects
of Hcys on TXNIP, in particular, in podocyte or glomerular injury, which was one of the goals in
the current study.

Using RNA interference and pharmacologic inhibitors of TXNIP, we found that TXNIP
mRNA and protein expression was significantly reduced after transfection of siRNA into
cultured mouse podocytes (data not shown) and local transfection of TXNIP shRNA in vivo into
mouse kidneys. To complement this RNA manipulation, we used pharmacologic calcium
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channel blocker verapamil to inhibit TXNIP expression both in vitro and in vivo. It has been
demonstrated that verapamil, when administered to mice through the drinking water at an
average dose of 100 mg/kg/day, decreased diabetes-induced cardiomyocyte apoptosis, an effect
specifically due to its potent inhibition of TXNIP expression [168]. Additionally, verapamil
enhanced β-cell survival and function through its reduction of β-cell TXNIP expression [215],
and this may be due to verapamil-induced transcriptional repression of TXNIP [216]. It was
found that verapamil, at a dose of 50 μM, strongly inhibited TXNIP expression (data not shown),
blocked TXNIP binding to NLRP3, and prevented Hcys-induced NLRP3 inflammasome
formation and activation in podocytes. In vivo experiments furthermore displayed TXNIP
inhibition hindering caspase-1 activation and IL-1β maturation in hyperhomocysteinemic mice.
To our knowledge, this provides the first evidence showing the critical role of TXNIP-NLRP3
binding in mediating podocyte inflammasome activation in response to Hcys stimulation.

It is well known that prolonged elevation of blood homocysteine level results in hallmarks
typical of glomerular sclerosis, including glomerular hypercellularity, capillary collapse, and
fibrous extracellular matrix deposition [217-219]. However, inhibition of TXNIP by either
genetic manipulation or by verapamil treatment prevented the Hcys-induced detrimental effects
on both podocytes in culture and glomerular structure and function. Verapamil has long been
demonstrated to have glomerular protective effects [220-221]; however, our study is the first to
demonstrate that, at least in hHcys-induced glomerular injury, this protective effect of verapamil
is associated with its inhibitory action of TXNIP.
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In other studies, inhibition of TXNIP expression by verapamil has also been reported [222],
but this effect has been extended to other calcium channel blockers and inhibitors such as
diltiazem and NiCl2, as well as with calcium chelator EGTA. This suggests that this inhibition of
TXNIP function is perhaps not a direct effect of verapamil itself, but more likely due to a
reduction in intracellular calcium concentrations [215]. Additionally, calcium signaling is
emerging as an important component of NLRP3 inflammasome activation. Brough et al first
demonstrated such role of calcium signaling when they found suppressed IL-1β maturation
following pretreatment of cells with calcium chelator, BAPTA-AM [223]. This process may
involve endoplasmic reticulum (ER) stress, calcium release from ER, and TXNIP binding [223225]. Although these possible non-specific effects of calcium inhibition may not be excluded,
our multifaceted approach of genetic and pharmacologic interventions give us confidence that
the diminished NLRP3 inflammasome activation by verapamil is indeed due to the reduction in
TXNIP expression and binding. It should be noted that the contribution of various calcium
signaling pathways in the mediation or regulation of NLRP3 inflammasome activation in
podocytes or other cells indeed warrants future exploration.

TXNIP binding to NLRP3 appears to be an essential mechanism involved in the regulation
of NLRP3 inflammasome activation in response to elevated Hcys. TXNIP may initiate the
NLRP3 cascade by endogenously sensing the altered redox status of the cell, triggering the
secretion of pro-inflammatory cytokines like IL-1β to potentiate the inflammatory response.
Inhibition of TXNIP not only prevented NLRP3 inflammasome activation and Hcys-induced
podocyte injury in cultured cells, but also importantly preserved glomerular function and
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morphology in hyperhomocysteinemic mice, suggesting a critical in vivo role for TXNIP in this
sclerotic mechanism.

7.4

Activation of NADPH oxidase by Vav2 overexpression is sufficient to activate

NLRP3 inflammasomes in podocytes, independent of hHcys
The further mechanistic studies on NLRP3 inflammasome activation were proposed to
address the effect of NADPH oxidase activation through the overexpression of Vav2, which
attempted to test whether NADPH oxidase activation by other stimuli also lead to NLRP3
inflammasome activity in podocytes. In cultured podocytes and mice, oncoVav2 transfection was
found to result in NLRP3 inflammasome formation and activation as well as glomerular
dysfunction, independent of elevated Hcys. However, inhibition of Vav2 by RNA interference
prevented hHcys-induced caspase-1 activation and protected from albuminuria, indicating
NADPH oxidase activation alone can activate NLRP3 inflammasomes and Vav2 can stimulate
hHcys-induced detrimental effects.

There exists considerable controversy regarding the role of NADPH oxidase in the
activation of NLRP3 inflammasomes in response to a diverse range of stimuli. There is evidence
to suggest that NADPH oxidase and its gp91phox subunit are dispensable in terms of NLRP3
inflammasome activation. Wu et al demonstrated that mechanical ventilation causes IL-1β
release in the lung; however, there was no inhibitory effect on released IL-1β in cyclic-stretched
mouse alveolar macrophages isolated from gp91phox−/− mice [158]. Instead, it was concluded that
ROS derived from mitochondria was necessary for NLRP3 inflammasome activation induced by
cyclic stretch. Furthermore, some studies showed that peripheral blood mononuclear cells
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isolated from chronic granulomatous disease (CGD) patients exhibit normal secretion of IL-1β
and even exacerbated caspase-1 activation when compared to healthy controls [157, 226-227].
Interestingly, in human neutrophils isolated from CGD patients having mutations in the gp91phox
subunit of NADPH oxidase displayed impaired IL-1β release but displayed no difference in the
ability to activate caspase-1 when compared to neutrophils from control patients [228]. This
suggested that NADPH oxidase, specifically gp91phox, and the production of ROS are
dispensable for NLRP3 inflammasome activation, but crucial for IL-1β secretion. This finding is
altogether different from Bauernfield et al who found that ROS is necessary for the priming and
regulation of NLRP3 inflammasome protein expression, but not needed for its activation [156].
On the other hand, NADPH oxidase and gp91phox are required for ATP-induced NLRP3
inflammasome activation in LPS-primed murine macrophages, where general NADPH oxidase
inhibitors DPI and apocynin as well as specific gp91phox siRNA inhibited caspase-1 activation
and IL-1β secretion [195]. Similar results have been found in response to many NLRP3
inflammasome stimulators like TNF-α and free fatty acids, where the effects of these stimulators
can be blocked upon NADPH oxidase inhibition [153-154]. With all these contradicting findings,
we sought to better understand the role of NADPH oxidase in Hcys-induced NLRP3
inflammasome activation in podocytes. Upon Vav2 overexpression, we found that NADPH
oxidase activation alone led to caspase-1 activation and IL-1β production in cultured podocytes,
indicating that NLRP3 inflammasome activation may vary with different stimuli, but if NADPH
oxidase is activated, NLRP3 inflammasomes can become activated in podocytes.

Rac1, considered the major Rac GTPase isoform in nonphagocytic cells, mediates NADPH
oxidase activity by switching between a GTP-bound “active” and a GDP-bound “inactive”
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conformational state. In the presence of various stimuli, guanine nucleotide exchange factors
(GEFs) like Vav and Tiam1 are responsible for this switching of Rac/Rho GTPases, leading to
multiple downstream effects limited not only to NADPH oxidase activation, but also regulating
cellular processes including proliferation, differentiation, and cytoskeletal arrangement [229].
The Vav family of GEFs, exhibiting high specificity to Rac-mediated NADPH oxidase
activation, consists of three members – Vav1, Vav2, and Vav3, with reports of Vav2 being
importantly expressed in podocytes [230]. It has been demonstrated by Inoue et al that Rac1
inhibitor NSC23766 suppressed ATP-induced ROS production and IL-1β secretion in bone
marrow macrophages [231]. Additionally, macrophages isolated from NLRP3−/− and ASC−/−
mice demonstrated no changes in Rac or Vav expression or ROS production, strongly suggesting
these molecules to be upstream of the NLRP3 inflammasome. Our results coincide with these
recent findings, supporting the manipulation of GEF Vav2 as an effective approach in
modulating NADPH oxidase activity. Indeed, we found that inhibition of Vav2 reduced NADPH
oxidase-derived O2•−, attenuated caspase-1 activation and IL-1β production, and protected
podocytes and mouse glomeruli from hHcys-induced injury.

Collectively, through specific activation of NADPH oxidase by overexpression of Vav2,
our studies provided strong evidence for a central and crucial role for NADPH oxidase in hHcysinduced NLRP3 inflammasome activation. This stimulation of NADPH oxidase, independent of
Hcys, importantly demonstrated that regardless of upstream stimulation, the activation of
NADPH oxidase and the production of ROS are sufficient to stimulate aggregation and
activation of NLRP3 inflammasomes. Therefore, these mechanisms may not be limited to only
elevated Hcys, but to any stimulator of NADPH oxidase.
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7.5

Summary and conclusions

The major findings of the present study are summarized below, and represented in Figure 35.

1. As previously demonstrated, we showed that hHcys-induced glomerular injury occured in an
NLRP3 inflammasome-dependent mechanism. However, blockade of NADPH oxidase
through the inhibition of its gp91phox subunit attenuated Hcys-induced NLRP3 inflammasome
activation in cultured podocytes as well as preserved podocyte function and integrity. In
hyperhomocysteinemic mice, gp91phox−/− as well as mice receiving a gp91ds-tat peptide
displayed diminished NADPH oxidase activation, as exhibited through reduced O2•− levels,
which contributed to the reduction in NLRP3 inflammasome formation and activation in
vivo. Together, these results reveal an essential role for NADPH oxidase activation and the
production of local oxidative stress in the triggering of NLRP3 inflammasomes in response
to hHcys.

2. Dismutation of O2•− by TEMPOL and decomposition of H2O2 by catalase prevented the
colocalization of NLRP3 inflammasome proteins, and reduced caspase-1 activity and IL-1β
production both in cultured podocytes and in glomeruli of hyperhomocysteinemic mice.
Specific ROS scavenging studies revealed that O2•− and H2O2, but not •OH or ONOO-,
distinctly contribute to NLRP3 inflammasome formation and activation during elevated
Hcys.

3. Through size-exclusion chromatography experiments, Hcys-treated podocytes exhibited both
increased expression and recruitment of TXNIP to high molecular weight fractions,
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indicative of TXNIP aggregation to the NLRP3 inflammasome. Confirmed by coimmunoprecipitation studies, robust increases in TXNIP-NLRP3 binding were found in
cultured

podocytes

with

Hcys

exposure

and

in

renal

cortical

tissue

from

hyperhomocysteinemic mice. Inhibition of TXNIP either by shRNA transfection or by
verapamil administration blocked TXNIP-NLRP3 binding and interfered with NLRP3
inflammasome activation, demonstrating the crucial role of TXNIP in hHcys-induced
NLRP3 inflammasome activation.

4. TXNIP expression was upregulated in podocytes in response to elevated Hcys, and in vivo
TXNIP inhibition significantly preserved glomerular morphology and function during hHcys.
FF diet-maintained mice receiving either TXNIP shRNA transfection or verapamil exhibited
drastically reduced proteinuria and albuminuria, as well as protection from hHcys-induced
glomerular sclerotic changes. To our knowledge, this is the first study elucidating that
TXNIP inhibition is glomerular protective against hHcys-induced insult.

5. The inhibition of guanine nucleotide exchange factor Vav2 prevented hHcys-induced NLRP3
inflammasome

formation

and

activation

in

both

cultured

podocytes

and

hyperhomocysteinemic mice, further verifying the important role of functional NADPH
oxidase in this mechanism. However, overexpression of Vav2 and consequent activation of
NADPH oxidase, independent of elevated Hcys, were also able to produce these
inflammasome-activating effects, suggesting that NADPH oxidase activation alone via Vav2
is sufficient to initiate the cascade that leads to NLRP3 inflammasome activation and
downstream glomerular injury.
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In conclusion, evidenced by gp91phox and Vav2 inhibition, NADPH oxidase is
demonstrated to be critical in mediating NLRP3 inflammasome formation, with O2•− and H2O2
being important signaling messengers. TXNIP may be the unique key that is responsible for
sensing these changes in these signaling ROS and initiating the cascade of NLRP3
inflammasome activation, eventually progressing to the pathogenesis of glomerular sclerosis
during hHcys. Activation of NADPH oxidase via overexpression of Vav2 was sufficient to
stimulate aggregation and activation of NLRP3 inflammasomes, suggesting these mechanisms
may not be limited to only elevated Hcys, but other potential pathogenic processes involving
NADPH oxidase activation.

Figure 35. Summary Diagram.
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7.6

Significance and perspectives
hHcys is widely recognized as an important, independent risk factor for the progression of

various sclerotic diseases, including glomerular sclerosis and ESRD. However, the therapeutic
value of Hcys-lowering interventions is marginal, and this may be attributed to Hcys-induced
irreversible detrimental effects on glomerular structure and function, on which Hcys-lowering
therapies would have negligible effects. Thus, our focus has been centered on identifying the
initiating and promoting mechanisms that occur during early stages of hHcys. In our search of
early biomarkers, the NLRP3 inflammasome became an attractive target since its major
functional role is to proteolytically cleave caspases leading to the maturation of proinflammatory cytokines and initiate the innate immune response from the single cell level. The
presence of activated NLRP3 inflammasomes, perhaps in the urine, may be an early biomarker,
useful in the diagnosis of early damage and the prevention of more serious glomerular sclerosis.
Importantly, sustained NLRP3 inflammasome activation may be a perpetual cellular trigger
responsible for initiating both inflammatory and non-inflammatory-related injury of podocytes,
ultimately resulting in progressive glomerular disease leading to ESRD. The findings in the
present study indicate the essential role of NADPH oxidase and the production of ROS,
specifically O2•− and H2O2, in hHcys-induced NLRP3 inflammasome formation and activation,
which may be a target to terminate inflammasome activation. TXNIP is also critical in this
NLRP3 inflammasome-activating mechanism because it is a ROS sensor linking NADPH
oxidase-derived ROS to NLRP3 inflammasome stimulation. Together, these findings provide
the first evidence that targeting either NLRP3 inflammasomes directly or their activating
mechanisms may be an effective therapeutic strategy for the prevention, detection, and early
treatment of glomerular sclerosis and other end-stage organ damage resulted from hHcys.

112
REFERENCES

[1]

Gonzalez, S.; Huerta, J. M.; Fernandez, S.; Patterson, A. M.; Lasheras, C. Homocysteine
increases the risk of mortality in elderly individuals. Br J Nutr 97:1138-1143; 2007.

[2]

Herrmann, W.; Obeid, R. Homocysteine: a biomarker in neurodegenerative diseases.
Clin Chem Lab Med 49:435-441; 2011.

[3]

McCully, K. S. Vascular pathology of homocysteinemia: implications for the
pathogenesis of arteriosclerosis. Am J Pathol 56:111-128; 1969.

[4]

Refsum, H.; Smith, A. D.; Ueland, P. M.; Nexo, E.; Clarke, R.; McPartlin, J.; Johnston,
C.; Engbaek, F.; Schneede, J.; McPartlin, C.; Scott, J. M. Facts and recommendations
about total homocysteine determinations: an expert opinion. Clin Chem 50:3-32; 2004.

[5]

Walker, W. G. Hypertension-related renal injury: a major contributor to end-stage renal
disease. Am J Kidney Dis 22:164-173; 1993.

[6]

Zhuo, J. M.; Pratico, D. Normalization of hyperhomocysteinemia improves cognitive
deficits and ameliorates brain amyloidosis of a transgenic mouse model of Alzheimer's
disease. FASEB J 24:3895-3902; 2010.

[7]

Zhang, C.; Yi, F.; Xia, M.; Boini, K. M.; Zhu, Q.; Laperle, L. A.; Abais, J. M.; Brimson,
C. A.; Li, P. L. NMDA receptor-mediated activation of NADPH oxidase and
glomerulosclerosis in hyperhomocysteinemic rats. Antioxid Redox Signal 13:975-986;
2010.

[8]

Hwang, S. Y.; Siow, Y. L.; Au-Yeung, K. K.; House, J.; O, K. Folic acid
supplementation inhibits NADPH oxidase-mediated superoxide anion production in the
kidney. Am J Physiol Renal Physiol 300:F189-198; 2011.

113
[9]

Wu, C. C.; Zheng, C. M.; Lin, Y. F.; Lo, L.; Liao, M. T.; Lu, K. C. Role of
homocysteine in end-stage renal disease. Clin Biochem 45:1286-1294; 2012.

[10]

de Koning, L.; Hu, F. B. Homocysteine lowering in end-stage renal disease: is there any
cardiovascular benefit? Circulation 121:1379-1381; 2010.

[11]

Perla-Kajan, J.; Jakubowski, H. Paraoxonase 1 and homocysteine metabolism. Amino
Acids 43:1405-1417; 2012.

[12]

Cavalca, V.; Cighetti, G.; Bamonti, F.; Loaldi, A.; Bortone, L.; Novembrino, C.; De
Franceschi, M.; Belardinelli, R.; Guazzi, M. D. Oxidative stress and homocysteine in
coronary artery disease. Clin Chem 47:887-892; 2001.

[13]

Bialecka, M.; Kurzawski, M.; Roszmann, A.; Robowski, P.; Sitek, E. J.; Honczarenko,
K.; Gorzkowska, A.; Budrewicz, S.; Mak, M.; Jarosz, M.; Golab-Janowska, M.;
Koziorowska-Gawron, E.; Drozdzik, M.; Slawek, J. Association of COMT, MTHFR,
and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive
impairment in Parkinson's disease. Pharmacogenet Genomics 22:716-724; 2012.

[14]

Schalinske, K. L.; Smazal, A. L. Homocysteine imbalance: a pathological metabolic
marker. Adv Nutr 3:755-762; 2012.

[15]

Yu, M.; Sturgill-Short, G.; Ganapathy, P.; Tawfik, A.; Peachey, N. S.; Smith, S. B. Agerelated changes in visual function in cystathionine-beta-synthase mutant mice, a model
of hyperhomocysteinemia. Exp Eye Res 96:124-131; 2012.

[16]

McLean, R. R.; Jacques, P. F.; Selhub, J.; Tucker, K. L.; Samelson, E. J.; Broe, K. E.;
Hannan, M. T.; Cupples, L. A.; Kiel, D. P. Homocysteine as a predictive factor for hip
fracture in older persons. N Engl J Med 350:2042-2049; 2004.

114
[17]

Schafer, S. A.; Mussig, K.; Stefan, N.; Haring, H. U.; Fritsche, A.; Balletshofer, B. M.
Plasma homocysteine concentrations in young individuals at increased risk of type 2
diabetes are associated with subtle differences in glomerular filtration rate but not with
insulin resistance. Exp Clin Endocrinol Diabetes 114:306-309; 2006.

[18]

Yi, F.; Li, P. L. Mechanisms of homocysteine-induced glomerular injury and sclerosis.
Am J Nephrol 28:254-264; 2008.

[19]

Brosnan, J. T.; Jacobs, R. L.; Stead, L. M.; Brosnan, M. E. Methylation demand: a key
determinant of homocysteine metabolism. Acta Biochim Pol 51:405-413; 2004.

[20]

Guttormsen, A. B.; Ueland, P. M.; Svarstad, E.; Refsum, H. Kinetic basis of
hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 52:495-502;
1997.

[21]

Bostom, A.; Brosnan, J. T.; Hall, B.; Nadeau, M. R.; Selhub, J. Net uptake of plasma
homocysteine by the rat kidney in vivo. Atherosclerosis 116:59-62; 1995.

[22]

Finkelstein, J. D. The metabolism of homocysteine: pathways and regulation. Eur J
Pediatr 157 Suppl 2:S40-44; 1998.

[23]

Selhub, J.; Jacques, P. F.; Wilson, P. W.; Rush, D.; Rosenberg, I. H. Vitamin status and
intake as primary determinants of homocysteinemia in an elderly population. JAMA
270:2693-2698; 1993.

[24]

Pastore, A.; De Angelis, S.; Casciani, S.; Ruggia, R.; Di Giovamberardino, G.; Noce, A.;
Splendiani, G.; Cortese, C.; Federici, G.; Dessi, M. Effects of folic acid before and after
vitamin B12 on plasma homocysteine concentrations in hemodialysis patients with
known MTHFR genotypes. Clin Chem 52:145-148; 2006.

115
[25]

Bailey, L. B.; Gregory, J. F., 3rd. Polymorphisms of methylenetetrahydrofolate
reductase and other enzymes: metabolic significance, risks and impact on folate
requirement. J Nutr 129:919-922; 1999.

[26]

Brattstrom, L.; Lindgren, A.; Israelsson, B.; Malinow, M. R.; Norrving, B.; Upson, B.;
Hamfelt, A. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to
type of stroke and stroke risk factors. Eur J Clin Invest 22:214-221; 1992.

[27]

Malinow, M. R.; Kang, S. S.; Taylor, L. M.; Wong, P. W.; Coull, B.; Inahara, T.;
Mukerjee, D.; Sexton, G.; Upson, B. Prevalence of hyperhomocyst(e)inemia in patients
with peripheral arterial occlusive disease. Circulation 79:1180-1188; 1989.

[28]

Malinow, M. R.; Levenson, J.; Giral, P.; Nieto, F. J.; Razavian, M.; Segond, P.; Simon,
A. Role of blood pressure, uric acid, and hemorheological parameters on plasma
homocyst(e)ine concentration. Atherosclerosis 114:175-183; 1995.

[29]

Nygard, O.; Vollset, S. E.; Refsum, H.; Stensvold, I.; Tverdal, A.; Nordrehaug, J. E.;
Ueland, M.; Kvale, G. Total plasma homocysteine and cardiovascular risk profile. The
Hordaland Homocysteine Study. JAMA 274:1526-1533; 1995.

[30]

Perry, I. J. Homocysteine, hypertension and stroke. J Hum Hypertens 13:289-293; 1999.

[31]

Brattstrom, L.; Wilcken, D. E. Homocysteine and cardiovascular disease: cause or
effect? Am J Clin Nutr 72:315-323; 2000.

[32]

Wilcken, D. E.; Gupta, V. J.; Reddy, S. G. Accumulation of sulphur-containing amino
acids including cysteine-homocysteine in patients on maintenance haemodialysis. Clin
Sci (Lond) 58:427-430; 1980.

116
[33]

Arnadottir, M.; Hultberg, B.; Nilsson-Ehle, P.; Thysell, H. The effect of reduced
glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab
Invest 56:41-46; 1996.

[34]

Bostom, A. G.; Lathrop, L. Hyperhomocysteinemia in end-stage renal disease:
prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int
52:10-20; 1997.

[35]

Kundu, S.; Tyagi, N.; Sen, U.; Tyagi, S. C. Matrix imbalance by inducing expression of
metalloproteinase and oxidative stress in cochlea of hyperhomocysteinemic mice. Mol
Cell Biochem 332:215-224; 2009.

[36]

Solini, A.; Santini, E.; Nannipieri, M.; Ferrannini, E. High glucose and homocysteine
synergistically affect the metalloproteinases-tissue inhibitors of metalloproteinases
pattern, but not TGFB expression, in human fibroblasts. Diabetologia 49:2499-2506;
2006.

[37]

Steed, M. M.; Tyagi, N.; Sen, U.; Schuschke, D. A.; Joshua, I. G.; Tyagi, S. C.
Functional consequences of the collagen/elastin switch in vascular remodeling in
hyperhomocysteinemic wild-type, eNOS-/-, and iNOS-/- mice. Am J Physiol Lung Cell
Mol Physiol 299:L301-311; 2010.

[38]

Yi, F.; Xia, M.; Li, N.; Zhang, C.; Tang, L.; Li, P. L. Contribution of guanine nucleotide
exchange

factor

Vav2

to

hyperhomocysteinemic

glomerulosclerosis

in

rats.

Hypertension 53:90-96; 2009.
[39]

Gill, P. S.; Wilcox, C. S. NADPH oxidases in the kidney. Antioxid Redox Signal 8:15971607; 2006.

117
[40]

Jiang, F. NADPH oxidase in the kidney: a Janus in determining cell fate. Kidney Int
75:135-137; 2009.

[41]

McCully, K. S. Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative
stress, endothelial dysfunction, and inflammation. Ann Clin Lab Sci 39:219-232; 2009.

[42]

Upchurch, G. R., Jr.; Welch, G. N.; Fabian, A. J.; Freedman, J. E.; Johnson, J. L.;
Keaney, J. F., Jr.; Loscalzo, J. Homocyst(e)ine decreases bioavailable nitric oxide by a
mechanism involving glutathione peroxidase. J Biol Chem 272:17012-17017; 1997.

[43]

Upchurch, G. R., Jr.; Welch, G. N.; Fabian, A. J.; Pigazzi, A.; Keaney, J. F., Jr.;
Loscalzo, J. Stimulation of endothelial nitric oxide production by homocyst(e)ine.
Atherosclerosis 132:177-185; 1997.

[44]

Yi, F.; Chen, Q. Z.; Jin, S.; Li, P. L. Mechanism of homocysteine-induced
Rac1/NADPH oxidase activation in mesangial cells: role of guanine nucleotide
exchange factor Vav2. Cell Physiol Biochem 20:909-918; 2007.

[45]

Yi, F.; Jin, S.; Zhang, F.; Xia, M.; Bao, J. X.; Hu, J.; Poklis, J. L.; Li, P. L. Formation of
lipid raft redox signalling platforms in glomerular endothelial cells: an early event of
homocysteine-induced glomerular injury. J Cell Mol Med 13:3303-3314; 2009.

[46]

Zhang, C.; Hu, J. J.; Xia, M.; Boini, K. M.; Brimson, C.; Li, P. L. Redox signaling via
lipid raft clustering in homocysteine-induced injury of podocytes. Biochim Biophys Acta
1803:482-491; 2010.

[47]

Edirimanne, V. E.; Woo, C. W.; Siow, Y. L.; Pierce, G. N.; Xie, J. Y.; O, K.
Homocysteine stimulates NADPH oxidase-mediated superoxide production leading to
endothelial dysfunction in rats. Can J Physiol Pharmacol 85:1236-1247; 2007.

118
[48]

Zhang, C.; Hu, J. J.; Xia, M.; Boini, K. M.; Brimson, C. A.; Laperle, L. A.; Li, P. L.
Protection of podocytes from hyperhomocysteinemia-induced injury by deletion of the
gp91phox gene. Free Radic Biol Med 48:1109-1117; 2010.

[49]

Zhang, C.; Boini, K. M.; Xia, M.; Abais, J. M.; Li, X.; Liu, Q.; Li, P. L. Activation of
Nod-like receptor protein 3 inflammasomes turns on podocyte injury and glomerular
sclerosis in hyperhomocysteinemia. Hypertension 60:154-162; 2012.

[50]

Watanabe, M.; Osada, J.; Aratani, Y.; Kluckman, K.; Reddick, R.; Malinow, M. R.;
Maeda, N. Mice deficient in cystathionine beta-synthase: animal models for mild and
severe homocyst(e)inemia. Proc Natl Acad Sci U S A 92:1585-1589; 1995.

[51]

Mudd, S. H.; Skovby, F.; Levy, H. L.; Pettigrew, K. D.; Wilcken, B.; Pyeritz, R. E.;
Andria, G.; Boers, G. H.; Bromberg, I. L.; Cerone, R.; et al. The natural history of
homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 37:131; 1985.

[52]

Jiang, X.; Yang, F.; Tan, H.; Liao, D.; Bryan, R. M., Jr.; Randhawa, J. K.; Rumbaut, R.
E.; Durante, W.; Schafer, A. I.; Yang, X.; Wang, H. Hyperhomocystinemia impairs
endothelial function and eNOS activity via PKC activation. Arterioscler Thromb Vasc
Biol 25:2515-2521; 2005.

[53]

Schwahn, B. C.; Laryea, M. D.; Chen, Z.; Melnyk, S.; Pogribny, I.; Garrow, T.; James,
S. J.; Rozen, R. Betaine rescue of an animal model with methylenetetrahydrofolate
reductase deficiency. Biochem J 382:831-840; 2004.

[54]

Chen, Z.; Karaplis, A. C.; Ackerman, S. L.; Pogribny, I. P.; Melnyk, S.; Lussier-Cacan,
S.; Chen, M. F.; Pai, A.; John, S. W.; Smith, R. S.; Bottiglieri, T.; Bagley, P.; Selhub, J.;
Rudnicki, M. A.; James, S. J.; Rozen, R. Mice deficient in methylenetetrahydrofolate

119
reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with
neuropathology and aortic lipid deposition. Hum Mol Genet 10:433-443; 2001.
[55]

Swanson, D. A.; Liu, M. L.; Baker, P. J.; Garrett, L.; Stitzel, M.; Wu, J.; Harris, M.;
Banerjee, R.; Shane, B.; Brody, L. C. Targeted disruption of the methionine synthase
gene in mice. Mol Cell Biol 21:1058-1065; 2001.

[56]

Lentz, S. R.; Haynes, W. G. Homocysteine: is it a clinically important cardiovascular
risk factor? Cleve Clin J Med 71:729-734; 2004.

[57]

Bylund, J.; Brown, K. L.; Movitz, C.; Dahlgren, C.; Karlsson, A. Intracellular generation
of superoxide by the phagocyte NADPH oxidase: how, where, and what for? Free Radic
Biol Med 49:1834-1845; 2010.

[58]

Lambeth, J. D. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol
4:181-189; 2004.

[59]

Cai, H.; Griendling, K. K.; Harrison, D. G. The vascular NAD(P)H oxidases as
therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 24:471-478; 2003.

[60]

Griendling, K. K.; Sorescu, D.; Lassegue, B.; Ushio-Fukai, M. Modulation of protein
kinase activity and gene expression by reactive oxygen species and their role in vascular
physiology and pathophysiology. Arterioscler Thromb Vasc Biol 20:2175-2183; 2000.

[61]

Bayraktutan, U.; Blayney, L.; Shah, A. M. Molecular characterization and localization
of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells.
Arterioscler Thromb Vasc Biol 20:1903-1911; 2000.

[62]

Zou, A. P.; Cowley, A. W., Jr. Reactive oxygen species and molecular regulation of
renal oxygenation. Acta Physiol Scand 179:233-241; 2003.

120
[63]

Lee, H. B.; Yu, M. R.; Yang, Y.; Jiang, Z.; Ha, H. Reactive oxygen species-regulated
signaling pathways in diabetic nephropathy. J Am Soc Nephrol 14:S241-245; 2003.

[64]

Malinowska, J.; Olas, B. Effect of resveratrol on hemostatic properties of human
fibrinogen and plasma during model of hyperhomocysteinemia. Thromb Res 126:e379382; 2010.

[65]

Yi, F.; Zhang, A. Y.; Janscha, J. L.; Li, P. L.; Zou, A. P. Homocysteine activates
NADH/NADPH oxidase through ceramide-stimulated Rac GTPase activity in rat
mesangial cells. Kidney Int 66:1977-1987; 2004.

[66]

Takeya, R.; Sumimoto, H. Regulation of novel superoxide-producing NAD(P)H
oxidases. Antioxid Redox Signal 8:1523-1532; 2006.

[67]

Bokoch, G. M.; Diebold, B. A. Current molecular models for NADPH oxidase
regulation by Rac GTPase. Blood 100:2692-2696; 2002.

[68]

Hordijk, P. L. Regulation of NADPH oxidases: the role of Rac proteins. Circ Res
98:453-462; 2006.

[69]

Evers, E. E.; Zondag, G. C.; Malliri, A.; Price, L. S.; ten Klooster, J. P.; van der
Kammen, R. A.; Collard, J. G. Rho family proteins in cell adhesion and cell migration.
Eur J Cancer 36:1269-1274; 2000.

[70]

Etienne-Manneville, S.; Hall, A. Rho GTPases in cell biology. Nature 420:629-635;
2002.

[71]

Ippagunta, S. K.; Malireddi, R. K.; Shaw, P. J.; Neale, G. A.; Vande Walle, L.; Green,
D. R.; Fukui, Y.; Lamkanfi, M.; Kanneganti, T. D. The inflammasome adaptor ASC
regulates the function of adaptive immune cells by controlling Dock2-mediated Rac
activation and actin polymerization. Nat Immunol 12:1010-1016; 2011.

121
[72]

Abo, A.; Pick, E.; Hall, A.; Totty, N.; Teahan, C. G.; Segal, A. W. Activation of the
NADPH oxidase involves the small GTP-binding protein p21rac1. Nature 353:668-670;
1991.

[73]

Werner, E. GTPases and reactive oxygen species: switches for killing and signaling. J
Cell Sci 117:143-153; 2004.

[74]

Ming, W.; Li, S.; Billadeau, D. D.; Quilliam, L. A.; Dinauer, M. C. The Rac effector
p67phox regulates phagocyte NADPH oxidase by stimulating Vav1 guanine nucleotide
exchange activity. Mol Cell Biol 27:312-323; 2007.

[75]

Hornstein, I.; Alcover, A.; Katzav, S. Vav proteins, masters of the world of cytoskeleton
organization. Cell Signal 16:1-11; 2004.

[76]

Miletic, A. V.; Graham, D. B.; Montgrain, V.; Fujikawa, K.; Kloeppel, T.; Brim, K.;
Weaver, B.; Schreiber, R.; Xavier, R.; Swat, W. Vav proteins control MyD88-dependent
oxidative burst. Blood 109:3360-3368; 2007.

[77]

Utomo, A.; Cullere, X.; Glogauer, M.; Swat, W.; Mayadas, T. N. Vav proteins in
neutrophils are required for FcgammaR-mediated signaling to Rac GTPases and
nicotinamide adenine dinucleotide phosphate oxidase component p40(phox). J Immunol
177:6388-6397; 2006.

[78]

Geiszt, M.; Kopp, J. B.; Varnai, P.; Leto, T. L. Identification of renox, an NAD(P)H
oxidase in kidney. Proc Natl Acad Sci U S A 97:8010-8014; 2000.

[79]

Banfi, B.; Molnar, G.; Maturana, A.; Steger, K.; Hegedus, B.; Demaurex, N.; Krause, K.
H. A Ca(2+)-activated NADPH oxidase in testis, spleen, and lymph nodes. J Biol Chem
276:37594-37601; 2001.

122
[80]

Sedeek, M.; Nasrallah, R.; Touyz, R. M.; Hebert, R. L. NADPH oxidases, reactive
oxygen species, and the kidney: friend and foe. J Am Soc Nephrol 24:1512-1518; 2013.

[81]

Winiarska, K.; Grabowski, M.; Rogacki, M. K. Inhibition of renal gluconeogenesis
contributes to hypoglycaemic action of NADPH oxidase inhibitor, apocynin. Chem Biol
Interact 189:119-126; 2011.

[82]

Han, H. J.; Lee, Y. J.; Park, S. H.; Lee, J. H.; Taub, M. High glucose-induced oxidative
stress inhibits Na+/glucose cotransporter activity in renal proximal tubule cells. Am J
Physiol Renal Physiol 288:F988-996; 2005.

[83]

Liu, R.; Ren, Y.; Garvin, J. L.; Carretero, O. A. Superoxide enhances tubuloglomerular
feedback by constricting the afferent arteriole. Kidney Int 66:268-274; 2004.

[84]

Silva, E.; Soares-da-Silva, P. Reactive oxygen species and the regulation of renal Na+K+-ATPase in opossum kidney cells. Am J Physiol Regul Integr Comp Physiol
293:R1764-1770; 2007.

[85]

Silva, G. B.; Garvin, J. L. Rac1 mediates NaCl-induced superoxide generation in the
thick ascending limb. Am J Physiol Renal Physiol 298:F421-425; 2010.

[86]

Mamenko, M.; Zaika, O.; Ilatovskaya, D. V.; Staruschenko, A.; Pochynyuk, O.
Angiotensin II increases activity of the epithelial Na+ channel (ENaC) in distal nephron
additively to aldosterone. J Biol Chem 287:660-671; 2012.

[87]

Kitiyakara, C.; Chabrashvili, T.; Chen, Y.; Blau, J.; Karber, A.; Aslam, S.; Welch, W. J.;
Wilcox, C. S. Salt intake, oxidative stress, and renal expression of NADPH oxidase and
superoxide dismutase. J Am Soc Nephrol 14:2775-2782; 2003.

123
[88]

Lerman, L. O.; Nath, K. A.; Rodriguez-Porcel, M.; Krier, J. D.; Schwartz, R. S.; Napoli,
C.; Romero, J. C. Increased oxidative stress in experimental renovascular hypertension.
Hypertension 37:541-546; 2001.

[89]

Fukuda, M.; Nakamura, T.; Kataoka, K.; Nako, H.; Tokutomi, Y.; Dong, Y. F.; Ogawa,
H.; Kim-Mitsuyama, S. Potentiation by candesartan of protective effects of pioglitazone
against type 2 diabetic cardiovascular and renal complications in obese mice. J
Hypertens 28:340-352; 2010.

[90]

Huang, A.; Sun, D.; Kaley, G.; Koller, A. Superoxide released to high intra-arteriolar
pressure reduces nitric oxide-mediated shear stress- and agonist-induced dilations. Circ
Res 83:960-965; 1998.

[91]

Katusic, Z. S.; Vanhoutte, P. M. Superoxide anion is an endothelium-derived contracting
factor. Am J Physiol 257:H33-37; 1989.

[92]

Zou, A. P.; Li, N.; Cowley, A. W., Jr. Production and actions of superoxide in the renal
medulla. Hypertension 37:547-553; 2001.

[93]

O'Connor, W., Jr.; Harton, J. A.; Zhu, X.; Linhoff, M. W.; Ting, J. P. Cutting edge:
CIAS1/cryopyrin/PYPAF1/NALP3/CATERPILLER 1.1 is an inducible inflammatory
mediator with NF-kappa B suppressive properties. J Immunol 171:6329-6333; 2003.

[94]

Martinon, F.; Agostini, L.; Meylan, E.; Tschopp, J. Identification of bacterial muramyl
dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr Biol 14:1929-1934;
2004.

[95]

Petrilli, V.; Martinon, F. The inflammasome, autoinflammatory diseases, and gout. Joint
Bone Spine 74:571-576; 2007.

124
[96]

Yin, Y.; Pastrana, J. L.; Li, X.; Huang, X.; Mallilankaraman, K.; Choi, E. T.; Madesh,
M.; Wang, H.; Yang, X. F. Inflammasomes: sensors of metabolic stresses for vascular
inflammation. Front Biosci (Landmark Ed) 18:638-649; 2013.

[97]

Bakker, P. J.; Butter, L. M.; Kors, L.; Teske, G. J.; Aten, J.; Sutterwala, F. S.; Florquin,
S.; Leemans, J. C. Nlrp3 is a key modulator of diet-induced nephropathy and renal
cholesterol accumulation. Kidney Int; 2013.

[98]

Martinon, F.; Tschopp, J. NLRs join TLRs as innate sensors of pathogens. Trends
Immunol 26:447-454; 2005.

[99]

Sutterwala, F. S.; Ogura, Y.; Flavell, R. A. The inflammasome in pathogen recognition
and inflammation. J Leukoc Biol 82:259-264; 2007.

[100]

Yang, F.; Wang, Z.; Wei, X.; Han, H.; Meng, X.; Zhang, Y.; Shi, W.; Li, F.; Xin, T.;
Pang, Q.; Yi, F. NLRP3 deficiency ameliorates neurovascular damage in experimental
ischemic stroke. J Cereb Blood Flow Metab; 2014.

[101]

Masters, S. L. Specific inflammasomes in complex diseases. Clin Immunol 147:223228; 2013.

[102]

Martinon, F.; Burns, K.; Tschopp, J. The inflammasome: a molecular platform
triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell
10:417-426; 2002.

[103]

Bauernfeind, F.; Ablasser, A.; Bartok, E.; Kim, S.; Schmid-Burgk, J.; Cavlar, T.;
Hornung, V. Inflammasomes: current understanding and open questions. Cell Mol Life
Sci 68:765-783; 2011.

[104]

Dinarello, C. A. Immunological and inflammatory functions of the interleukin-1 family.
Annu Rev Immunol 27:519-550; 2009.

125
[105]

Faustin, B.; Lartigue, L.; Bruey, J. M.; Luciano, F.; Sergienko, E.; Bailly-Maitre, B.;
Volkmann, N.; Hanein, D.; Rouiller, I.; Reed, J. C. Reconstituted NALP1
inflammasome reveals two-step mechanism of caspase-1 activation. Mol Cell 25:713724; 2007.

[106]

Boyden, E. D.; Dietrich, W. F. Nalp1b controls mouse macrophage susceptibility to
anthrax lethal toxin. Nat Genet 38:240-244; 2006.

[107]

Kofoed, E. M.; Vance, R. E. Innate immune recognition of bacterial ligands by NAIPs
determines inflammasome specificity. Nature 477:592-595; 2011.

[108]

Miao, E. A.; Mao, D. P.; Yudkovsky, N.; Bonneau, R.; Lorang, C. G.; Warren, S. E.;
Leaf, I. A.; Aderem, A. Innate immune detection of the type III secretion apparatus
through the NLRC4 inflammasome. Proc Natl Acad Sci U S A 107:3076-3080; 2010.

[109]

Zhao, Y.; Yang, J.; Shi, J.; Gong, Y. N.; Lu, Q.; Xu, H.; Liu, L.; Shao, F. The NLRC4
inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature
477:596-600; 2011.

[110]

Hornung, V.; Ablasser, A.; Charrel-Dennis, M.; Bauernfeind, F.; Horvath, G.; Caffrey,
D. R.; Latz, E.; Fitzgerald, K. A. AIM2 recognizes cytosolic dsDNA and forms a
caspase-1-activating inflammasome with ASC. Nature 458:514-518; 2009.

[111]

Cassel, S. L.; Sutterwala, F. S. Sterile inflammatory responses mediated by the NLRP3
inflammasome. Eur J Immunol 40:607-611; 2010.

[112]

Ichinohe, T.; Lee, H. K.; Ogura, Y.; Flavell, R.; Iwasaki, A. Inflammasome recognition
of influenza virus is essential for adaptive immune responses. J Exp Med 206:79-87;
2009.

126
[113]

Thomas, P. G.; Dash, P.; Aldridge, J. R., Jr.; Ellebedy, A. H.; Reynolds, C.; Funk, A. J.;
Martin, W. J.; Lamkanfi, M.; Webby, R. J.; Boyd, K. L.; Doherty, P. C.; Kanneganti, T.
D. The intracellular sensor NLRP3 mediates key innate and healing responses to
influenza A virus via the regulation of caspase-1. Immunity 30:566-575; 2009.

[114]

Muruve, D. A.; Petrilli, V.; Zaiss, A. K.; White, L. R.; Clark, S. A.; Ross, P. J.; Parks, R.
J.; Tschopp, J. The inflammasome recognizes cytosolic microbial and host DNA and
triggers an innate immune response. Nature 452:103-107; 2008.

[115]

Mariathasan, S.; Weiss, D. S.; Newton, K.; McBride, J.; O'Rourke, K.; Roose-Girma,
M.; Lee, W. P.; Weinrauch, Y.; Monack, D. M.; Dixit, V. M. Cryopyrin activates the
inflammasome in response to toxins and ATP. Nature 440:228-232; 2006.

[116]

Duncan, J. A.; Gao, X.; Huang, M. T.; O'Connor, B. P.; Thomas, C. E.; Willingham, S.
B.; Bergstralh, D. T.; Jarvis, G. A.; Sparling, P. F.; Ting, J. P. Neisseria gonorrhoeae
activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and
ASC-containing inflammasome. J Immunol 182:6460-6469; 2009.

[117]

Joly, S.; Ma, N.; Sadler, J. J.; Soll, D. R.; Cassel, S. L.; Sutterwala, F. S. Cutting edge:
Candida albicans hyphae formation triggers activation of the Nlrp3 inflammasome. J
Immunol 183:3578-3581; 2009.

[118]

Martinon, F.; Petrilli, V.; Mayor, A.; Tardivel, A.; Tschopp, J. Gout-associated uric acid
crystals activate the NALP3 inflammasome. Nature 440:237-241; 2006.

[119]

Hornung, V.; Bauernfeind, F.; Halle, A.; Samstad, E. O.; Kono, H.; Rock, K. L.;
Fitzgerald, K. A.; Latz, E. Silica crystals and aluminum salts activate the NALP3
inflammasome through phagosomal destabilization. Nat Immunol 9:847-856; 2008.

127
[120]

Dostert, C.; Petrilli, V.; Van Bruggen, R.; Steele, C.; Mossman, B. T.; Tschopp, J. Innate
immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science
320:674-677; 2008.

[121]

Pelegrin, P.; Surprenant, A. Pannexin-1 mediates large pore formation and interleukin1beta release by the ATP-gated P2X7 receptor. EMBO J 25:5071-5082; 2006.

[122]

Halle, A.; Hornung, V.; Petzold, G. C.; Stewart, C. R.; Monks, B. G.; Reinheckel, T.;
Fitzgerald, K. A.; Latz, E.; Moore, K. J.; Golenbock, D. T. The NALP3 inflammasome
is involved in the innate immune response to amyloid-beta. Nat Immunol 9:857-865;
2008.

[123]

Griffin, W. S.; Stanley, L. C.; Ling, C.; White, L.; MacLeod, V.; Perrot, L. J.; White, C.
L., 3rd; Araoz, C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down
syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 86:7611-7615; 1989.

[124]

Duewell, P.; Kono, H.; Rayner, K. J.; Sirois, C. M.; Vladimer, G.; Bauernfeind, F. G.;
Abela, G. S.; Franchi, L.; Nunez, G.; Schnurr, M.; Espevik, T.; Lien, E.; Fitzgerald, K.
A.; Rock, K. L.; Moore, K. J.; Wright, S. D.; Hornung, V.; Latz, E. NLRP3
inflammasomes are required for atherogenesis and activated by cholesterol crystals.
Nature 464:1357-1361; 2010.

[125]

Yamasaki, K.; Muto, J.; Taylor, K. R.; Cogen, A. L.; Audish, D.; Bertin, J.; Grant, E. P.;
Coyle, A. J.; Misaghi, A.; Hoffman, H. M.; Gallo, R. L. NLRP3/cryopyrin is necessary
for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger
of inflammation in response to injury. J Biol Chem 284:12762-12771; 2009.

128
[126]

Zhou, R.; Tardivel, A.; Thorens, B.; Choi, I.; Tschopp, J. Thioredoxin-interacting
protein links oxidative stress to inflammasome activation. Nat Immunol 11:136-140;
2010.

[127]

Watanabe, H.; Gaide, O.; Petrilli, V.; Martinon, F.; Contassot, E.; Roques, S.; Kummer,
J. A.; Tschopp, J.; French, L. E. Activation of the IL-1beta-processing inflammasome is
involved in contact hypersensitivity. J Invest Dermatol 127:1956-1963; 2007.

[128]

Nishi, Y.; Satoh, M.; Nagasu, H.; Kadoya, H.; Ihoriya, C.; Kidokoro, K.; Sasaki, T.;
Kashihara, N. Selective estrogen receptor modulation attenuates proteinuria-induced
renal tubular damage by modulating mitochondrial oxidative status. Kidney Int 83:662673; 2013.

[129]

Wang, C.; Pan, Y.; Zhang, Q. Y.; Wang, F. M.; Kong, L. D. Quercetin and allopurinol
ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3
inflammasome activation and lipid accumulation. PLoS One 7:e38285; 2012.

[130]

Wang, W.; Wang, X.; Chun, J.; Vilaysane, A.; Clark, S.; French, G.; Bracey, N. A.;
Trpkov, K.; Bonni, S.; Duff, H. J.; Beck, P. L.; Muruve, D. A. Inflammasomeindependent NLRP3 augments TGF-beta signaling in kidney epithelium. J Immunol
190:1239-1249; 2013.

[131]

Spranger, J.; Kroke, A.; Mohlig, M.; Hoffmann, K.; Bergmann, M. M.; Ristow, M.;
Boeing, H.; Pfeiffer, A. F. Inflammatory cytokines and the risk to develop type 2
diabetes: results of the prospective population-based European Prospective Investigation
into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52:812-817; 2003.

129
[132]

Larsen, C. M.; Faulenbach, M.; Vaag, A.; Volund, A.; Ehses, J. A.; Seifert, B.;
Mandrup-Poulsen, T.; Donath, M. Y. Interleukin-1-receptor antagonist in type 2 diabetes
mellitus. N Engl J Med 356:1517-1526; 2007.

[133]

Stienstra, R.; Joosten, L. A.; Koenen, T.; van Tits, B.; van Diepen, J. A.; van den Berg,
S. A.; Rensen, P. C.; Voshol, P. J.; Fantuzzi, G.; Hijmans, A.; Kersten, S.; Muller, M.;
van den Berg, W. B.; van Rooijen, N.; Wabitsch, M.; Kullberg, B. J.; van der Meer, J.
W.; Kanneganti, T.; Tack, C. J.; Netea, M. G. The inflammasome-mediated caspase-1
activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 12:593605; 2010.

[134]

Vandanmagsar, B.; Youm, Y. H.; Ravussin, A.; Galgani, J. E.; Stadler, K.; Mynatt, R.
L.; Ravussin, E.; Stephens, J. M.; Dixit, V. D. The NLRP3 inflammasome instigates
obesity-induced inflammation and insulin resistance. Nat Med 17:179-188; 2011.

[135]

Frantz, S.; Ducharme, A.; Sawyer, D.; Rohde, L. E.; Kobzik, L.; Fukazawa, R.; Tracey,
D.; Allen, H.; Lee, R. T.; Kelly, R. A. Targeted deletion of caspase-1 reduces early
mortality and left ventricular dilatation following myocardial infarction. J Mol Cell
Cardiol 35:685-694; 2003.

[136]

Syed, F. M.; Hahn, H. S.; Odley, A.; Guo, Y.; Vallejo, J. G.; Lynch, R. A.; Mann, D. L.;
Bolli, R.; Dorn, G. W., 2nd. Proapoptotic effects of caspase-1/interleukin-converting
enzyme dominate in myocardial ischemia. Circ Res 96:1103-1109; 2005.

[137]

Kawaguchi, M.; Takahashi, M.; Hata, T.; Kashima, Y.; Usui, F.; Morimoto, H.; Izawa,
A.; Takahashi, Y.; Masumoto, J.; Koyama, J.; Hongo, M.; Noda, T.; Nakayama, J.;
Sagara, J.; Taniguchi, S.; Ikeda, U. Inflammasome activation of cardiac fibroblasts is
essential for myocardial ischemia/reperfusion injury. Circulation 123:594-604; 2011.

130
[138]

Iyer, S. S.; Pulskens, W. P.; Sadler, J. J.; Butter, L. M.; Teske, G. J.; Ulland, T. K.;
Eisenbarth, S. C.; Florquin, S.; Flavell, R. A.; Leemans, J. C.; Sutterwala, F. S. Necrotic
cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl
Acad Sci U S A 106:20388-20393; 2009.

[139]

Vilaysane, A.; Chun, J.; Seamone, M. E.; Wang, W.; Chin, R.; Hirota, S.; Li, Y.; Clark,
S. A.; Tschopp, J.; Trpkov, K.; Hemmelgarn, B. R.; Beck, P. L.; Muruve, D. A. The
NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc
Nephrol 21:1732-1744; 2010.

[140]

Matsumoto, K.; Kanmatsuse, K. Elevated interleukin-18 levels in the urine of nephrotic
patients. Nephron 88:334-339; 2001.

[141]

Sassy-Prigent, C.; Heudes, D.; Mandet, C.; Belair, M. F.; Michel, O.; Perdereau, B.;
Bariety, J.; Bruneval, P. Early glomerular macrophage recruitment in streptozotocininduced diabetic rats. Diabetes 49:466-475; 2000.

[142]

Niemir, Z. I.; Stein, H.; Dworacki, G.; Mundel, P.; Koehl, N.; Koch, B.; Autschbach, F.;
Andrassy, K.; Ritz, E.; Waldherr, R.; Otto, H. F. Podocytes are the major source of IL-1
alpha and IL-1 beta in human glomerulonephritides. Kidney Int 52:393-403; 1997.

[143]

Benko, S.; Philpott, D. J.; Girardin, S. E. The microbial and danger signals that activate
Nod-like receptors. Cytokine 43:368-373; 2008.

[144]

Henao-Mejia, J.; Elinav, E.; Jin, C.; Hao, L.; Mehal, W. Z.; Strowig, T.; Thaiss, C. A.;
Kau, A. L.; Eisenbarth, S. C.; Jurczak, M. J.; Camporez, J. P.; Shulman, G. I.; Gordon, J.
I.; Hoffman, H. M.; Flavell, R. A. Inflammasome-mediated dysbiosis regulates
progression of NAFLD and obesity. Nature 482:179-185; 2012.

131
[145]

Overley-Adamson, B.; Artlett, C. M.; Stephens, C.; Sassi-Gaha, S.; Weis, R. D.;
Thacker, J. D. Targeting the unfolded protein response, XBP1, and the NLRP3
inflammasome in fibrosis and cancer. Cancer Biol Ther 15; 2014.

[146]

Mariathasan, S. ASC, Ipaf and Cryopyrin/Nalp3: bona fide intracellular adapters of the
caspase-1 inflammasome. Microbes Infect 9:664-671; 2007.

[147]

Bauernfeind, F. G.; Horvath, G.; Stutz, A.; Alnemri, E. S.; MacDonald, K.; Speert, D.;
Fernandes-Alnemri, T.; Wu, J.; Monks, B. G.; Fitzgerald, K. A.; Hornung, V.; Latz, E.
Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license
NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 183:787791; 2009.

[148]

Surprenant, A.; Rassendren, F.; Kawashima, E.; North, R. A.; Buell, G. The cytolytic
P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science
272:735-738; 1996.

[149]

Tschopp, J.; Schroder, K. NLRP3 inflammasome activation: The convergence of
multiple signalling pathways on ROS production? Nat Rev Immunol 10:210-215; 2010.

[150]

Bae, J. Y.; Park, H. H. Crystal structure of NALP3 protein pyrin domain (PYD) and its
implications in inflammasome assembly. J Biol Chem 286:39528-39536; 2011.

[151]

Cruz, C. M.; Rinna, A.; Forman, H. J.; Ventura, A. L.; Persechini, P. M.; Ojcius, D. M.
ATP activates a reactive oxygen species-dependent oxidative stress response and
secretion of proinflammatory cytokines in macrophages. J Biol Chem 282:2871-2879;
2007.

132
[152]

Hewinson, J.; Moore, S. F.; Glover, C.; Watts, A. G.; MacKenzie, A. B. A key role for
redox signaling in rapid P2X7 receptor-induced IL-1 beta processing in human
monocytes. J Immunol 180:8410-8420; 2008.

[153]

Wen, H.; Gris, D.; Lei, Y.; Jha, S.; Zhang, L.; Huang, M. T.; Brickey, W. J.; Ting, J. P.
Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin
signaling. Nat Immunol 12:408-415; 2011.

[154]

Alvarez, S.; Munoz-Fernandez, M. A. TNF-Alpha may mediate inflammasome
activation in the absence of bacterial infection in more than one way. PLoS One
8:e71477; 2013.

[155]

Xiao, H.; Lu, M.; Lin, T. Y.; Chen, Z.; Chen, G.; Wang, W. C.; Marin, T.; Shentu, T. P.;
Wen, L.; Gongol, B.; Sun, W.; Liang, X.; Chen, J.; Huang, H. D.; Pedra, J. H.; Johnson,
D. A.; Shyy, J. Y. Sterol regulatory element binding protein 2 activation of NLRP3
inflammasome

in

endothelium

mediates

hemodynamic-induced

atherosclerosis

susceptibility. Circulation 128:632-642; 2013.
[156]

Bauernfeind, F.; Bartok, E.; Rieger, A.; Franchi, L.; Nunez, G.; Hornung, V. Cutting
edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3
inflammasome. J Immunol 187:613-617; 2011.

[157]

van Bruggen, R.; Koker, M. Y.; Jansen, M.; van Houdt, M.; Roos, D.; Kuijpers, T. W.;
van den Berg, T. K. Human NLRP3 inflammasome activation is Nox1-4 independent.
Blood 115:5398-5400; 2010.

[158]

Wu, J.; Yan, Z.; Schwartz, D. E.; Yu, J.; Malik, A. B.; Hu, G. Activation of NLRP3
inflammasome in alveolar macrophages contributes to mechanical stretch-induced lung
inflammation and injury. J Immunol 190:3590-3599; 2013.

133
[159]

Zhou, R.; Yazdi, A. S.; Menu, P.; Tschopp, J. A role for mitochondria in NLRP3
inflammasome activation. Nature 469:221-225; 2011.

[160]

Bulua, A. C.; Simon, A.; Maddipati, R.; Pelletier, M.; Park, H.; Kim, K. Y.; Sack, M.
N.; Kastner, D. L.; Siegel, R. M. Mitochondrial reactive oxygen species promote
production of proinflammatory cytokines and are elevated in TNFR1-associated periodic
syndrome (TRAPS). J Exp Med 208:519-533; 2011.

[161]

Liu, B. P.; Burridge, K. Vav2 activates Rac1, Cdc42, and RhoA downstream from
growth factor receptors but not beta1 integrins. Mol Cell Biol 20:7160-7169; 2000.

[162]

Yi, F.; Zhang, A. Y.; Li, N.; Muh, R. W.; Fillet, M.; Renert, A. F.; Li, P. L. Inhibition of
ceramide-redox signaling pathway blocks glomerular injury in hyperhomocysteinemic
rats. Kidney Int 70:88-96; 2006.

[163]

Neuman,

J.

C.;

Albright,

K.

A.;

Schalinske,

K.

L.

Exercise

prevents

hyperhomocysteinemia in a dietary folate-restricted mouse model. Nutr Res 33:487-493;
2013.
[164]

Jackson, E. K.; Gillespie, D. G.; Zhu, C.; Ren, J.; Zacharia, L. C.; Mi, Z. Alpha2adrenoceptors enhance angiotensin II-induced renal vasoconstriction: role for NADPH
oxidase and RhoA. Hypertension 51:719-726; 2008.

[165]

Rey, F. E.; Cifuentes, M. E.; Kiarash, A.; Quinn, M. T.; Pagano, P. J. Novel competitive
inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood
pressure in mice. Circ Res 89:408-414; 2001.

[166]

Nishiyama, A.; Yoshizumi, M.; Hitomi, H.; Kagami, S.; Kondo, S.; Miyatake, A.;
Fukunaga, M.; Tamaki, T.; Kiyomoto, H.; Kohno, M.; Shokoji, T.; Kimura, S.; Abe, Y.

134
The SOD mimetic tempol ameliorates glomerular injury and reduces mitogen-activated
protein kinase activity in Dahl salt-sensitive rats. J Am Soc Nephrol 15:306-315; 2004.
[167]

Sousa, T.; Oliveira, S.; Afonso, J.; Morato, M.; Patinha, D.; Fraga, S.; Carvalho, F.;
Albino-Teixeira, A. Role of H(2)O(2) in hypertension, renin-angiotensin system
activation and renal medullary disfunction caused by angiotensin II. Br J Pharmacol
166:2386-2401; 2012.

[168]

Chen, J.; Cha-Molstad, H.; Szabo, A.; Shalev, A. Diabetes induces and calcium channel
blockers prevent cardiac expression of proapoptotic thioredoxin-interacting protein. Am
J Physiol Endocrinol Metab 296:E1133-1139; 2009.

[169]

Abais, J. M.; Zhang, C.; Xia, M.; Liu, Q.; Gehr, T. W.; Boini, K. M.; Li, P. L. NADPH
oxidase-mediated triggering of inflammasome activation in mouse podocytes and
glomeruli during hyperhomocysteinemia. Antioxid Redox Signal 18:1537-1548; 2013.

[170]

Abais, J. M.; Xia, M.; Li, G.; Gehr, T. W.; Boini, K. M.; Li, P. L. Contribution of
endogenously produced reactive oxygen species to the activation of podocyte NLRP3
inflammasomes in hyperhomocysteinemia. Free Radic Biol Med 67:211-220; 2014.

[171]

Boini, K. M.; Xia, M.; Li, C.; Zhang, C.; Payne, L. P.; Abais, J. M.; Poklis, J. L.;
Hylemon, P. B.; Li, P. L. Acid sphingomyelinase gene deficiency ameliorates the
hyperhomocysteinemia-induced glomerular injury in mice. Am J Pathol 179:2210-2219;
2011.

[172]

Zhang, C.; Xia, M.; Boini, K. M.; Li, C. X.; Abais, J. M.; Li, X. X.; Laperle, L. A.; Li,
P. L. Epithelial-to-mesenchymal transition in podocytes mediated by activation of
NADPH oxidase in hyperhomocysteinemia. Pflugers Arch 462:455-467; 2011.

135
[173]

Yang, L.; Zheng, S.; Epstein, P. N. Metallothionein over-expression in podocytes
reduces adriamycin nephrotoxicity. Free Radic Res 43:174-182; 2009.

[174]

De Miguel, C.; Guo, C.; Lund, H.; Feng, D.; Mattson, D. L. Infiltrating T lymphocytes
in the kidney increase oxidative stress and participate in the development of
hypertension and renal disease. Am J Physiol Renal Physiol 300:F734-742; 2011.

[175]

Li, N.; Yi, F.; dos Santos, E. A.; Donley, D. K.; Li, P. L. Role of renal medullary heme
oxygenase in the regulation of pressure natriuresis and arterial blood pressure.
Hypertension 49:148-154; 2007.

[176]

Boini, K. M.; Xia, M.; Xiong, J.; Li, C.; Payne, L. P.; Li, P. L. Implication of CD38
gene in podocyte epithelial-to-mesenchymal transition and glomerular sclerosis. J Cell
Mol Med 16:1674-1685; 2012.

[177]

Raij, L.; Azar, S.; Keane, W. Mesangial immune injury, hypertension, and progressive
glomerular damage in Dahl rats. Kidney Int 26:137-143; 1984.

[178]

Chen, Y. F.; Li, P. L.; Zou, A. P. Effect of hyperhomocysteinemia on plasma or tissue
adenosine levels and renal function. Circulation 106:1275-1281; 2002.

[179]

Boini, K. M.; Xia, M.; Abais, J. M.; Xu, M.; Li, C. X.; Li, P. L. Acid sphingomyelinase
gene knockout ameliorates hyperhomocysteinemic glomerular injury in mice lacking
cystathionine-beta-synthase. PLoS One 7:e45020; 2012.

[180]

Koshikawa, M.; Mukoyama, M.; Mori, K.; Suganami, T.; Sawai, K.; Yoshioka, T.;
Nagae, T.; Yokoi, H.; Kawachi, H.; Shimizu, F.; Sugawara, A.; Nakao, K. Role of p38
mitogen-activated protein kinase activation in podocyte injury and proteinuria in
experimental nephrotic syndrome. J Am Soc Nephrol 16:2690-2701; 2005.

136
[181]

Jin, C.; Flavell, R. A. Inflammasome activation. The missing link: how the
inflammasome senses oxidative stress. Immunol Cell Biol 88:510-512; 2010.

[182]

Gross, O.; Thomas, C. J.; Guarda, G.; Tschopp, J. The inflammasome: an integrated
view. Immunol Rev 243:136-151; 2011.

[183]

Villegas, L. R.; Kluck, D.; Field, C.; Oberley-Deegan, R. E.; Woods, C.; Yeager, M. E.;
El Kasmi, K. C.; Savani, R. C.; Bowler, R. P.; Nozik-Grayck, E. Superoxide dismutase
mimetic, MnTE-2-PyP, attenuates chronic hypoxia-induced pulmonary hypertension,
pulmonary vascular remodeling, and activation of the NALP3 inflammasome. Antioxid
Redox Signal 18:1753-1764; 2013.

[184]

Floege, J.; Alpers, C. E.; Sage, E. H.; Pritzl, P.; Gordon, K.; Johnson, R. J.; Couser, W.
G. Markers of complement-dependent and complement-independent glomerular visceral
epithelial cell injury in vivo. Expression of antiadhesive proteins and cytoskeletal
changes. Lab Invest 67:486-497; 1992.

[185]

Kawachi, H.; Miyauchi, N.; Suzuki, K.; Han, G. D.; Orikasa, M.; Shimizu, F. Role of
podocyte slit diaphragm as a filtration barrier. Nephrology (Carlton) 11:274-281; 2006.

[186]

Kang, D. H.; Johnson, R. J. Vascular endothelial growth factor: a new player in the
pathogenesis of renal fibrosis. Curr Opin Nephrol Hypertens 12:43-49; 2003.

[187]

Boini, K. M.; Xia, M.; Abais, J. M.; Li, G.; Pitzer, A. L.; Gehr, T. W.; Zhang, Y.; Li, P.
L. Activation of inflammasomes in podocyte injury of mice on the high fat diet: Effects
of ASC gene deletion and silencing. Biochim Biophys Acta 1843:836-845; 2014.

[188]

Henegar, J. R.; Bigler, S. A.; Henegar, L. K.; Tyagi, S. C.; Hall, J. E. Functional and
structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol
12:1211-1217; 2001.

137
[189]

Dai, J.; Wang, X. Immunoregulatory effects of homocysteine on cardiovascular
diseases. Sheng Li Xue Bao 59:585-592; 2007.

[190]

Wang, G.; Woo, C. W.; Sung, F. L.; Siow, Y. L.; O, K. Increased monocyte adhesion to
aortic endothelium in rats with hyperhomocysteinemia: role of chemokine and adhesion
molecules. Arterioscler Thromb Vasc Biol 22:1777-1783; 2002.

[191]

Postea, O.; Koenen, R. R.; Hristov, M.; Weber, C.; Ludwig, A. Homocysteine upregulates vascular transmembrane chemokine CXCL16 and induces CXCR6+
lymphocyte recruitment in vitro and in vivo. J Cell Mol Med 12:1700-1709; 2008.

[192]

Kriz, W. Podocyte is the major culprit accounting for the progression of chronic renal
disease. Microsc Res Tech 57:189-195; 2002.

[193]

Marshall, C. B.; Pippin, J. W.; Krofft, R. D.; Shankland, S. J. Puromycin
aminonucleoside induces oxidant-dependent DNA damage in podocytes in vitro and in
vivo. Kidney Int 70:1962-1973; 2006.

[194]

Takano, Y.; Yamauchi, K.; Hayakawa, K.; Hiramatsu, N.; Kasai, A.; Okamura, M.;
Yokouchi, M.; Shitamura, A.; Yao, J.; Kitamura, M. Transcriptional suppression of
nephrin in podocytes by macrophages: roles of inflammatory cytokines and involvement
of the PI3K/Akt pathway. FEBS Lett 581:421-426; 2007.

[195]

Liao, P. C.; Chao, L. K.; Chou, J. C.; Dong, W. C.; Lin, C. N.; Lin, C. Y.; Chen, A.; Ka,
S. M.; Ho, C. L.; Hua, K. F. Lipopolysaccharide/adenosine triphosphate-mediated signal
transduction in the regulation of NLRP3 protein expression and caspase-1-mediated
interleukin-1beta secretion. Inflamm Res 62:89-96; 2013.

138
[196]

Varga, A.; Budai, M. M.; Milesz, S.; Bacsi, A.; Tozser, J.; Benko, S. Ragweed pollen
extract intensifies lipopolysaccharide-induced priming of NLRP3 inflammasome in
human macrophages. Immunology 138:392-401; 2013.

[197]

Cassel, S. L.; Eisenbarth, S. C.; Iyer, S. S.; Sadler, J. J.; Colegio, O. R.; Tephly, L. A.;
Carter, A. B.; Rothman, P. B.; Flavell, R. A.; Sutterwala, F. S. The Nalp3 inflammasome
is essential for the development of silicosis. Proc Natl Acad Sci U S A 105:9035-9040;
2008.

[198]

Pelegrin, P.; Surprenant, A. Dynamics of macrophage polarization reveal new
mechanism to inhibit IL-1beta release through pyrophosphates. EMBO J 28:2114-2127;
2009.

[199]

Lindauer, M.; Wong, J.; Magun, B. Ricin Toxin Activates the NALP3 Inflammasome.
Toxins (Basel) 2:1500-1514; 2010.

[200]

Tojo, A.; Asaba, K.; Onozato, M. L. Suppressing renal NADPH oxidase to treat diabetic
nephropathy. Expert Opin Ther Targets 11:1011-1018; 2007.

[201]

Wilcox, C. S. Effects of tempol and redox-cycling nitroxides in models of oxidative
stress. Pharmacol Ther 126:119-145; 2010.

[202]

Peixoto, E. B.; Papadimitriou, A.; Lopes de Faria, J. M.; Lopes de Faria, J. B. Tempol
reduces podocyte apoptosis via PARP signaling pathway in experimental diabetes
mellitus. Nephron Exp Nephrol 120:e81-90; 2012.

[203]

Yang, Z. Z.; Zhang, A. Y.; Yi, F. X.; Li, P. L.; Zou, A. P. Redox regulation of HIF1alpha levels and HO-1 expression in renal medullary interstitial cells. Am J Physiol
Renal Physiol 284:F1207-1215; 2003.

139
[204]

Beaman, M.; Birtwistle, R.; Howie, A. J.; Michael, J.; Adu, D. The role of superoxide
anion and hydrogen peroxide in glomerular injury induced by puromycin
aminonucleoside in rats. Clin Sci (Lond) 73:329-332; 1987.

[205]

Birtwistle, R. J.; Michael, J.; Howie, A. J.; Adu, D. Reactive oxygen products in
heterologous anti-glomerular basement membrane nephritis in rats. Br J Exp Pathol
70:207-213; 1989.

[206]

Kelner, M. J.; Bagnell, R.; Welch, K. J. Thioureas react with superoxide radicals to yield
a sulfhydryl compound. Explanation for protective effect against paraquat. J Biol Chem
265:1306-1311; 1990.

[207]

Wasil, M.; Halliwell, B.; Grootveld, M.; Moorhouse, C. P.; Hutchison, D. C.; Baum, H.
The specificity of thiourea, dimethylthiourea and dimethyl sulphoxide as scavengers of
hydroxyl radicals. Their protection of alpha 1-antiproteinase against inactivation by
hypochlorous acid. Biochem J 243:867-870; 1987.

[208]

Cheng, Z.; Jiang, X.; Kruger, W. D.; Pratico, D.; Gupta, S.; Mallilankaraman, K.;
Madesh, M.; Schafer, A. I.; Durante, W.; Yang, X.; Wang, H. Hyperhomocysteinemia
impairs

endothelium-derived

hyperpolarizing

factor-mediated

vasorelaxation

in

transgenic cystathionine beta synthase-deficient mice. Blood 118:1998-2006; 2011.
[209]

Prathapasinghe, G. A.; Siow, Y. L.; O, K. Detrimental role of homocysteine in renal
ischemia-reperfusion injury. Am J Physiol Renal Physiol 292:F1354-1363; 2007.

[210]

Savage, C. D.; Lopez-Castejon, G.; Denes, A.; Brough, D. NLRP3-Inflammasome
Activating DAMPs Stimulate an Inflammatory Response in Glia in the Absence of
Priming Which Contributes to Brain Inflammation after Injury. Front Immunol 3:288;
2012.

140
[211]

Minn, A. H.; Pise-Masison, C. A.; Radonovich, M.; Brady, J. N.; Wang, P.;
Kendziorski, C.; Shalev, A. Gene expression profiling in INS-1 cells overexpressing
thioredoxin-interacting protein. Biochem Biophys Res Commun 336:770-778; 2005.

[212]

Advani, A.; Gilbert, R. E.; Thai, K.; Gow, R. M.; Langham, R. G.; Cox, A. J.; Connelly,
K. A.; Zhang, Y.; Herzenberg, A. M.; Christensen, P. K.; Pollock, C. A.; Qi, W.; Tan, S.
M.; Parving, H. H.; Kelly, D. J. Expression, localization, and function of the thioredoxin
system in diabetic nephropathy. J Am Soc Nephrol 20:730-741; 2009.

[213]

Li, X.; Rong, Y.; Zhang, M.; Wang, X. L.; LeMaire, S. A.; Coselli, J. S.; Zhang, Y.;
Shen, Y. H. Up-regulation of thioredoxin interacting protein (Txnip) by p38 MAPK and
FOXO1 contributes to the impaired thioredoxin activity and increased ROS in glucosetreated endothelial cells. Biochem Biophys Res Commun 381:660-665; 2009.

[214]

Shah, A.; Xia, L.; Goldberg, H.; Lee, K. W.; Quaggin, S. E.; Fantus, I. G. Thioredoxininteracting protein mediates high glucose-induced reactive oxygen species generation by
mitochondria and the NADPH oxidase, Nox4, in mesangial cells. J Biol Chem
288:6835-6848; 2013.

[215]

Xu, G.; Chen, J.; Jing, G.; Shalev, A. Preventing beta-cell loss and diabetes with calcium
channel blockers. Diabetes 61:848-856; 2012.

[216]

Cha-Molstad, H.; Xu, G.; Chen, J.; Jing, G.; Young, M. E.; Chatham, J. C.; Shalev, A.
Calcium channel blockers act through nuclear factor Y to control transcription of key
cardiac genes. Mol Pharmacol 82:541-549; 2012.

[217]

Li, N.; Chen, Y. F.; Zou, A. P. Implications of hyperhomocysteinemia in glomerular
sclerosis in hypertension. Hypertension 39:443-448; 2002.

141
[218]

Sen, U.; Munjal, C.; Qipshidze, N.; Abe, O.; Gargoum, R.; Tyagi, S. C. Hydrogen
sulfide regulates homocysteine-mediated glomerulosclerosis. Am J Nephrol 31:442-455;
2010.

[219]

Cao, L.; Lou, X.; Zou, Z.; Mou, N.; Wu, W.; Huang, X.; Tan, H. Folic acid attenuates
hyperhomocysteinemia-induced glomerular damage in rats. Microvasc Res 89:146-152;
2013.

[220]

Harris, D. C.; Hammond, W. S.; Burke, T. J.; Schrier, R. W. Verapamil protects against
progression of experimental chronic renal failure. Kidney Int 31:41-46; 1987.

[221]

Pelayo, J. C.; Harris, D. C.; Shanley, P. F.; Miller, G. J.; Schrier, R. W. Glomerular
hemodynamic adaptations in remnant nephrons: effects of verapamil. Am J Physiol
254:F425-431; 1988.

[222]

Al-Gayyar, M. M.; Abdelsaid, M. A.; Matragoon, S.; Pillai, B. A.; El-Remessy, A. B.
Thioredoxin interacting protein is a novel mediator of retinal inflammation and
neurotoxicity. Br J Pharmacol 164:170-180; 2011.

[223]

Brough, D.; Le Feuvre, R. A.; Wheeler, R. D.; Solovyova, N.; Hilfiker, S.; Rothwell, N.
J.; Verkhratsky, A. Ca2+ stores and Ca2+ entry differentially contribute to the release of
IL-1 beta and IL-1 alpha from murine macrophages. J Immunol 170:3029-3036; 2003.

[224]

Lerner, A. G.; Upton, J. P.; Praveen, P. V.; Ghosh, R.; Nakagawa, Y.; Igbaria, A.; Shen,
S.; Nguyen, V.; Backes, B. J.; Heiman, M.; Heintz, N.; Greengard, P.; Hui, S.; Tang, Q.;
Trusina, A.; Oakes, S. A.; Papa, F. R. IRE1alpha induces thioredoxin-interacting protein
to activate the NLRP3 inflammasome and promote programmed cell death under
irremediable ER stress. Cell Metab 16:250-264; 2012.

142
[225]

Oslowski, C. M.; Hara, T.; O'Sullivan-Murphy, B.; Kanekura, K.; Lu, S.; Hara, M.;
Ishigaki, S.; Zhu, L. J.; Hayashi, E.; Hui, S. T.; Greiner, D.; Kaufman, R. J.; Bortell, R.;
Urano, F. Thioredoxin-interacting protein mediates ER stress-induced beta cell death
through initiation of the inflammasome. Cell Metab 16:265-273; 2012.

[226]

van de Veerdonk, F. L.; Smeekens, S. P.; Joosten, L. A.; Kullberg, B. J.; Dinarello, C.
A.; van der Meer, J. W.; Netea, M. G. Reactive oxygen species-independent activation
of the IL-1beta inflammasome in cells from patients with chronic granulomatous
disease. Proc Natl Acad Sci U S A 107:3030-3033; 2010.

[227]

Meissner, F.; Seger, R. A.; Moshous, D.; Fischer, A.; Reichenbach, J.; Zychlinsky, A.
Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from
patients with chronic granulomatous disease. Blood 116:1570-1573; 2010.

[228]

Gabelloni, M. L.; Sabbione, F.; Jancic, C.; Bass, J. F.; Keitelman, I.; Iula, L.; Oleastro,
M.; Geffner, J. R.; Trevani, A. S. NADPH oxidase derived reactive oxygen species are
involved in human neutrophil IL-1beta secretion but not in inflammasome activation.
Eur J Immunol 43:3324-3335; 2013.

[229]

Rossman, K. L.; Der, C. J.; Sondek, J. GEF means go: turning on RHO GTPases with
guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol 6:167-180; 2005.

[230]

Lu, T. C.; He, J. C.; Wang, Z. H.; Feng, X.; Fukumi-Tominaga, T.; Chen, N.; Xu, J.;
Iyengar, R.; Klotman, P. E. HIV-1 Nef disrupts the podocyte actin cytoskeleton by
interacting with diaphanous interacting protein. J Biol Chem 283:8173-8182; 2008.

[231]

Inoue, M.; Williams, K. L.; Oliver, T.; Vandenabeele, P.; Rajan, J. V.; Miao, E. A.;
Shinohara, M. L. Interferon-beta therapy against EAE is effective only when

143
development of the disease depends on the NLRP3 inflammasome. Sci Signal 5:ra38;
2012.

144
VITA
1. PERSONAL INFORMATION:
1.1 Name: Justine Mangubat Abais
1.2 Home Address:
711 South Laurel Street
Richmond, VA 23220
Phone: (757) 274-4883
1.3 Office Address:
Virginia Commonwealth University
Department of Pharmacology & Toxicology
MMRB, 3rd Floor, Room 3055
1220 East Broad Street
Richmond, VA 23298-0613
Phone:
Fax:
E-mail:

804-628-4507
804-828-4794
abaisjm@vcu.edu

2. EDUCATION:
2005-2009
2009-

B.S., Chemistry, Summa Cum Laude
Virginia Commonwealth University, Richmond VA
Ph.D., Pharmacology & Toxicology
Virginia Commonwealth University, Richmond VA

3. MEMBERSHIP – SCIENTIFIC, HONORARY, AND PROFESSIONAL SOCIETIES:
2011-2012
2011-2013
2013-present
2013-present

Virginia Academy of Science, Chair, Medical Sciences Section
Phi Kappa Phi
American Physiological Society
American Society for Pharmacology and Experimental
Therapeutics
2013-present American Society of Nephrology
4. SPECIAL AWARDS, FELLOWSHIPS AND OTHER HONORS:
4.1 Awards
2005-2009
2007
2008
2009
2011

VCU Provost Scholarship Recipient
Multicultural Academic Achievement Award
VCU University Leadership Award
B.S. awarded with University Honors and Summa Cum Laude
VCU School of Medicine C.C. Clayton Award

145
2011
2012
2012
2013
2013
2014
2014
4.2

4.3

Grants
2012

Training
2013

Who‟s Who Among Students in American Universities & Colleges
APS Predoctoral Excellence in Renal Research Award Finalist
VCU Department of Pharmacology & Toxicology Anthony
Ambrose Best Graduate Student Award
VCU Graduate School Travel Grant Recipient
VAS Medical Sciences Section Oral Presentation Winner
Finalist for ASPET CVP Graduate Student Competition
ASPET Graduate Student Travel Award Recipient

F31 Ruth L. Kirschstein National Research Service Award for
Individual Predoctoral Fellows, NIH National Institute of Aging
NIH Clinical Center‟s Clinical and Translational Research Course
for Ph.D. Students

4.4

Oral Presentations
2011
Experimental Biology, NADPH oxidase-mediated activation of
inflammasomes by increased homocysteine in mouse podocytes
and glomeruli, Washington DC
2011
89th Annual Virginia Academy of Science, NADPH oxidasemediated inflammasome activation by elevated homocysteine in
mouse podocytes and glomeruli, Richmond VA
2013
91st Annual Virginia Academy of Science, Thioredoxin-interacting
protein mediates Hcys-induced NLRP3 inflammasome activation in
mouse podocytes, Blacksburg VA
2013
Carolina Cannabinoid Collaborative Conference, Inhibitory action
of prostamide E2 on homocysteine-induced NLRP3 inflammasome
activation and podocyte damage, Richmond VA
2014
Experimental Biology, Contribution of guanine nucleotide
exchange factor Vav2 to homocysteine-induced NLRP3
inflammasome activation in mouse podocytes, San Diego CA

4.5

Poster Presentations
2012
Experimental Biology, Role of different reactive oxygen species in
homocysteine-induced NALP3 inflammasome activation in mouse
podocytes; Inhibition
of NADPH oxidase attenuates
hyperhomocysteinemia-induced NALP3 inflammasome activation
in mouse glomeruli, San Diego CA
2013
Experimental Biology, Contribution of reactive oxygen species to
NLRP3 inflammasome activation in glomeruli of mice with
hyperhomocysteinemia; Thioredoxin-interacting protein mediates
Hcys-induced NLRP3 inflammasome activation in mouse
podocytes, Boston MA

146
2013

2014

American Society of Nephrology, Thioredoxin-interacting protein
mediates hHcys-induced NLRP3 inflammasome activation in
glomerular sclerosis, Atlanta GA
Experimental Biology, Contribution of guanine nucleotide
exchange factor Vav2 to homocysteine-induced NLRP3
inflammasome activation in mouse podocytes; Protective effects
of docosahexaenoic acid metabolites against homocysteineinduced podocyte injury by inhibition of NLRP3 inflammasomes,
San Diego CA

5. BIBLIOGRAPHY:

1

2

3

4

5

6

7

8

9

5.1 Papers Published
Zhang C, Yi F, Xia M, Boini KM, Zhu Q, Laperle LA, Abais JM, Brimson CA, Li PL.
NMDA receptor-mediated activation of NADPH oxidase and glomerulosclerosis in
hyperhomocysteinemic rats. Antioxid Redox Signal. 2010 Oct 1;13(7):975-86. PMID:
20406136
Zhang C, Xia M, Boini KM, Li CX, Abais JM, Li XX, Laperle LA, Li PL. Epithelial-tomesenchymal transition in podocytes mediated by activation of NADPH oxidase in
hyperhomocysteinemia Pflugers Arch - Eur J Physiol. 2011 Sep;462(3):455-67. PMID:
21647593
Boini KM, Xia M, Li CX, Zhang C, Payne LP, Abais JM, Poklis JL, Hylemon PB, Li PL.
Acid sphingomyelinase gene deficiency ameliorates the hyperhomocysteinemia-induced
glomerular injury in mice. Am J Pathol. 2011 Nov;179(5):2210-9. PMID: 21893018
Zhang C, Boini KM, Xia M, Abais JM, Li X, Liu Q, Li PL. Activation of Nod-like receptor
protein 3 inflammasomes turns on podocyte injury and glomerular sclerosis in
hyperhomocysteinemia. Hypertension. 2012 Jul;60(1):154-62. PMID: 22647887
Boini KM, Xia M, Abais JM, Xu M, Li CX, Li PL. Acid sphingomyelinase gene knockout
ameliorates hyperhomocysteinemic glomerular injury in mice lacking cystathionine-βsynthase. PLoS One. 7(9):e45020, 2012. PMID: 23024785
Abais JM, Zhang C, Xia M, Liu Q, Gehr T, Boini KM, Li PL. NADPH oxidase-mediated
triggering of inflammasome activation in mouse podocytes and glomeruli during
hyperhomocysteinemia. Antioxid Redox Signal. 2013 May 1;18(13):1537-48. PMID:
23088210
Xu M, Li X, Walsh SW, Zhang Y, Abais JM, Boini KM, Li PL.M, Intracellular two-phase
Ca2+ release and apoptosis controlled by TRP-ML1 channel activity in coronary arterial
myocytes. Am J Physiol Cell Physiol. 2013 Mar 1;304(5):C458-66. PMID: 23283937
Xiong J, Xia M, Abais JM, Li CX, Boini KM, Li PL. Regulation of renin release via cyclic
adp-ribose-mediated signaling: evidence from mice lacking CD38 gene. Cell Physiol
Biochem. 2013 Jan 14;31(1):44-55. PMID: 23343681
Wei YM, Li X, Xiong J, Abais JM, Xia M, Boini KM, Zhang Y, Li PL. Attenuation by
statins of membrane raft-redox signaling in coronary arterial endothelium. J Pharmacol
Exp Ther. 2013 May;345(2):170-9. PMID: 23435541

147
10

11

12
13

14

15

16

17

18

Li C, Xia M, Abais JM, Liu X, Li N, Boini KM, Li PL. Protective role of growth hormone
against hyperhomocysteinemia-induced glomerular injury. Naunyn Schmiedebergs Arch
Pharmacol. 2013 Jun;386(6):551-61. PMID: 23529346
Wei YM, Li X, Xu M, Abais JM, Chen Y, Riebling CR, Boini KM, Li PL, Zhang Y.
Enhancement of autophagy by simvastatin through inhibition of Rac1-mTOR signaling
pathway in coronary arterial myocytes. Cell Physiol Biochem. 2013;31(6):925-37. PMID:
23817226
Li PL, Zhang Y, Abais JM, Ritter JK, Zhang F. Cyclic ADP-Ribose and NAADP in
Vascular Regulation and Diseases. Messenger. 2013; 2, 63-85. PMID: 24749015
Xu M, Li XX, Ritter JK, Abais JM, Zhang Y, Li PL. Contribution of NADPH oxidase to
membrane CD38 internalization and activation in coronary arterial myocytes. PLoS One.
2013 Aug 7;8(8):e71212. PMID: 23940720
Abais JM, Xia M, Gehr T, Boini KM, Li PL. Contribution of endogenously produced
reactive oxygen species to the activation of podocyte NLRP3 inflammasomes in
hyperhomocysteinemia. Free Radic Biol Med. 2014 Feb; 67:211-20. PMID: 24140862
Xiong J, Xia M, Xu M, Zhang Y, Abais JM, Li G, Riebling CR, Ritter JK, Boini KM, Li
PL. Autophagy maturation associated with CD38-mediated regulation of lysosome
function in mouse glomerular podocytes. J Cell Mol Med. 2013 Dec; 17(12):1598-607.
PMID: 24238063
Boini KM, Xia M, Abais JM, Li G, Pitzer AL, Gehr TW, Zhang Y, Li PL. Activation of
inflammasomes in podocyte injury of mice on the high fat diet: Effects of ASC gene
deletion and silencing. Biochim Biophys Acta. 2014 May; 1843(5):836-45. PMID:
24508291
Xia M, Boini KM, Abais JM, Xu M, Zhang Y, Li PL. Endothelial NLRP3 inflammasome
activation and enhanced neointima formation in mice by adipokine visfatin. Am J Pathol.
2014 Mar 13. [Epub ahead of print] PMID: 24140862
Wang M, Abais JM, Meng N, Zhang Y, Ritter JK, Li PL, Tang WX. Upregulation of
cannabinoid receptor-1 and fibrotic activation of mouse hepatic stellate cells during
Schistosoma J. infection: role of NADPH oxidase. Free Radic Biol Med. 2014 Mar 18.
[Epub ahead of print] PMID: 24657416

5.2 Papers In Preparation
19 Abais JM, Xia M, Boini KM, Li PL. NLRP3 inflammasome activation and podocyte injury
via thioredoxin-interacting protein during hyperhomocysteinemia. J Biol Chem. (In
Revision).
20 Abais JM, Zhang Y, Boini KM, Li PL. Redox Regulation of Inflammasomes: ROS as
Trigger or Effector? Antioxid Redox Signal. (In Preparation)
5.3 Abstracts
21 Yi F, Abais JM, Jin S, Zhang F, Li N and Li PL. NMDA receptors mediates homocysteineinduced sclerotic action on rat mesangial cells. The FASEB Journal. 22:748.1. 2008.

148
22

23

24

25

26
27
28

29

30

31

32

33

34

35

36

Abais JM, Zhang C, Xia M, Boini KM, Li X, Laperle LA, Thacker AM, Li PL. NADPH
oxidase-mediated activation of inflammasomes by increased homocysteine in mouse
podocytes and glomeruli. The FASEB Journal. 25:1030.5. 2011.
Boini KM, Xia M, Zhang C, Abais JM, Li CX, and Li PL. Activation of inflammasomes as
a triggering mechanism of glomerular injury in mice on the high fat diet. The FASEB
Journal 25:1028.6. 2011.
Xia M, Boini KM, Abais JM, Li PL. Silencing of acid sphingomyelinase gene prevented
glomerular oxidative stress and sclerosis in hyperhomocysteinemic mice. The FASEB
Journal. 25:667.12. 2011.
Xu M, Zhang F, Xia M, Li XX, Abais JM, Boini KM, Li PL. Lysosomal regulation of
autophagy efflux via CD38-mediated signaling in mouse coronary arterial myocytes.
Hypertension. 2011
Xia M, Boini KM, Abais JM, Li XX , Mu X, Li PL. NALP3 inflammasome activation in
the coronary arterial wall of obese mice. FASEB J. 26:877.7. 2012.
Xia M, Xiong J, Boini KM, Abais JM, Li PL. Characteristics and hypertensive actions of
renal medullary NALP3 inflammasomes in mice. FASEB J. 26:879.4. 2012.
Abais JM, Boini KM, Xia M, Li PL. Role of different reactive oxygen species in
homocysteine-induced NALP3 inflammasome activation in mouse podocytes. FASEB J.
26:691.9. 2012.
Abais JM, Boini KM, Xia M, Li PL. Inhibition of NADPH oxidase attenuates
hyperhomocysteinemia-induced NALP3 inflammasome activation in mouse glomeruli.
FASEB J. 26:691.10. 2012.
Boini KM, Xia M, Abais JM, Li PL. Instigation of NALP3 inflammasome activation and
glomerular injury in mice on the high fat diet: role of acid sphingomyelinase gene.
FASEB J. 26:690.7. 2012.
Xiong J, Xia M, Xu M, Li XX, Abais JM, Boini KM, Li PL. Autophagy maturation
controlled by CD38-lysosome signaling in glomerular podocytes of mice. FASEB J.
26:690.14. 2012.
Abais JM, Boini KM, Xia M, Li PL. Thioredoxin interacting protein mediates Hcysinduced NLRP3 inflammasome activation in mouse podocytes. FASEB J. 27:704.7.
2013.
Abais JM, Boini KM, Xia M, Li PL. Contribution of reactive oxygen species to NLRP3
inflammasome activation in glomeruli of mice with hyperhomocysteinemia. FASEB J.
27:890.3. 2013.
Boini KM, Xia M, Abais JM, Zhang Y, Li PL. Inhibition of hyperhomocysteinemiainduced inflammasome activation and glomerular sclerosis by NLRP3 gene deletion.
FASEB J. 27:704.6. 2013.
Boini KM, Xia M, Abais JM, Zhang Y, Li PL. High fat diet failed to induce NALP3
inflammasome activation and glomerular injury in apoptosis-associated speck-like
protein (ASC) knockout mice. FASEB J. 27:889.5. 2013.
Xia M, Xiong J, Abais JM, Boini KM, Li PL. Regulation of renal sodium excretion by
medullary NLRP3 inflammasome activation beyond turning on inflammation. FASEB J.

149

37

38

39

40

41
42

27:1115.5. 2013.
Xia M, Li CX, Li C, Abais JM, Zhang Y, Boini KM, Li PL. Epithelial-to-mesenchymal
transition induced by accumulation of autophagosomes in podocytes. FASEB J.
27:889.7. 2013.
Abais JM, Xia M, Boini KM, Li PL. Contribution of guanine nucleotide exchange factor
Vav2 to homocysteine-induced NLRP3 inflammasome activation in mouse podocytes.
FASEB J. 28:1063.6. 2014.
Abais JM, Xia M, Boini KM, Li PL. Protective effects of docosahexaenoic acid metabolites
against homocysteine-induced podocyte injury by inhibition of NLRP3 inflammasomes.
FASEB J. 28:1134.8. 2014.
Boini KM, Xia M, Abais JM, Li PL. Podocyte NLRP3 inflammasome activation and
glomerular injury by adipokine visfatin: in vitro and in vivo evidence. FASEB J.
28:1134.7. 2014.
Boini KM, Xia M, Abais JM, Li G, Li PL. Enhanced dedifferentiation and injury in mouse
podocytes lacking CD38 gene. FASEB J. 28:691.4. 2014.
Wang M, Abais JM, Meng N, Zhang Y, Ritter JK, Li PL, Tang WX. Upregulation of
cannabinoid receptor-1 and fibrotic activation of mouse hepatic stellate cells during
Schistosoma J. infection: role of NADPH oxidase. FASEB J. 28:693.13. 2014.

